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MHC class I antigen presentation to CD8 T cells 
Major histocompatibility complex (MHC) class I molecules are expressed on the surface 
of all nucleated cells (Figure 1.1). These molecules typically present peptides derived 
from intracellular proteins to T cell receptors (TCR) of CD8 T cells. The MHC class I 
molecule – TCR interaction (Figure 1.2) is crucial for the development, maintenance, 
tolerance and activation of CD8 T cells (Ernst et al., 1999; Goldrath and Bevan, 1999; 








Figure 1.1. Crystal structure of a human MHC class I molecule in complex with a 
peptide [PDB ID 3OXR; (Liu et al., 2011)]. (A) MHC class I heavy chain (depicted in 
green) in shown in complex with the light chain !2m (depicted in blue). The heavy chain 
is made up of three domains: a membrane bound immunoglobulin-like domain ("3) and 
the folded "1 and "2 domains, which form the peptide binding groove. The light chain 
(!2m) is composed of an immunoglobulin-like domain and is non-covalently bound to 
the heavy chain. (B) Top view of the MHC class I peptide binding groove. The peptide 














Figure 1.2. Crystal structure of a TCR binding to a MHC class I–peptide complex [PDB 
ID 3O4L; (Miles et al., 2010)]. (A, B) The TCR (depicted in orange) simultaneously 
binds residues of the MHC class I heavy chain (depicted in green) and peptide (depicted 
in red). !2m is depicted in blue. A close up of the interaction between TCR and MHC 
class I – peptide complex is shown in B. 
 
The activation of CD8 T cells by antigen presenting cells (APC) occurs primarily 
in secondary lymphoid organs (lymph nodes and spleen) and requires two signals (Figure 
1.3). Signal 1 involves signaling through the TCR; this signal is provided by a MHC class 
I molecule – peptide complex against which the TCR is specific. This interaction alone 
will not result in the activation of the CD8 T cell. If a CD8 T cell receives TCR 
stimulation in the absence of Signal 2, the T cell will become unable to further respond to 
stimulation (anergy). Anergy is thought to prevent the activation of self-reactive CD8 T 
cells and contribute to maintaining peripheral tolerance.  Cell surface molecules on the 
APC that are upregulated in response to pathogens or inflammatory environment provide
! %!
signal 2. The best-characterized molecules that provide signal 2 (co-stimulatory 
molecules) on APCs are B7.1 (CD80) and B7.2 (CD86), which interact with CD28 on the 
CD8 T cell.  
Under steady-state conditions, MHC class I molecules on APCs are loaded with 
self-derived peptides. Additionally, surface levels of MHC class I and other co-
stimulatory molecules are relatively low. When APCs are exposed to foreign pathogens 
or inflammatory cytokines, the APCs undergo a process called maturation, which 
includes the up-regulation MHC and co-stimulatory molecules. The phagocytic capacity 
of mature APCs is diminished and APC efforts are diverted to processing of antigen and 
loading it onto MHC molecules to stimulate T cell activation. As the APCs migrate to the 
nearest draining lymph node, maturation continues. Pathogenic material acquired via 
phagocytosis or direct infection is processed into smaller peptides to be loaded onto 
MHC molecules. In the draining lymph node, the migrating APCs (and resident lymph 
node APCs that have been exposed to the foreign pathogen) activate naïve CD8 T cells 
that bind APCs via interactions mediated by the TCR and MHC class I – pathogen 
derived peptide complexes [reviewed in (Sille et al., 2005)]. Depending on the pathogen 
and extent of inflammation within the lymph node, CD4 T cell help may be required for 
the activation of CD8 T cells. MHC class II molecules present peptides derived from 
extracellular proteins to CD4 TCR. MHC class II molecules are highly similar in 
structure to MHC class I molecules. The most notable differences between the two are 
that 1) the ends of the peptide binding cleft of MHC class II molecules are open, 
permitting the loading of longer peptides, and 2) MHC class II molecules are made up of 
two membrane bound dimers (the " and ! chain) whereas MHC class I is made up of a 
membrane bound " chain and soluble !2m [reviewed in (Wolf and Ploegh, 1995)]. CD4 
T cell help comes in the form of cytokines and ligands that activate APCs. Activated CD4 
T cells secrete inflammatory IFN# and upregulate cell surface CD40L, the latter of which 
binds to CD40 on the APC. The CD40L-CD40 interaction and IFN# both induce the 
upregulation of co-stimulatory molecules on the APC, which provides Signal 2 to the 
CD8 T cell. Once a CD8 T cell is activated, it clonally expands and migrates out of the 
lymph node to the site of infection. In addition to TCR and CD28 signaling, 
! &!
inflammatory cytokines such as IL-12 help in expanding the antigen-specific CD8 T cell 
population in the lymph node. 
 
 
Figure 1.3. Naïve CD8 T cells require two signals provided by APCs for activation. 
Upon exposure to pathogens, inflammatory cytokines or CD40 engagement on the APC 
by CD40L expressed on activated CD4 T helper cells, APCs upregulate the co-
stimulatory molecules B7.1 and B7.2. These molecules provide Signal 2 to the naïve CD8 
T cell. TCR signaling via MHC class I-peptide engagement provides Signal 1 to the naïve 
CD8 T cell. Upon receiving both signals, naïve CD8 T cells clonally expand and 
differentiate into cytotoxic effector T cells.  
 
In the periphery, the CD8 T cell engages with cellular MHC class I molecule – 
peptide complexes of the same specificity as that which caused initial activation of the 
CD8 T cell. At this stage, only Signal 1 is needed to initiate the effector function of 
activated CD8 T cells. Upon engagement, the cytotoxic T cell kills the infected cells by 
one of two, or both, mechanisms.  Cytotoxic T cells are able to kill target cells via 
interactions between Fas ligand and the Fas receptor on the cytotoxic T cell and target 
cell, respectively. Engagement of the Fas receptor induces programmed cell death 
! '!
(apoptosis) of the target cell. The cytotoxic T cell can also induce apoptosis of the target 
cell by secreting granules containing perforin and granzymes directly at the target cell 
(Figure 1.4). Perforin is a pore-forming protein and granzymes are a family of pro-
apoptotic serine proteases. Perforin is essential for the delivery of granzymes into the 
cytosol. However, whether perforin forms pores on the cell surface of the target cell or 
within endosomal compartments of the target cell is not yet completely understood. Once 
in the cytosol, the granzymes act on number of different substrates. The cleavage of these 
substrates results in the initiation of apoptosis. The secretory granules do not affect the 
cytotoxic T cell. Rather, after initiating apoptosis in the infected target cell, the cytotoxic 
T cell disengages from the target cell and continues surveillance of the periphery for 
other infected cells. In addition to inducing apoptosis in infected cells, cytotoxic T cells 
also release the pro-inflammatory cytokines IFN# and TNF" at the site of infection. 
Finally, to inhibit peripheral tissue injury, the immunosuppressive cytokine IL-10 is 
secreted by cytotoxic T cells. [reviewed in (Hoves et al., 2010) and (Zhang and Bevan, 
2011)].  
Thus, MHC class I molecules are crucial for the activation and peripheral effector 
function of CD8 T cells. We addressed a number of outstanding questions in the field of 
MHC class I antigen presentation and CD8 T cell activation. Our findings contribute to 














Figure 1.4. Activated CD8 T cells require only Signal 1 to induce effector function. 
Upon engagement with a MHC class I molecule – peptide complexes of the same 
specificity as that which caused initial activation of the cytotoxic T cell, the target cell is 
killed. Depicted here is the secretion of granules containing perforin and granzymes. The 
pore-forming protein (perforin) will facilitate the entry of the granzymes into the cytosol 
of the infected cell. Once in the cytosol, the granzymes will cleave a number of 
substrates. The cleavage of the substrates will initiate apoptosis in the infected cell. The 
cytotoxic T cell continues to survey the peripheral environment for additional infected 
cells. 
 
MHC class I peptide loading complex  
MHC class I molecules are composed of a heavy chain, a light chain (!2m), 
and a peptide of about 8-10 amino acids in length (Figure 1.1) (Bjorkman et al., 1987). 
This trimeric protein is assembled in the lumen of the endoplasmic reticulum (ER) by a 
group of chaperones and assembly factors termed the MHC class I peptide loading 
complex (PLC). This complex consists of the transporter associated with antigen 
processing (TAP), tapasin, the lectin-like chaperone calreticulin and the thiol 
oxidoreductase ERp57 (Figure 1.5). Upon translation, MHC class I heavy chains fold 
with the help of the membrane bound homologue of calreticulin, calnexin, and its partner 
ERp57. MHC class I heavy chains may undergo disulfide bond isomerization at this 
! )!
stage, which is facilitated by ERp57. !2m forms complexes with the heavy chains, and 
MHC class I heterodimers associate with the PLC. Within the PLC, the MHC class I 
molecules are loaded with optimal peptides, which helps stabilize the MHC class I 
molecules. Stable MHC class I molecules are transported to the cell surface where the 
TCR – MHC class I-peptide interaction occurs. MHC class I molecules loaded with sub-
optimal peptide are unstable on the cell-surface, which reduces the efficiency of the TCR 
– MHC class I-peptide interaction (Garbi et al., 2000). Thus, maintaining quality control 
of MHC class I molecules is vital for the development and function of CD8 T cells.  
Peptides that bind to MHC class I molecules are typically derived from the 
cytosol. In the cytosol, a large multi subunit called the proteosome degrades proteins into 
peptides [reviewed in (Sijts and Kloetzel, 2011)]. The derived peptides are extended at 
the N-terminus while the C-terminus is compatible for binding to the MHC class I 
peptide groove. TAP is a transmembrane ABC-transporter, and the cytoplasmic side of 
TAP binds to these extended peptides and transports them into the ER in an ATP 
hydrolysis dependent manner [reviewed in (Procko and Gaudet, 2009)]. Within the ER 
lumen, the aminopeptidade ERAAP (ERAAP in mice; ERAP1 in humans) trims the N-
terminally extended peptides to generate peptides of 8-10 amino acids in length, which fit 
into the groove of MHC class I molecule. ERAAP deficiency disrupts the stability of 
MHC class I-peptides complexes, vastly changes the peptide repertoire, and reduces CD8 
T cell responses in mice (Hammer et al., 2006).  
Tapasin, ERp57 and calreticulin work cooperatively to assemble stable MHC 
class I molecules that are loaded with optimal peptides [reviewed in (Raghavan et al., 
2008) and (Cresswell et al., 2005)]. The absence of any one of the PLC components 
results in reduced surface expression and sub-optimal assembly of MHC class I 
(Gabathuler et al., 1994; Gao et al., 2002; Garbi et al., 2000; Garbi et al., 2006). Within 
the PLC, TAP binds to tapasin (Lehner et al., 1998; Sadasivan et al., 1996). Tapasin 
stabilizes TAP, which allows for a greater flow of peptides into the ER (Lehner et al., 
1998). In addition, the TAP-tapasin interaction concentrates the influx of peptides around 
folding MHC class I molecules. Tapasin also interacts with ERp57 via a stable disulfide 
bond (Peaper et al., 2005). MHC class I also interacts directly with tapasin (Bangia et al., 
1999; Rizvi and Raghavan, 2006). Thus, tapasin functions as the bridge between MHC 
! *!
class I and TAP. Calreticulin binds directly to ERp57 via residues in the calreticulin P 
domain (Frickel et al., 2002). Calreticulin also binds MHC class I, and this interaction is 
reduced in cells treated with the glucosidase I and II inhibitor castanospermine, which 
inhibits the trimming of the 3 terminal glucose residues on N-linked glycans (Sadasivan 
et al., 1996). The interactions of calreticulin with substrates containing N-linked glycans 
are dependent on the ability of calreticulin to interact with monoglucosylated glycans on 
the glycoprotein substrate. Castanospermine treatment inhibits the generation of glycans 
containing single terminal glucose residues. Hence, the finding that castanospermine 
treatment of cells reduced MHC class I - calreticulin interactions (Sadasivan et al., 1996) 
suggested that calreticulin – MHC class I binding is dependent on a glycan interaction.  
Tapasin is suggested to be the “peptide editor” of the PLC [reviewed in (Wearsch 
and Cresswell, 2008)]. In doing so, tapasin displaces low affinity peptides bound to the 
MHC class I peptide binding groove and facilitates the exchange for high affinity 
peptides (Howarth et al., 2004). Tapasin is also believed to have the ability to detect the 
presence of empty MHC class I heterodimers or those loaded with sub-optimal peptides 
and prevent the export of these unstable MHC class I molecules from the ER. The 
functions of ERp57 and calreticulin within the PLC are not fully understood, however 
both are required to generate stably loaded MHC class I molecules. [reviewed in (Peaper 
and Cresswell, 2008)]. ERp57 appears to have a structural role in the PLC, as the redox 
activity of ERp57 is not required for the stabilization of the PLC or for the generation of 
stable MHC class I molecules (Zhang et al., 2009). In this study, we investigated modes 






Figure 1.5. The MHC class I PLC. Tapasin binds TAP and MHC class via non-covalent 
interactions. Tapasin also forms a stable disulfide bond with ERp57. Via interactions 
through its P domain, calreticulin interacts with ERp57. Studies described in Chapter 2 
contributed to a better understanding of how calreticulin is recruited to the PLC.   
 
Calreticulin 
Calreticulin is a soluble calcium binding ER resident chaperone that aids in the folding of 
nascent glycoproteins [reviewed in (Michalak et al., 2009)] Calreticulin is composed of 
three domains, and each domain serves a role in the protein’s various functions. The 
domains are: a globular domain, P-domain, and acidic C-terminal domain (Figure 1.6A).  
The globular domain of calreticulin is composed of both the N- and C- terminal 
regions.  These regions come together to form a !-strand sandwich and a C-terminal helix 
that spans both the globular and acidic C-terminal domains. The glycan binding site is 
located within the globular domain (Figure 1.6B) (Kozlov et al., 2010). The glycan 
binding site play an important role in calreticulin substrate recognition as discussed 
below. Calreticulin also contains calcium-binding sites. One of these sites, the high 
affinity site, resides in the globular domain (Figure 1.6B). This site binds a calcium ion 
with an affinity of ~16 µM. The C-terminal acidic domain of calreticulin contains 
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multiple low affinity calcium binding sites (binding affinity of ~590 µM) (Wijeyesakere 
et al., 2011). It is suggested that calreticulin binds about 50% of the calcium stored in the 
ER (Nakamura et al., 2001). Accordingly, calreticulin deficiency results in embryonic 
lethality in mice due to impairments in cardiac development. This is caused by alterations 
in calcium signaling that impact cardiac development (Mesaeli et al., 1999). Calreticulin-
deficient mouse embryonic fibroblasts (MEF) have been utilized to understand the 
various functions of calreticulin [reviewed in (Michalak et al., 2009)]. MHC class I 
assembly is impaired in calreticulin-deficient MEFs, and MHC classs I molecules that do 
traffic to the surface of the cell are unstable. Importantly, the antigen presentation by 
calreticulin-deficient MEFs is compromised compared to their wild-type counterparts 
(Gao et al., 2002). Calreticulin has also been shown to play a positive role in cell 
adhesion, wound healing and apoptosis (Fadel et al., 1999; Nakamura et al., 2000; 
Nanney et al., 2008). Calcium release from the ER is involved in the initiation of certain 
types of apoptosis. Thus, increased calreticulin expression results in increased apoptosis, 
as increased calreticulin levels enhance the calcium concentration in the ER. On the other 
hand, calreticulin-deficiency results in a resistance to apoptosis, as calcium levels in the 




Figure 1.6. Structure of calreticulin. A. Homology model of calreticulin based on the 
crystal structure of the calreticulin globular domain (PDB ID 3O0V) and calnexin (PDB 
ID 1JHN) (Kozlov et al., 2010; Schrag et al., 2001). The globular domain is depicted in 
blue (N-terminus of calreticulin) and green (C-terminus of calreticulin). The P domain, 
which contains an ERp57 binding site, is depicted in purple. The C-terminal acidic 
domain is not included in the model. This model combining the globular and P domain 
was built by Sanjeeva J. Wijeyesakere. B. Putative glycan-binging residues of calreticulin 
domain [(PDB ID 3O0W) (Kozlov et al., 2010)] are highlighted in purple, and the region 
of the calreticulin model corresponding to the glycan binding site is boxed. The Glc1Man3 
ligand is depicted in pink. The high affinity calcium binding site is occupied by a calcium 
ion (depicted as a yellow sphere). Mutagenesis studies and recent crystal structure studies 
have implicated highlighted residues (blue) in glycan binding. C. NMR structure of the P 
domain of calreticulin (PDB ID 1K9C) (Ellgaard et al., 2002). ERp57 binding sites are 





Both calreticulin and its membrane bound homologue calnexin bind ERp57 
through residues at the tip of the hook-shaped, proline-rich P-domain (Frickel et al., 
2002) (Figure 1.6C). In cooperation with ERp57, calreticulin and calnexin aid in the 
folding of nascent glycoproteins. This process is dependant on the recognition by 
calreticulin or calnexin of modified glycans on nascent glycoproteins. Upon translation in 
the ER, an N-linked glycan with three terminal glucose residues (Glc3Man9GlcNAc2, 
Figure 1.7) is attached to nascent glycoproteins. ER localized "-glucosidase I cleaves the 
first glucose and "-glucosidase II cleaves second glucose. What remains is a 
monoglucosylated N-linked glycan (Glc1Man9GlcNAc2, Figure 1.7). Calreticulin and 
calnexin bind to monoglucosylated N-linked glycans through a glycan-binding site 
located within their globular domains (Kozlov et al., 2010; Peterson et al., 1995; Spiro et 
al., 1996; Ware et al., 1995) (Figure 1.6B). Calreticulin/calnexin bind glycoprotein 
substrates, and ERp57 facilitates isomerization of disulfide bonds within the substrates. 
Upon cleavage of the terminal glucose residue by "-glucosidase II, release of substrate 
from calreticulin/calnexin is thought to be initiated. If folded correctly, the glycoproteins 
can proceed through the secretory pathway. A soluble enzyme, UDP-
Glucose:glycoprotein glucosyltransferase (UGGT), senses improperly folded 
glycoproteins. UGGT re-glucosylates the N-linked glycan of the misfolded glycoproteins. 
The misfolded glycoprotein is now tagged for re-entry into the calreticulin/calnexin 
cycle. In this model, UGGT is the protein-folding sensor, and calreticulin and calnexin 
bind substrate via glycan-based interactions and initiate the interaction between substrate 
and ERp57 [reviewed in (Rutkevich and Williams, 2011)]. Hence, calreticulin and 




Figure 1.7. N-linked glycan modification. (A) A core glycan consisting of 2 N-
acetylglucosamines (depicted as blue squares), 9 mannoses (depicted as green 
pentagons), and 3 glucoses (depicted as purple circles) are attached to nascent 
glycoproteins in the ER. "-glucosidase I cleaves the terminal glucose residue, and "-
glucosidase II cleaves the second glucose residue. What remains is a monoglucosylated 
N-linked glycan residue (B), to which calreticulin and calnexin bind via sites located in 
their globular domains. "-glucosidase II can also cleave the terminal glucose residue if 
this residue becomes fully exposed.  
 
In 1999, it was demonstrated that calreticulin also has the ability bind and inhibit 
the thermal aggregation of non-glycosylated misfolded polypeptide substrates in vitro 
(Saito et al., 1999). Subsequently, within cells, calreticulin was shown to bind de-
glycosylated MHC class I heavy chains under ER stress conditions (tunicamycin 
treatment) (Rizvi et al., 2004). Thus, once it was recognized that calreticulin can also 
bind and chaperone non-glycosylated polypeptide substrates, the questions arose whether 
calreticulin recruitment into the PLC is based on polypeptide, rather than glycan-based, 
interactions with MHC class I. Evidence to support both models – (a) calreticulin 
recruitment into the PLC via ERp57 and MHC class I glycan-based interactions and (b) 
calreticulin recruitment into the PLC via MHC class I polypeptide-based interactions – 
have been proposed (Dong et al., 2009; Sadasivan et al., 1996; Zhang et al., 2009). In 
Chapter 2, we undertook experiments to examine impacts of mutations within the glycan 
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and ERp57 binding sites of calreticulin on MHC class I assembly and calreticulin 
recruitment to the PLC.  
MHC class I antigen cross-presentation 
APCs typically present endogenously synthesized peptides (both self and foreign) in the 
context of MHC class I molecules to CD8 T cells. APCs can also present exogenously 
derived peptides in the context of MHC class I. This process, termed cross-presentation, 
is important for initiating cytotoxic responses against many intracellular pathogens and 
tumor cells as well as for maintaining peripheral tolerance [(Luckashenak et al., 2008) 
and reviewed in (Amigorena and Savina, 2010)]. As described above, conventional MHC 
class I antigen presentation involves the degradation of proteins in the cytosol into 
smaller peptides. After being transported into the ER by TAP, the peptides are trimmed 
and loaded onto folding MHC class I molecules. MHC class I antigen cross-presentation 
involves the uptake of both soluble and cell-associated antigens by the general 
mechanisms of endocytosis and phagocytosis by APC. In addition to being targeted for 
MHC class II presentation to CD4 T cells, peptides generated from the exogenously 
acquired proteins are loaded onto MHC class I molecules for presentation to CD8 T cells.  
Mechanisms of MHC class I antigen cross-presentation 
 There are several models proposed for the mechanism by which cross-presentation 
occurs (Figure 1.8) [reviewed in (Raghavan et al., 2008)]. They can be divided into two 
main categories: one that is dependent on TAP and the proteosome and one that is 
independent of these two factors. TAP-independent cross-presentation has been termed 
the “vacuolar pathway” (Figure 1.7a) Upon uptake into an endosome, an antigen 
degraded into smaller peptides by cysteine proteases such as cathepsin S. The peptides 
are loaded onto recycling MHC class I molecules within the endosome, and the new 
MHC class I – peptide complex is trafficked to the surface of the cell. TAP and 
proteosome dependant mechanisms require that the exogenous protein reach the cytosol. 
One mechanism depicted in Figure 1.8b involves the retrograde transport of antigen from 
the extracellular environment to the ER. Within the ER, the antigen is transported to the 
cytosol via Sec61, which is a putative translocon channel thought to function in the 
transport of substrates from the ER ! cytosol. Sec61 plays a role in ER-associated 
degradation (ERAD) (Schafer and Wolf, 2009), which exports terminally misfolded 
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proteins out of the ER into the cytoplasm for degradation. In the cytoplasm, the 
exogenously derived protein is processed via the conventional MHC class I pathway. The 
antigen is degraded by the proteosome, and the peptides are transported into the ER by 
TAP. The second TAP and proteosome dependant pathway is depicted in Figure 1.8c. 
Via this pathway, the exogenous antigen is transported into the cytosol directly from a 
phagosome. This pathway is somewhat controversial [reviewed in (Amigorena and 
Savina, 2010)], as the presence of ERAD machinery within phagosomes has been highly 
debated. Finally, it has also been proposed that TAP itself is recruited to early endosomes 
via TLR4/MyD88 signaling (Burgdorf et al., 2008). This pathway (Figure 1.8d) proposes 
that exogenous antigens are first translocated from the endosome to the cytosol, where 
the antigen is degraded by the proteosome. The peptides are then translocated back into 
the endosome via TAP. The peptide products are loaded onto recycling MHC class I 
molecules and transported back to the surface of the cell, similarly to the vacuolar 
pathway (Figure 1.8a). As mentioned above, ERAP plays a role in trimming N-terminally 
extended peptides that are transported into the ER by TAP. Another aminopeptidase, 
insulin-regulated aminopeptidase (IRAP), has been implicated in cross-presentation by its 




Figure 1.8. Proposed pathways for MHC class I antigen cross-presentation. (a) TAP-
independent vacuolar pathway; endocytosed antigens are proteolytically processed by 
cysteine proteases such as cathepsin S. Peptide is loaded onto recycling MHC class I 
molecules within the endosome, and the newly formed MHC class I-peptide complex 
traffics back to the plasma membrane. (b) The retrograde translocation model proposes 
that some soluble antigens are directly targeted to the ER following retro-trafficking 
through the trans-Golgi network and Golgi. Once in the ER, the antigen is retro-
translocated into the cytosol by ERAD machinery (Sec61) and processed similarly to an 
endogenous protein for MHC class I presentation. (c) The TAP-dependent phagosomal 
pathway; phagocytosed antigens use the Sec61 channel to egress out of the phagosome, 
are proteasomally processed and are reimported into the phagosome for loading onto 
MHC class I molecules within the phagosome. Once the MHC class I molecules are 
loaded, they traffic to the plasma membrane. Phagocytosed antigens that have egressed 
into the cytoplasm could also follow the classical ER-routed MHC class I pathway for 
endogenous proteins. (d) The TAP-dependent endosomal pathway proposes that TAP is 
recruited to an early endosome through TLR4/MyD88 signaling. Antigen egresses from 
the endosome by an unknown transporter and after proteasomal proteolysis, processed 
peptides are shuttled back into endosomes by recruited TAP and loaded onto recycling 








APC subsets and receptors involved in MHC class I cross-presentation 
  Antigen uptake by receptors has been closely examined in the context of cross-
presentation. Most notably, cross-presentation of soluble ovalbumin (OVA) has been 
shown to be dependant on the mannose receptor, which is a C-type lectin receptor. 
Mannose receptor mediated uptake traffics OVA to early endosomes, which are favorable 
for cross-presentation onto MHC class I molecules (pathway depicted in Figure 1.8d). 
However, uptake via scavenger receptors traffics OVA to lysosomes, which are favorable 
for MHC class II presentation, but not for MHC class I presentation (Burgdorf et al., 
2007; Burgdorf et al., 2008). The requirement for the mannose receptor in the cross-
presentation of OVA remains a controversial issue (Burgdorf et al., 2010; Segura et al., 
2009). Fc receptors and a number of other C-type lectin receptors have also been shown 
to support the cross-presentation of exogenous proteins [reviewed in (Kurts et al., 2010)].  
 The relevant APC that cross-primes a CD8 T cell is dependant on a number of 
factors. For example, subcutaneously delivered apoptotic cells are cross-presented by 
CD169+ macrophages (M$). This is largely due to the location of the M$ within the 
draining lymph node (Asano et al., 2011). Dendritic cells (DC) are able to cross-present 
the same apoptotic cells in vitro, but do not have access to the cells in vivo due to the 
architecture of the lymph node. However, when apoptotic cells are injected intravenously, 
extracted CD8"+ lymphoid (CD11b-) DC have the ability cross-prime CD8 T cells in 
vitro, whereas myeloid (CD11b+) CD8"- DC or M$ do not (den Haan et al., 2000). A 
later study implicating DCs in the cross-priming of CD8 T cells in vivo did so by ablating 
all CD11c+ cells (Jung et al., 2002). Various antigens (cell-associated OVA, the 
bacterium Listeria monocytogenes, and Plasmodium yoelii sporozoites) in that study were 
delivered intravenously. Further support for a role of CD8 DC in cross-priming CD8 T 
cells has been generated by selectively ablating CD8 DC by cytochrome c administration. 
Mice treated with cytochrome C are shown to be impaired in cross-priming CD8 T cells 
against intravenously delivered cell-associated OVA (Lin et al., 2008). Recently, a subset 
within the CD8 DC population located in the marginal zone of lymph nodes has been 
implicated in tolerizing CD8 T cell responses against apoptotic cell-associated antigens 
(Qiu et al., 2009). Finally, steady-state and activated CD8 DC are both shown to be 
competent for cross-priming soluble OVA, but different pathways are utilized depending 
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on whether or not CD8 DCs are activated (Segura et al., 2009). Thus, it appears that there 
may be a number of factors involved in determining what APC subset is responsible for 
cross-presenting antigen to CD8 T cells. These factors may include mode of delivery, 
size of antigen, inflammatory environment, and the extent of pathogen load.    
The ability of an APC to preserve antigen within a phagosome enhances the 
efficiency of cross-presentation of antigen-derived peptides. Neutral pH and low 
phagosomal proteolytic activity within the first few hours after phagocytosis are thought 
to favor cross-presentation by bone marrow-derived DC (BMDC) (Mantegazza et al., 
2008; Savina et al., 2009). The recruitment of NADPH oxidase (NOX2) to the 
phagosomes/endosomes is important for maintaining a neutral pH in the phagosomal 
lumen, thus inhibiting rapid degradation of antigens. Interestingly, CD8 splenic DC, but 
not CD8- splenic DC, alkalinize their phagosomes/endosomes in a NOX2 dependant 
manner (Savina et al., 2009).  
Finally, exploring factors that determine the induction of tolerance or activation of 
CD8 T cell responses against apoptotic cell-associated antigens is an emerging area in the 
field of antigen cross-presentation. The mode of administration is one determinant of 
ensuing CD8 T cell fate. Whereas intravenous delivery of antigen bearing apoptotic cells 
induces CD8 T cell tolerance (Qiu et al., 2009), subcutaneous injection of apoptotic cells 
induces an effector response (Asano et al., 2011; Obeid et al., 2007b). However, not all 
modes of cell death are immunogenic (Obeid et al., 2007b). Determining what types of 
cell death are immunogenic and the mechanism behind the immunogenicity is of great 
relevance for the chemotherapeutic treatment of solid tumors (reviewed in (Kepp et al., 
2011)).  
Role of heat shock proteins in the cross-presentation of soluble antigen 
Heat shock proteins (HSP), including calreticulin, gp96, HSP90 and HSP70, bind 
immunogenic peptides (Basu and Srivastava, 1999; Binder and Srivastava, 2005). 
Exogenously delivered HSP-peptide complexes enhance the cross-presentation of 
associated peptides to CD8 T cells (Basu et al., 2001; Basu and Srivastava, 1999). 
Additionally, immunizing mice with HSPs isolated from tumor cells results in protection 
from a subsequent live tumor challenge (Basu and Srivastava, 1999; Binder and 
Srivastava, 2004; Nair et al., 1999). The advantage to this immunization method is that 
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specific antigenic tumor peptides do not need to be identified. Clinical trials have been 
undertaken using autologous HSP from patients with established tumors. Vitespan (aka 
Prophage), an autologous tumor-derived HSP gp96-peptide complex vaccine, showed 
promise in Phase III clinical trials for treatment of Stage IV melanoma (Testori et al., 
2008). Notably, this treatment has already been approved in Russia to treat patients who 
are at an intermediate risk for disease (kidney cancer) recurrence. In addition to HSPs 
isolated from tumor cells, the engineered surface expression of gp96 on tumor cells or 
secretion of gp96 from cells has been shown to elicit a more potent immune response 
against the cells compared to cells that do secrete or express surface gp96 [reviewed in 
(Tsan and Gao, 2009)]. 
The immunogenicity of autologous HSPs derived from established tumors is 
attributed to the binding of HSPs including gp96, calreticulin and HSP70 to the APC 
receptor CD91 (Basu et al., 2001). It is hypothesized that HSPs target associated peptides 
directly to APCs via CD91. CD91-mediated uptake of the HSP facilitates the enhanced 
uptake and cross-presentation of HSP-associated peptides. In addition to CD91, HSPs 
have been shown to bind to other scavenger receptors. LOX-1 has been shown to bind 
and facilitate the cross-presentation of HSP70 associated antigen (Delneste, 2004). 
Scavenger receptor-A and scavenger receptor expressed by endothelial cell-I (SREC-I) 
have been shown to mediate the internalization of gp96 and calreticulin (Berwin et al., 
2004; Berwin et al., 2003). SREC-I has also been shown to internalize and cross-present 
HSP90 associated antigen (Murshid et al., 2010). It is apparent that there are a number of 
different phagocytic receptors that facilitate the uptake of a number of different HSPs. It 
is therefore not surprising that cross-priming of CD8 T cells was not negatively impacted 
when a single HSP (gp96) was knocked down in vivo (Lev et al., 2009). All together, 
these studies suggest redundancy in HSPs and their receptors.  
The success of HSP-based vaccines may also be attributed to the ability of the 
HSPs to protect the associated peptides from rapid degradation in the extracellular 
environment, thus preserving antigen for cross-presentation. Alternatively, the ability of 
HSPs to signal through CD91 and induce the activation of pro-inflammatory cytokines 
may be the factor determining the immunogenicity of HSP-peptide complexes (Pawaria 
and Binder, 2011) rather than their enhanced cross-presentation. It has been suggested 
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that HPSs directly activate APCs, inducing them to secrete a wide array of pro-
inflammatory cytokines and upregulate co-stimulatory molecules. In this model, HSPs 
serve as “danger signals.” However, when controlled for specific TLR stimuli, 
stimulatory effects of HSPs are lost [reviewed in (Tsan and Gao, 2009)]. 
We assessed whether calreticulin enhances the cross-presentation of an associated 
soluble antigen. In Chapter 3, we accomplished this by assessing whether proliferation of 
naïve CD8 T cells in vitro and in vivo was enhanced in response to a calreticulin-
associated antigen (fusion or bead-associated) compared to the antigen alone.  
Role of calreticulin in the efferocytosis of cells 
 Receptors, ligands and pathways involved in the uptake of apoptotic cells are 
different than those involved in phagocytosis of antibody-mediated opsonized particles or 
cells. Hence, the phagocytosis of dying cells has been termed “efferocytosis” to 
distinguish it from other types of phagocytosis [reviewed in (Gardai et al., 2006)]. 
Apoptotic cells express a number of cell-surface phagocytic molecules that distinguish 
them from live cells. These molecules are termed “eat me” signals, as they induce the 
uptake and clearance of apoptotic cells (reviewed in (Erwig and Henson, 2008) and 
(Gardai et al., 2006)). The most widely characterized of these molecules is 
phosphatidylserine (PS). PS is normally located on the inner leaflet of the plasma 
membrane. However, it is found on the outer leaflet of apoptotic cells due to the 
inhibition of a translocase that normally localizes PS to the outer leaflet and the 
scrambling of the lipid bilayer (Bratton et al., 1997; Verhoven et al., 1995). A number of 
bridging molecules have been shown to bind PS and bridge apoptotic cells to receptors on 
efferocytes (cells that phagocytose apoptotic cells) [reviewed in (Ravichandran, 2011)]. 
Calreticulin has also been identified as an “eat me” signal on apoptotic and pre-apoptotic 
cells; CD91 is the proposed receptor that binds calreticulin on the cell-surface (Gardai et 
al., 2005; Kuraishi et al., 2007; Obeid et al., 2007b). Collectins have also been shown to 
bind to and opsonize apoptotic cells to mediate efferocytosis. Interestingly, C1q (a 
member of the collected family) has been shown to bind calreticulin. It is possible that 
C1q binds calreticulin on apoptotic cells, enhancing the number of “eat me” signals on 
the apoptotic cell or that a C1q coated apoptotic cell binds low levels of surface 
calreticulin on efferocytes. “Don’t eat me” molecules are typically present on live cells 
! ##!
and downregulated or redistributed on apoptotic cells. CD47 is the best-characterized 
“don’t eat me” signal, binding SIRP" on the phagocyte (Gardai et al., 2005; Oldenborg et 
al., 2000). The balance between “eat me” and “don’t eat me” signals determines the 
phagocytic fate of a cell (Figure 1.9). In addition, clustering of “eat me” signals in 
patches removed of “don’t eat me” signals may be an additional mechanism to mediate 





Figure 1.9. Surface ligands on cells mediate their removal. Live healthy cells express low 
levels of the “eat me” signals calreticulin and PS and high levels of the “don’t eat me” 
signal CD47. Apoptotic cells upregulate both calreticulin and PS and downregulate 
CD47. The balance is shifted towards “eat me,” and the dying cell is engulfed by an 
efferocyte. CD91 and SIRP" are known receptors for calreticulin and CD47, 
respectively. A number of receptors recognize PS directly including TIM-4, BAI1 and 
Stabilin-2. Soluble extracellular bridging molecules, such as MFG-E8, can also bind PS 
and facilitate uptake of apoptotic cells by binding to receptors on effectocytes [reviewed 






Immunogenicity of cell-surface and extracellular calreticulin 
 Calreticulin is upregulated on apoptotic murine cells and is redistributed on 
Drosophila cells in response to UV-irradiation. Both the upregulation and redistribution 
of calreticulin result in calreticulin-dependant phagocytosis of the treated cells (Gardai et 
al., 2005; Kuraishi et al., 2007). Calreticulin is also upregulated on the surface of pre-
apoptotic (cells that have yet not upregulated PS) tumor cells treated with anthracyclins, 
oxaliplatin or ionizing radiation (Obeid et al., 2007a; Obeid et al., 2007b; Tesniere et al., 
2010). These treatments induce immunogenic tumor cell death, which is partially 
dependant on calreticulin (reviewed in (Kepp et al., 2011)). Specifically, mice immunized 
with calreticulin deficient tumor cells treated with drug form tumors at high frequencies 
in subsequent live tumor challenges compared to mice immunized with calreticulin 
sufficient drug-treated cells (Obeid et al., 2007b). Thus, the presence of calreticulin in the 
immunizing cell population enhances the generation of an anti-tumor immune response. 
The immunogenicity of tumor cells induced by anthracyclins, oxaliplatin and ionizing 
radiation is linked to: (1) the upregulation of surface calreticulin (an “eat me signal”) and 
(2) the secretion of HMGB1 and ATP (both “danger signals”). It is suggested that the 
ability of calreticulin to facilitate uptake of the tumor cells treated with drug enhances 
antigen delivery to APCs, thus enhancing CD8 T cell cross-priming against tumor cell-
associated antigens. However, this possibility has not been directly demonstrated.  
In Chapter 3, we evaluated the impact of calreticulin induction on the surface of 
an antigen donor cell upon CD8 T cell proliferation in response to cell-associated antigen.  
 
Effect of innate signaling on the cross-presentation of cell-associated antigen 
The effect of innate signaling on antigen presentation has just recently been explored. 
Within an APC, each phagosome is autonomous, and only those that contain a TLR 
ligand mature and load exogenously derived peptides on MHC class II molecules. Hence, 
naïve murine CD4 T cells do not proliferate or secrete IFN# in response to apoptotic cell-
associated antigens, even in the presence of bacteria because the phagosomes containing 
apoptotic cells lack TLR ligands that are necessary for efficient MHC class II antigen 
presentation (Blander and Medzhitov, 2006). Surprisingly, in contrast to CD4 T cells, 
CD8 T cells proliferate and are activated in response to apoptotic cell-associated antigen 
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(Frleta et al., 2009). However, proliferation and cytotoxicity are inhibited when the 
apoptotic cell expresses a TLR ligand. The observed CD8 T cell inhibition suggests that 
CD8 T cell activation against apoptotic cell-associated antigen is inhibited the presence 
TLR stimuli.  
Studies examining T cell responses to apoptotic cell-associated antigen in the 
presence of TLR ligands have mostly been performed in vitro. The in vivo T cell response 
to apoptotic cell-associated antigen in the presence of innate signaling is not well 
characterized. In Chapter 3 we examined the proliferation of naïve CD8 T cells to cell-
associated antigen in the presence of lipopolysaccharide (LPS).  
 
 In summary, we posed a number of questions relating to the functions of 
calreticulin in antigen presentation. First, we investigated the relevant mode of 
calreticulin recruitment into the PLC (as MHC class I molecules are the best-
characterized substrates of calreticulin). To this end, understanding the interactions that 
mediate calreticulin recruitment into the PLC would elucidate mechanisms for MHC 
class I assembly and mechanisms of the general chaperone function of calreticulin. 
Following this, we sought to determine the role of calreticulin in antigen cross-
presentation. It is expected that a more complete understanding of the role of calreticulin 
in antigen cross-presentation would be a valuable initial step towards the development of 











Modes of calreticulin recruitment to the Major Histocompatibility Complex 
Assembly pathway 
Abstract 
MHC class I molecules are ligands for TCRs of CD8 T cells and inhibitory receptors of 
natural killer cells. Assembly of the heavy chain, light chain, and peptide components of 
MHC class I molecules occurs in the ER. Specific assembly factors and generic ER 
chaperones, collectively called the MHC class I PLC, are required for MHC class I 
assembly. Calreticulin has an important role within the PLC and induces MHC class I 
cell surface expression, but the interactions and mechanisms involved are incompletely 
understood. We show that interactions with the thiol oxidoreductase ERp57 and substrate 
glycans are important for the recruitment of calreticulin into the PLC and for its 
functional activities in MHC class I assembly. Additionally, we show that !2m promotes 
calreticulin and ERp57 stabilization within the PLC through direct or indirect 
interactions. The glycan and ERp57 binding sites of calreticulin contribute directly or 
indirectly to complexes between calreticulin and the MHC class I assembly factor tapasin 
and are important for maintaining steady-state levels of both tapasin and MHC class I 
heavy chains. A number of destabilizing conditions and mutations induce generic 
polypeptide binding sites on calreticulin and contribute to calreticulin-mediated 
suppression of misfolded protein aggregation in vitro. We show that generic polypeptide 
binding sites per se are insufficient for stable recruitment of calreticulin to PLC 
substrates in cells. However, such binding sites could contribute to substrate stabilization 




Calreticulin is a soluble protein of the ER, where it functions in calcium binding and as a 
molecular chaperone (Michalak et al., 2009). Calreticulin binds to monoglucoslyated N-
linked oligosaccharides on newly synthesized glycoproteins and maintains quality control 
of glycoprotein folding in the ER. A structural model for calreticulin was derived (Figure 
2.1A) using the crystal structure of the calreticulin globular domain (Kozlov et al., 2010) 
and the crystal structure of the closely related protein, calnexin (Schrag et al., 2001). 
Calreticulin contains three structural domains. The first is a large globular domain 
comprising the N- and C-terminal regions of the protein that form a !-stranded sandwich 
and a C-terminal helix (Figure 2.1A, green, dark blue, and light blue). The glycan binding 
site is located within this domain (Figure 2.1B). A second hook- shaped P-domain forms 
a !-stranded hairpin structure inserted in the middle of the globular domain (Figure 2.1A, 
purple). The tip of this domain forms a binding site for ERp57 (Frickel et al., 2002), an 
ER oxidoreductase that works cooperatively with calreticulin and calnexin in 
glycoprotein folding (Oliver et al., 1999). A third C-terminal domain, rich in acidic 
amino acids, is functional as a low affinity/high capacity calcium coordination site 




Figure 2.1. Structural model for calreticulin and depiction of truncation mutants and 
glycan-binding site. (A) A model for the calreticulin structure was based on the crystal 
structure of the calreticulin globular domain (PDB ID 3O0V) (Kozlov et al., 2010) and 
calnexin (PDB ID 1JHN) (Schrag et al., 2001). Calreticulin residues 1-32 are depicted in 
green. The C-terminal helix is depicted in light blue, and the core calreticulin structure in 
shown in dark blue. The P-domain is depicted in purple. The C-terminal acidic domain is 
not included in the model. This model was built by Sanjeeva J. Wijeyesakere. (B) 
Putative glycan-binding residues of calreticulin are highlighted in purple, and the region 
of the calreticulin model corresponding to the glycan binding site is boxed. This model 
was based on the crystal structure of the calreticulin globular domain (PDB ID 3O0V). 
Mutagenesis studies and recent crystal structure studies (Gopalakrishnapai et al., 2006; 






 In vitro studies have shown that calreticulin can bind to misfolded non-glycosylated 
polypeptides and suppress their irreversible aggregation (Saito et al., 1999). This activity 
is induced by various conditions associated with ER stress, including calcium depletion 
and heat shock (Rizvi et al., 2004). These conditions also induce calreticulin 
oligomerization (Jorgensen et al., 2003; Rizvi et al., 2004). Much remains to be 
understood about the one or more binding sites on calreticulin that are used to suppress 
substrate aggregation, as well as the relevance of this activity to calreticulin-mediated 
protein folding under physiological non-stress conditions. 
Calreticulin is a key player in the MHC class I assembly pathway (Gao et al., 
2002). The MHC class I-dedicated assembly factors, TAP and tapasin, as well as the 
generic ER-folding factors ERp57 and calreticulin, form a large complex with MHC class 
I molecules, collectively called the PLC. TAP provides a major source of peptides for 
MHC class I molecules, whereas tapasin, ERp57, and calreticulin facilitate assembly of 
MHC class I molecules with peptides [reviewed in (Raghavan et al., 2008)]. Calreticulin 
is a component of the PLC, and calreticulin-deficient cells express reduced cell surface 
MHC class I molecules (Gao et al., 2002). The mechanisms by which calreticulin 
contributes to enhanced MHC class I assembly are not well understood. 
 Early studies with glycosylation inhibitors, MHC class I mutants, and in vitro 
binding analyses suggested that glycan-based interactions with MHC class I molecules 
recruit calreticulin into the PLC (Harris et al., 1998; Sadasivan et al., 1996; Wearsch et 
al., 2004). More recent studies with calreticulin mutants that are defective for glycan or 
ERp57 binding have suggested that calreticulin can be recruited into the PLC in the 
absence of interactions with both ERp57 and substrate glycans and that polypeptide-
based interactions are important for calreticulin recruitment (Ireland et al., 2008; Zhang et 
al., 2009). However, partial truncation of the P-domain of calreticulin (including residues 
mediating ERp57 binding) impacted calreticulin recruitment to the PLC (Zhang et al., 
2009), and ERp57- and tapasin-deficient cells have impaired recruitment of calreticulin 
into the PLC (Garbi et al., 2006; Grandea et al., 2000). Thus, although MHC class I 
molecules are one of the best-characterized substrates of calreticulin, the precise 
mechanism by which calreticulin is recruited into the PLC remains unclear. Furthermore, 
whereas numerous studies involving glycosylation inhibitors and substrates lacking 
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glycans have shown that the presence of monoglucosylated glycans on substrate 
glycoproteins are important for calreticulin binding and ER quality control, whether or 
not substrate glycans alone are sufficient for calreticulin recruitment is not well 
understood, and neither is the molecular basis for differences in substrate profiles 
between calnexin and calreticulin. Additionally the roles of ERp57, polypeptide-based, 
and other interactions in substrate recruitment to calreticulin have not been well studied. 
To address some of these questions, various truncation mutants targeting different 
domains of calreticulin and point mutants targeting glycan and ERp57 binding residues 
were generated. These constructs were used to understand the impacts of truncations and 
mutations on calreticulin structure and stability, to investigate modes of calreticulin 
binding to PLC components, and to examine reconstitution of MHC class I assembly in 
calreticulin-deficient cells. With these mutants we were able to show that calreticulin 
recruitment into the PLC is largely dependant on glycan- and ERp57-based interactions. 
Additionally, tapasin and MHC class I glycan mutants were generated and expressed in 
tapasin deficient and MHC class I deficient cells, respectively, to show that the glycan of 
tapasin influences calreticulin recruitment into the PLC more so than that of the MHC 
class I heavy chain. 
Results 
C- and N-terminal Truncations Destabilize Monomers of Calreticulin 
The first 32 residues of the calreticulin globular domain lack significant predicted 
secondary structure, with the exception of a short !-strand. Near the calreticulin C 
terminus, preceding the acidic domain is an "-helix, the major predicted helix in the 
calreticulin structure (Figure 2.1). Based on these predicted structural features, we made 
truncated versions of calreticulin using Ala-1 and Val-33 as start sites, and Asp-318, Gln-
339, Glu-362, and Leu-399 as stop sites. Asp-318 truncates the protein prior to the C-
terminal helix, Gln-339 truncates the protein following the C-terminal helix and just prior 
to the acidic region, whereas Glu-362 extends the calreticulin sequence several residues 
into the C-terminal acidic domain and just prior to the end of the C-terminal helix. A 
construct in which the entire P-domain of calreticulin was deleted (amino acids 187–283) 
and replaced by two glycine residues was also generated. 
 Following protein expression in E. coli and purification on a nickel column, gel-
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filtration analysis indicated that full-length calreticulin, mCRT1–399 (mCRT(WT)), was 
present largely in the monomeric form (Sp1, Figure 2.2A), as expected. Native PAGE 
analysis of purified protein verified that mCRT(WT) (12 µM) was largely monomeric at 
4 °C, in the presence of 1 mM CaCl2 (Figure 2.2D, lane 1). As previously described 
(Jorgensen et al., 2003; Rizvi et al., 2004), the formation of dimers and oligomers of 
mCRT(WT) was induced by heat treatment or calcium depletion (Figure 2.2D, lane 1 
compared with lanes 2–4). C-terminal deletion constructs mCRT1–362 and mCRT1–339 
(mCRT(%C)) were also largely monomeric, although the extent of oligomeric forms of 
these proteins was enhanced relative to mCRT(WT) (Figure 2.2A). In response to heat 
treatment or calcium depletion, dimeric and oligomeric structures were enhanced for 
mCRT1–362 and mCRT1–339 (mCRT(%C)), relative to mCRT(WT) (Figure 2.2, compare 
D–F). Additional deletion of the C-terminal helix (mCRT1–318) dramatically affected 
calreticulin structure (Figure 2.2A). No monomers were recovered from the purification 
(Figure 2.2, A and G), and the major peak migrated in the column void volume. This 
construct was not used further in this study. 
 N-terminal truncation of calreticulin (mCRT33–362) also impacted calreticulin 
structure (Figure 2.2B). Oligomeric species were recovered, and monomers were absent. 
Different oligomeric forms were classified based on the gel-filtration chromatograms and 
native PAGE analyses as: Sp3, consisting largely of the dimeric form of the protein and 
Sp4 and Sp5, consisting of higher order oligomeric forms (Figure 2.2, A, B, G, and H). 
         The calreticulin %P mutant (mCRT(%P)) was recoverable as monomers following 
purification, as were mCRT(%C), mCRT1–362 , and mCRT(WT) (Figure 2.2C). The 
oligomerization phenotype for mCRT(%P) resembled that of mCRT(WT) (Figure 2.2I). 
 A thermostability assay was next used to compare heat-induced unfolding of mCRT 
constructs. A fluorescent dye (Sypro Orange) was used that displays enhanced binding to 
proteins following thermal unfolding. CD studies at 280 nm have previously revealed the 
occurrence of a conformational change in human calreticulin, which has a transition 
midpoint (Tm) value of 46.4 °C in the presence of 1 mM CaCl2 (Li et al., 2001). A similar 
Tm value was measured for mCRT(WT) in the Sypro Orange-based thermostability assay 
(Tm value 47.96 +/- 0.21 °C) (Figure 2.2J). In the presence of the calreticulin-binding 
glycan Glc"1–3Man"1– 2Man"1–2Man-OH (G1M3), the Tm value was significantly 
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right-shifted to 51.08 +/- 0.18°C indicating that the glycan had slightly stabilized 
calreticulin. Both mCRT(%P) and mCRT(%C) displayed fluorescence profiles similar to 
those obtained with mCRT(WT), and both were right-shifted by G1M3 (Figure 2.2, K 
and L). However, the Tm value measured for mCRT(%C) was 44.29 +/- 0.44 °C in the 
absence of G1M3, and 46.91 +/- 0.17 °C in the presence of G1M3. These findings 
indicate that mCRT(%C) is less resistant to heat-induced structural changes than 
mCRT(WT). However, mCRT(%C) was able to bind to and be stabilized by G1M3, as 
was mCRT(%P) (Table 2.1). Different species of the oligomeric mCRT33–362 construct did 
not display thermostability profiles resembling those of mCRT(WT) and did not bind 
G1M3 as indicated by the thermostability-shift assays (data not shown) and, therefore, 
are not described further in this study.  
 A Biacore-based assay was used to measure ERp57 binding to the monomeric 
truncation constructs. mCRT(WT) and mCRT(%C) bound to ERp57, whereas binding 
was essentially undetectable with mCRT(%P), as expected (Frickel et al., 2002) (Figure 
2.2M). Calculated KD values were 0.55 +/- 0.26 µM and 1.2 +/- 0.8!µM, respectively, for 






Figure 2.2. Impacts of calreticulin domains on structure and functional activities. 
Analytical gel-filtration chromatography of C-terminal (A), N-terminal (B), and P-
domain (C) truncation mutants of mCRT. All constructs were directly analyzed following 
nickel affinity chromatography, except mCRT(%P) for which monomers were first 
isolated by gel filtration and then re-analyzed by a second analytical gel-filtration step 
shown. Following gel-filtration chromatography, peak fractions were analyzed by native-
PAGE following protein (12 µM) incubations for 1 h in 1 mM CaCl2 or 10 mM EDTA at 
4 or 42 °C (D–F and I). Fractions corresponding to the indicated oligomeric species 
(Sp2–Sp5) of mCRT1–318 or mCRT33–362 were directly analyzed by native PAGE (1 mM 
CaCl2, 4 °C) (G and H). One representative analysis is shown of two or more independent 
analyses. J–L, monomeric mCRT constructs were incubated with the fluorophore SYPRO 
Orange and subjected to a thermal stability analysis using a real-time PCR machine. 
Normalized fluorescence data (mean of triplicate wells ±S.E.) for one of three 
independent experiments are shown. Compiled Tm values for all constructs discussed in 
this report are shown in Table 2.1. M and N, mCRT constructs were immobilized on a 
Biacore CM5 chip to response unit (RU) values of 438, 426, and 480 (respectively, for 
WT, %P, and %C), and human ERp57 was injected over each surface or a control bovine 
serum albumin surface. Representative sensorgrams following subtraction of 
corresponding sensorgrams from the bovine serum albumin surface are shown in M. 
Dose-response graphs for binding constant calculations are shown in N. One 
representative of two (%C and %P) or five (WT) independent analyses of N are shown. 
Analyses shown in 2.2A, B, and D-H were performed by Ericca Stamper. Analyses 
shown in 2.2J-L were performed by Elise Jeffery. Analyses shown in 2.2M and N were 
performed by Syed Monem Rizvi.   
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Constructs Protein Protein + G1M3 Protein + ATP 
 Tm       SEM        n Tm       SEM        n Tm        SEM       n  
mCRT(WT) 47.96 ± 0.21 5 51.08 ± 0.18 5 46.24 ± 0.02 2 
 
mCRT(%C) 44.29 ± 0.44 3 46.91 ± 0.17 3 --- 
 
mCRT(%P) 47.63 ± 0.07 3 51.00 ± 0.27 3 45.49 ± 0.13 2 
 
mCRT(Y92A) 45.90 ± 0.31 2 46.23 ± 0.28 2 --- 
 
mCRT(W244A) 46.59 ± 0.46 2 50.74 ± 0.03 2 --- 
 
mCRT(Y92AW244A) 42.96 ± 0.55 2 43.82 ± 0.01 2 --- 
 
mCRT(W302A) 44.82 ± 0.55 3 45.67 ± 0.55 3 --- 
 
Table 2.1. Thermostability analyses of calreticulin constructs from SYPRO Orange 
binding assays. Indicated mCRT constructs (left column) were incubated with the 
fluorophore SYPRO Orange and subjected to a thermal stability analysis using a real time 
PCR machine. Proteins (16 µM ) were incubated alone (Protein), with 48 µM G1M3 
(Protein + G1M3), or with 3 mM ATP (Protein + ATP). Each condition was analyzed in 
triplicate within an experiment. For each experiment, mean % maximum fluorescence 
values from triplicate wells were plotted as a function of temperature, and Tm values were 
estimated as the temperatures at which 50% of the maximum fluorescence was observed. 
Tm values shown are the averaged Tm values from n independent experiments for each 
condition, SEM represents the standard error of the estimated mean Tm values. Analyses 





Compared with mCRT(WT), mCRT1–339 (%C) and mCRT(%P) Have Reduced 
Abilities to Mediate MHC Class I Assembly in CRT-/- Cells 
Calreticulin-deficient cells (K42) express reduced cell surface MHC class I, which can be 
restored by expression of wild-type calreticulin (Gao et al., 2002). Impacts of mCRT(%C) 
and mCRT(%P) truncations upon this activity were next assessed. The pMSCV-puro and 
pMSCV-ires-GFP viral vectors were utilized for stable and transient expressions, 
respectively. A small but reproducible induction of surface MHC class I (Kb) molecules 
was observed when K42 cells were infected with viruses encoding mCRT(WT) compared 
with those infected with viruses lacking the calreticulin DNA (Figure 2.3A). Using the 
pMSCV-puro viral vector system, mCRT(%P) was significantly impaired in the ability to 
induce the surface expression of the MHC class I allele H2-Kb relative to mCRT(WT) 
(Figure 2.3A; p-values of 0.0160 and 0.0089 were obtained using the antibodies Y3 and 
AF6, respectively). An impairment was also observed in the ability of mCRT(%P) to 
induce the surface expression of the MHC class I allele H2-Db compared to mCRT(WT), 
however the impairment did not reach statistical significance (Figure 2.3A; p=0.0823). 
Additionally, using the pMSCV-ires-GFP viral vector system, mCRT(%P) was impaired 
in the ability to induce the surface MHC class I allele H2-Kb relative to mCRT(WT), 
however the impairment did not reach significance (Figure 2.3A; p=0.0566).  Using both 
vector systems, a reduction in MHC class I cell-surface expression was also observed in 
the context of mCRT(%C) compared to mCRT(WT), although the reduction did not reach 
significance (Figure 2.3A). 
 Additional assays were developed to compare functional activities of the different 
calreticulin constructs. We noted that steady-state levels of tapasin and MHC class I 
heavy chains were significantly reduced in cells lacking mCRT compared with cells 
expressing mCRT(WT) (Figure 2.3B, lysates panels). This was a consistent phenotype in 
the lysate analyses. Cells expressing mCRT(%P) and mCRT(%C) also displayed lower 
steady-state levels of tapasin and MHC class I heavy chains, a phenotype that was more 
pronounced for mCRT(%P) compared with mCRT(%C) (Figure 2.3B, lysates panels and 
tapasin and MHC class I blots). Lower steady-state protein level was not a general 
phenotype of all ER proteins in K42 cells that lacked calreticulin. For example, ERp57 
levels appeared enhanced rather than reduced in the absence of calreticulin (Figure 2.3B, 
! $&!
lysates panels and ERp57 blots). 
 To assess interactions between PLC components, immunoprecipitations were first 
performed with a calreticulin-specific antibody, and immunoblotting analyses were 
undertaken with antibodies directed against different PLC components (Figure 2.3B, 
CRT IP). A strong signal for tapasin was observed with mCRT(WT) and mCRT(%C), 
whereas tapasin binding to mCRT(%P) was impaired (Figure 2.3B, CRT IP and tapasin 
blot). ERp57 binding to mCRT(WT) and mCRT(%C) was weakly detected in some 
assays (for example, Figure 2.3B, CRT IP and ERp57 blot), and undetectable in other 
assays (Figure 2.4, ERp57 blot), whereas ERp57 binding to mCRT(%P) was undetectable 
in all analyses. These results suggest that the known P domain-dependent calreticulin-
ERp57 interaction (Frickel et al., 2002) was at the detection threshold of these 
immunoprecipitation reactions. Tapasin forms a disulfide-linked heterodimer with 
ERp57, an interaction that is observable only if thiol-modifying agents are included 
during cell lysis (Peaper et al., 2005). Thiol-modifying agents modify free cysteines, thus 
preventing the disruption of pre-formed disulfide bonds (tapasin-ERp57). A thiol-
modifying agent, N-Ethylmaleimide (NEM), was not required to observe the calreticulin-
tapasin interaction (Figure 2.3B, tapasin blot, compare signals +/- NEM). MHC class I 
molecules were not detectable in the anti-calreticulin immunoprecipitations (Figure 2.4, 
MHC class I blot), indicating that glycan-based interactions between MHC class I and 
calreticulin per se are insufficient for stable detection of complex formation between 
these proteins. 
 Anti-TAP1 immunoprecipitations revealed incorporation of mCRT(%C) into the 
MHC class I PLC and a deficiency in mCRT(%P) incorporation, when expressed at levels 
similar to mCRT(%C) (Figure 2.3C, CRT blot and lanes 2, 3, 9, and 10). Tapasin was 
incorporated into the PLC of all cells (Figure 2.3C, tapasin blot and lanes 8 –11). Levels 
of MHC class I detectable within the PLC were reflective of steady-state levels of MHC 
class I, most readily detectable with mCRT(WT), and very weakly detectable with 
mCRT(%P) or cells expressing the control vector (Figure 2.3C, MHC class I blot and 
lanes 8 –11). Thus, although PLCs are observable in calreticulin-deficient cells as 
previously noted (Gao et al., 2002), the efficiency of incorporation of MHC class I 
molecules is significantly impacted by calreticulin deficiency. 
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 Immunoprecipitations with an anti-MHC class I antibody revealed that MHC class I 
binding to tapasin was most readily detectable in the context of mCRT(WT), with 
significant reductions noted in other cells (Figure 2.3D, tapasin blot and lane 8 compared 
with lanes 9 –11), reflective of alterations in steady-state levels of tapasin. Additionally, 
ERp57 binding to MHC class I was also most readily detectable in the context of 
mCRT(WT) (Figure 2.3D, ERp57 blot and lane 8 compared with lanes 9 –11). A very 
weak signal for mCRT(WT) was observed in the anti-MHC class I immunoprecipitations 
in two of four experiments (Figure 2.3D, CRT blot and lane 8; a nonspecific band is 
visualized just below this band), indicating this was also a weak interaction at the 
detection threshold. Neither of the two mutant calreticulin constructs was observable in 
these assays. 
 Together the results in Figure 2.3 indicated that calreticulin deficiency reduced 
steady-state levels of tapasin and MHC class I heavy chains and cell surface expression 
of MHC class I. Tapasin-calreticulin binding was readily detectable and abolished by the 
mCRT(%P) mutation, which also negatively impacted calreticulin and MHC class I 
incorporation into the PLC. Furthermore, the mCRT(%C) mutation reduced steady-state 





Figure 2.3. mCRT(%C) and mCRT(%P) have reduced abilities to mediate MHC class I 
assembly in calreticulin-deficient (K42) cells. A, flow cytometric analyses of cell surface 
expression of MHC class I on K42 cells infected with retroviruses generated with 
pMSCV-puro (left three sets of bar graphs) or pMSCV- ires-GFP (bar graph set on the 
extreme right) encoding indicated mCRT constructs or control virus lacking CRT. The -
fold induction of mean fluorescence relative to parallel control infections with vector 
alone is indicated. Y3 (anti-H2-Kb), AF6 (anti-H2-Kb), or 28-14-8S (anti-H2-Db) 
antibodies were used in the analyses as indicated. Data are averaged over seven 
independent analyses from four separate infection (Y3, left (MSCV-puro) panel), six 
independent analyses from two separate infection (AF6 and 28-14-8S panels), and three 
independent analyses from two separate infections (Y3, right (MSCV-IRES-GFP) panel). 
A pair-wise student t-test was used for statistical analysis. Mean ± s.e.m. is shown. B–D, 
immunoprecipitations from cells expressing indicated mCRT constructs or control 
vector-infected cells with anti-calreticulin (B) anti-TAP1 (C) or anti-MHC class I (D). 
Immunoblotting analyses of indicated cell lysates or immunoprecipitates were undertaken 
with antibodies directed against various PLC components. Lysates were generated in the 
presence or absence of NEM (B). Data are representative of five, two, or three 
independent analyses, respectively, for B–D. No antibody (No Ab) controls were 
performed by incubating indicated lysates with beads, and Buffer (Buf) indicates signals 





Figure 2.4. Calreticulin is required for the stabilization of the MHC class I – tapasin 
interaction within the PLC. The indicated cell lines were lysed in a digitonin lysis buffer. 
A rabbit anti-calreticulin antibody was used for the immunoprecipitation; lysates and 
samples were immunoblotted with goat anti-calreticulin, hamster anti-tapasin, or rabbit 
anti-ERp57 and anti-MHC class I antibodies. No antibody (No Ab) controls were 
performed by incubating indicated lysates with beads, and Buffer (Buf) indicates signals 
obtained with antibody alone (without lysates). NS indicates non-specific bands. 
 
The mCRT(%C) truncation impacts ER retention of calreticulin 
Truncating the acidic domain of calreticulin (mCRT(%C)) negatively impacted the 
stability of  the PLC and steady-state levels of tapasin and MHC class I (Figures 2.3). The 
acidic domain of calreticulin is functional as a low affinity/high capacity calcium 
coordination site. Accordingly, calreticulin deficient cells have a reduced level of calcium 
storage capacity, which affects agonist-mediated calcium release from the ER [reviewed 
in (Michalak et al., 2009)]. Additionally, previous studies have suggested that the C-
terminal domain of calreticulin, in part, mediates its ER retention (Sonnichsen et al., 
1994). To verify the latter results, we assessed whether mCRT(%C) displayed impaired 
ER retention in our system. Immunoprecipitations were performed with an anti-
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calreticulin antibody on supernatants of K42 cells expressing mCRT(WT), mCRT(%C) or 
mCRT(vec). Notably, the mCRT(%C) construct encodes a C-terminal KDEL motif, 
similar to mCRT(WT). Whereas mCRT(WT) was faintly detectable in the supernatant, 
mCRT(%C) was readily detectable (Figure 2.5, lane 4 compares to lane 5), in agreement 
with the previously published finding that the C-terminal domain of calreticulin is 
involved in the ER localization of calreticulin (Sonnichsen et al., 1994). Thus, inefficient 
ER retention of mCRT(%C) could in part explain the inefficiency of this construct in 
stabilizing interactions within the PLC and maintaining high steady state levels of MHC 
class I heavy chains and tapasin.  
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Figure 2.5. The C terminal domain of calreticulin mediates cellular retention of 
calreticulin. Immunoblotting analyses of indicated K42 cell lysates (lanes 1-3) and anti-
calreticulin immunoprecipitations (IP) of cell supernatants (lanes 4-6). Indicated cells 
were incubated at 37 °C for forty-eight hours before the anti-calreticulin 
immunoprecipitation was performed on cell supernatants. Data are representative of a 






Point Mutations Targeting the ERp57 and Glycan Binding Sites of Calreticulin 
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Impact the Efficiencies of Calreticulin-Tapasin Binding, Stabilization of Tapasin 
and MHC Class I, and Calreticulin Recruitment to the PLC 
Mutations of calreticulin at residues 92 (within the predicted glycan binding site of the 
globular domain, Figure 2.1B) and 244 (at the tip of the P domain) have previously been 
shown to strongly impact glycan and ERp57 binding, respectively (Kapoor et al., 2004; 
Martin et al., 2006); we assessed impacts of mutations at these sites upon MHC class I 
assembly. Following expression in E. coli and purification, mCRT(Y92A) and 
mCRT(Y92A/W244A) each eluted as a single major peak that was left-shifted compared 
with mCRT(WT) and mCRT(W244A) (Figure 2.6A). Native-PAGE revealed that the 
peak fraction of each protein was largely monomeric at 8 µM (37 °C, 0.5 mM CaCl2). 
Under these conditions, the double mutant showed a small induction of a dimer and 
oligomeric species (Figure 2.6B). These findings indicate that mCRT(Y92A) and 
mCRT(Y92A/W244A) equilibrate between monomeric and dimeric/higher order forms 
during purification (likely due to the high concentrations achieved during purification), 
but that the equilibriums shift predominantly to monomers at a concentration of 8 µM. 
The Tm values of mCRT(Y92A) and mCRT(W244A), 45.90 +/- 0.31 °C and 46.59 +/- 
0.46 °C, respectively, were slightly left-shifted relative to mCRT(WT) (47.96 +/- 0.21 
°C), and that of mCRT(Y92A/W244A) was more strongly left-shifted (42.96 +/- 0.55 
°C), indicating slightly lower resistance of the mutants to heat-induced structural changes 
(Figure 2.6C and Table 2.1). In the presence of G1M3, the Tm values for mCRT(Y92A) 
and mCRT(Y92A/W244A) did not significantly change, indicating these mutants are in 
fact deficient in glycan binding (Figure 2.6C and Table 2.1). Similar to mCRT(WT), the 
Tm value for mCRT(W244A) increased in the presence of G1M3 (50.74 +/- 0.03 °C) 
(Figure 2.6C and Table 2.1), verifying that this mutant binds glycans. ERp57 binding was 
strongly reduced with mCRT(W244A) and mCRT(Y92A/W244A) (Figure 2.6D; binding 
signals too low to allow for accurate KD value estimation), whereas mCRT(Y92A) 





Figure 2.6. Y92A, W244A, and Y92A/W244A mutants of mCRT display expected 
impairments in glycan and/or ERp57 binding. A, representative gel-filtration 
chromatograms of mCRT(WT), mCRT(Y92A), mCRT(W244A), and 
mCRT(Y92A/W244A) following nickel affinity purification. B, native PAGE analyses of 
pooled peak fractions from A, following incubation at 4 or 37 °C for 1 h (8 µM protein in 
1 mM CaCl2). C and D, thermostability and glycan and ERp57 binding analyses of 
indicated mCRT constructs were performed as described in Fig. 2.2. Data are 
representative of two independent sets of analyses, except ERp57 binding to the 
mCRT(Y92A/W244A), for which one analysis was performed. Analyses shown in 2.6C 







 With this knowledge of the conformational integrity and glycan and ERp57 binding 
phenotypes, mutants were expressed in K42 cells for further analyses. None of the 
mutants induced surface MHC class I to the same extent as mCRT(WT) (Figure 2.7A). 
Correlating with this result, and similar to the phenotypes seen with mCRT(%P), tapasin 
levels were reduced in the lysates of cells expressing mCRT(Y92A), mCRT(W244A), 
mCRT(Y92A/W244A), or the vector control (Figure 2.7B, lysate panels), despite the 
expression of the mutant calreticulin molecules at levels equal to or greater than 
mCRT(WT). 
 In anti-calreticulin-based immunoprecipitations, tapasin co-immunoprecipitation 
was essentially undetectable with each mutant, either in the presence or in the absence of 
NEM (Figure 2.7B, CRT IP, tapasin blot, and lanes 5–10). Anti-TAP1 
immunoprecipitations revealed reduced incorporation of mCRT(Y92A) and 
mCRT(W244A) and low or undetectable mCRT(Y92A/W244A) incorporation (Figure 
2.7C, CRT blot, and lanes 3– 6) despite expression of each mutant at a level similar to or 
greater than mCRT(WT). Correlating with lower steady-state MHC class I levels 
particularly in the context of mCRT(W244A) and mCRT(Y92A/W244A), and despite 
efficient tapasin incorporation into the PLC, reduced MHC class I incorporation into the 
PLC was also observed in K42 cells expressing each mutant (Figure 2.7C, MHC class I 
blot and lanes 3– 6). 
 Tyr-92 may be important for calreticulin binding to glycans of tapasin or MHC 
class I, as both proteins are glycosylated. To further examine the former possibility, K42 
cells expressing or lacking mCRT(WT) were pre-treated with the drug tunicamycin to 
block protein glycosylation to a point at which deglycosylated tapasin was the major 
observable species (Figure 2.7D, tapasin blot and lanes 2 and 4). Under these conditions, 
the major species that co-immunoprecipitated with calreticulin was the glycosylated form 
of tapasin, whereas de-glycosylated tapasin was the minor species (Figure 2.7D, tapasin 
blot and lane 8). These results suggest that the tapasin glycan contributes at least in part 
to the observed interactions between calreticulin and tapasin. However, the observation 
of the de-glycosylated tapasin band as a minor species in the anti-calreticulin 
immunoprecipitation suggests that there are additional modes of direct or indirect 
calreticulin-tapasin interactions that are independent of the tapasin glycan.  
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Figure 2.7. Y92A (Y), W244A (W), and Y92A/W244A (Y/W) mutants of mCRT are 
impaired in mediating MHC class I assembly. A, flow cytometric analyses were 
performed with the three indicated MHC class I-specific antibodies. The -fold induction 
of mean fluorescence by each mCRT relative to parallel control vector infections is 
indicated. Data are the averages of two to three independent experiments from a single 
infection. A pair-wise student t-test was used for statistical analysis where three 
independent experiments were performed. Mean ± s.e.m. is shown. B–D, 
immunoprecipitated proteins (IP) (anti-calreticulin or anti-TAP1) or lysates were 
analyzed by immunoblotting with the indicated antibodies. Lysates were generated in the 
presence or absence of NEM (B) and from untreated cells or cells pre-treated with 
tunicamycin (Tun) (D). Data are representative of two independent analyses. In D, G = 








 Trp-302 of calreticulin is in the vicinity of the glycan binding site of calreticulin 
(Kozlov et al., 2010) (Figure 2.1B) and impacts glycan binding (Gopalakrishnapai et al., 
2006). Additionally, Trp-302 has been implicated in the in vitro chaperone activity of 
calreticulin (Martin et al., 2006). Similar to mCRT(Y92A), mCRT(W302A) protein 
displayed a gel-filtration profile whose major peak was slightly left-shifted relative to that 
of mCRT(WT) (Figure 2.8A), while remaining largely monomeric at 4 and 37 °C at a 
concentration of 8 µM (Figure 2.8B, right panel). In a thermostability assay, 
mCRT(W302A) displayed a Tm value of 44.82 +/- 0.55 °C, lower than that of 
mCRT(WT) (Tm = 47.96 +/- 0.21 °C), and the Tm value of mCRT(W302A) did not right-
shift in the presence of G1M3 (Figure 2.8C and Table 2.1), indicating that the mutant has 
the expected deficiency in glycan binding. In Biacore assays, mCRT(W302A) was able to 
bind to ERp57 with a KD value of 0.88 µM, similar to mCRT(WT) (Figure 2.8D). 
 In K42 cells, mCRT(W302A) was unable to restore surface MHC class I (Figure 
2.8E). Steady-state levels of tapasin and MHC class I in the lysates of cells expressing 
mCRT(W302A) were reduced compared with those found in K42 cells expressing 
mCRT(WT) (Figure 2.8, F and G, lysate panels and lanes 8–10). Immunoprecipitations 
with anti-calreticulin revealed defects in tapasin binding by mCRT(W302A) (Figure 
2.8F, CRT IP, tapasin blot, and compare lane 2 with lane 3). Immunoprecipitation with 
anti-TAP1 revealed impaired incorporation of mCRT(W302A) into the PLC (Figure 
2.8G, TAP IP, CRT blot, and compare lane 2 with lane 3), and impaired MHC class I 
incorporation into the PLC in the context of mCRT(W302A) (Figure 2.8G, TAP IP, 




Figure 2.8. mCRT(W302A) is impaired in mediating MHC class I assembly. A, 
representative gel-filtration chromatograms of mCRT(WT) and mCRT(W302A) proteins 
following nickel affinity chromatography. B, native PAGE analysis of pooled peak 
fractions from A, following indicated incubations (in 0.5 mM CaCl2). C and D, 
thermostability, glycan, and ERp57 binding analyses for mCRT(W302A) performed as 
described in Fig. 2.2. Thermostability data are representative of three independent 
analyses, and ERp57 binding data is based on a single analysis. E, flow cytometric 
analyses of the ability of mCRT(WT-FLAG) and mCRT(W302A-FLAG) to restore MHC 
class I expression in K42 cells were performed as described in Fig. 2.6A. Data are 
representative of three experiments from two infections. Significance of the reduction of 
cell surface MHC class I in the context of the W302A-FLAG construct used in Figure 2.8 
is shown in (Jeffery et al., 2010). F and G, immunoprecipitated proteins (anti-calreticulin 
and anti-TAP1) or lysates were analyzed by immunoblotting with the indicated 
antibodies. Data are representative of two immunoprecipitations. Control lanes are 
labeled as indicated in Fig. 2.3. Analyses shown in Figure 2.8A-C and E-G were 
performed by Elise Jeffery. Analyses shown in Figure 2.8D were performed by Syed 
Monem Rizvi.  
 
 
!2m is required for efficient calreticulin and ERp57 recruitment to the PLC 
The findings described above indicated that calreticulin recruitment to the PLC was 
abrogated by mutations of the glycan and ERp57 binding sites of calreticulin. Previous 
studies have described that calreticulin recruitment to the PLC is also reduced in !2m-
deficient human cells (Diedrich et al., 2001; Sadasivan et al., 1996). To further 
investigate requirements for calreticulin and ERp57 recruitment, !2m-/- mouse 
splenocytes were analyzed for their PLC compositions (Figure 2.9). Steady-state levels of 
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MHC class I H chains are not reduced in the lysates of !2m-deficient cells compared 
with wild-type cells (Figure 2.9, lanes 1 and 2, MHC class I H chain blot). However, the 
species that exists is entirely ER localized as assessed by Endo H digestion, whereas a 
minority of the H chains in wild-type lysates is ER localized (data not shown). Splenic 
cell lysates from wild-type C57BL/6 or !2m-/- mice were immunoprecipitated with anti-
TAP1 (Figure 2.9). As expected based on previous results (Ortmann et al., 1994; Suh et 
al., 1994), MHC class I H chain recruitment was strongly impacted in cells lacking !2m 
compared with wild-type cells (Figure 2.9, class I H chain blot, lanes 6 and 7). 
Additionally, TAP–calreticulin association is essentially undetectable in cells lacking 
!2m compared with wild-type cells, as previously shown (Diedrich et al., 2001; 
Sadasivan et al., 1996) (Figure 2.9, CRT blot, lanes 6 and 7). Notably, ERp57 recruitment 
efficiency was also reduced in !2m-deficient cells (Figure 2.9, ERp57 blot, lanes 6 and 
7). ERp57 is thought to be recruited to the PLC via heterodimeric interactions with 
tapasin (Dick et al., 2002; Peaper et al., 2005). However, it appears that !2m also aids in 
the recruitment of ERp57 (Figure 2.9, ERp57 blot), either via direct interactions, or 
indirectly. MHC class I H chains have been shown in some studies to interact directly 
with ERp57 (Kienast et al., 2007; Lindquist et al., 2001). It is thus also possible that !2m 
indirectly facilitates recruitment of MHC class I-associated ERp57 by stabilizing a 




Figure 2.9. !2m-/- cells are deficient in recruiting CRT into the PLC. Anti-TAP1–
immunoprecipitated proteins (IP) or lysates were analyzed by immunoblotting with the 
indicated Abs. Splenic lysates from wild-type (WT) or !2m-/- mice were used for the 
immunoprecipitations. Data are representative of one analysis for !2m, two analyses for 
class I H chain, two analyses for ERp57, three analyses for tapasin, and five analyses for 
CRT. Two bands are observed for CRT, most likely corresponding to a full-length 
version and a degradation product. Two species of MHC class I H chains are observed in 
the cell lysates (labeled as HC1 and HC2), most likely corresponding to differently 
glycosylated forms of H chains. Only HC2 is detectable in the immunoprecipitations and 
in !2m-/- cells. No Ab controls were performed by incubating indicated lysates with 
protein G beads, and Ab indicates signals obtained with Ab alone (without lysates). Ab-










Various mCRT Mutants Induce the Activity of Calreticulin in Suppressing Protein 
Aggregation 
Calreticulin has previously been shown to inhibit thermal aggregation of various non-
glycosylated substrate proteins (Martin et al., 2006; Rizvi et al., 2004; Saito et al., 1999), 
a functional assay indicative of the polypeptide-binding activity of calreticulin. To assess 
this activity at 37 °C, listeriolysin O (LLO) was used as a substrate. LLO has been shown 
to aggregate at 37 °C and neutral pH (Schuerch et al., 2005), which was reproduced in the 
present study by gel-based aggregation assays and light scattering assays. By the gel-
based assay, in the presence of 0.5 mM CaCl2, mCRT(WT) was unable to significantly 
rescue LLO from precipitating at LLO:mCRT ratios up to 1:4 (Figure 2.10). Calcium 
depletion induced the aggregation suppression activity of mCRT(WT), as did the 
mCRT(%C) truncation, consistent with our previous findings with different substrates 
(Rizvi et al., 2004). 
 By the more sensitive light scattering assay, in 0.5 mM CaCl2, mCRT(WT) had low 
activity until high stoichiometric ratios were achieved (1:16 LLO:mCRT(WT); data not 
shown). mCRT(%C) displayed induced activity relative to mCRT(WT) (for example, 
Figure 2.11A). mCRT(Y92A) and mCRT(Y92A/W244A) displayed strongly induced 
activities relative to mCRT(WT) in all analyses undertaken (for example, Figure 2.11, B 
and C). mCRT(W244A) and mCRT(W302A) also displayed higher or equal activities 
relative to mCRT(WT) in the majority of conditions tested (14 of 18 conditions analyzed 
over 4 independent experiments for W244A, and 19 of 24 conditions analyzed over 6 
independent experiments for W302A; representative analyses shown in Figure 2.11, D 
and E). The W302A and W244A mutants of calreticulin have both previously been 
implicated as being impaired for rescue of aggregation of other substrates at 44 – 45 °C 
(Martin et al., 2006); our findings reflect different phenotypes of these two mutants in 
aggregation assays performed under a physiological non-stress condition. 
Compared with mCRT(WT), lower activity of mCRT(%P) was observed in 9 
analyses, and equal or higher activity was observed in 11 analyses of a total of 21 
comparisons over 4 independent experiments (for example, Figure 2.11F). These variable 
results taken together with previous findings that the P domain of calnexin facilitates 
suppression of substrate aggregation (Brockmeier et al., 2009) prompted us to use gel-
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based aggregation assays to further compare mCRT(%P) and mCRT(WT) activities. 
Because ATP is a factor that modulates the chaperone activity of calreticulin (Saito et al., 
1999), aggregation suppression activities of mCRT(WT) and mCRT(%P) were measured 
in 0.5 mM CaCl2 +/- 3 mM ATP. Both ATP and a 1:16 ratio of LLO to mCRT(WT) were 
required to partially inhibit LLO aggregation at 37 °C (in 0.5 mM CaCl2) (Figure 2.11G, 
middle panel, and compare lane 3 with lanes 1 and 5). The addition of 3 mM ATP also 
markedly induced the aggregation suppression activity of mCRT(%P) (Figure 2.11G, top 
and middle panels, and compare lane 7 with lanes 1 and 9). This impact of ATP was 
readily apparent with mCRT(%P) even at a 1:8 ratio (Figure 2.11G, upper panel, and 
compare lane 7 with lanes 1 and 9), and ATP induced a more marked left-shift of the Tm 
value for mCRT(%P) compared with mCRT(WT) (Figure 2.11H and Table 2.1, Tm values 
of 45.49 +/- 0.13 and 46.24 +/- 0.02 °C, respectively, in the presence of ATP). Thus, the 
removal of the P-domain rendered calreticulin more susceptible to ATP-induced 
structural changes, thereby enhancing its ability to suppress aggregation of a misfolded 
protein under a physiological condition. Furthermore, several mutations that impaired 
mCRT function in MHC class I assembly induced its ability to suppress aggregation of a 













Figure 2.10. Relative aggregation suppression activities of full-length and C-terminal 
truncation mutants of mCRT under various conditions. (A-D) Representative SDS-PAGE 
gels of aggregation assays with indicated mCRT constructs and OVA as a control. OVA 
or mCRT at indicated concentrations were incubated with 4 µM LLO in the presence of 
0.2-0.5 mM CaCl2 or 5 mM EDTA at 37 °C for 1 hour. Following incubations, 
aggregated proteins were separated from soluble proteins by centrifugation, and proteins 
present in supernatants (S) and pellets (P) were resolved by SDS-PAGE and visualized 
by staining with coomassie blue dye. (E and F) Band intensities of LLO in the pellet after 
incubation in the presence of mCRT or OVA were quantified, and are represented as a 
percentage relative to LLO observed in the pellet in the absence of mCRT or OVA. For 
each condition, data represent results from 3 or more experiments, except under 




Figure 2.11. Aggregation suppression activities of calreticulin mutants in vitro. A–F, 
light scattering-based aggregation assays of the abilities of indicated mCRT constructs to 
suppress LLO (1 µM) aggregation at 37 °C in the presence of 0.5 mM CaCl2. G, gel-
based aggregation assays. LLO alone (4 µM) or LLO with indicated amounts 
mCRT(WT) or mCRT(%P) were incubated in the presence of 0.5 mM CaCl2 ± 3 mM 
ATP at 37 °C for 1 h. Proteins present in supernatants (S) and pellets (P) were resolved 
by SDS-PAGE and visualized by staining with Coomassie Blue dye (top and middle 
panels). Lower panels, band intensities of LLO in the pellet were quantified and are 
represented as a percentage relative to LLO observed in the pellet in the absence of any 
mCRT. H, thermostability of mCRT(WT) or mCRT(%P) in the presence of 0.5 mM 
CaCl2 ± 3 mM ATP as indicated, were measured as described in Fig. 2.2. Analyses 
shown in Figure 2.11H were performed by Elise Jeffery. 
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Discussion 
In the N-terminally truncated calreticulin construct mCRT33–362, essentially all protein 
was purified as dimers and higher order oligomers in the presence of 1 mM CaCl2 (Figure 
2.2, B and H), suggesting that structural changes involving this region of calreticulin may 
be responsible for inducing oligomer formation under heat-shock or calcium-depleting 
conditions. The C-terminal helix was also critical for maintaining calreticulin monomers 
(Figure 2.2, A and G); the predominant species induced by this truncation migrated in the 
void volume. Conformational alterations and self-association interfered with the ability of 
the truncated variants to bind glycan substrates. A loss of just 20 residues internal to the 
acidic domain or 33 N-terminal residues is sufficient to induce profound conformational 
alterations. A number of functional studies of calreticulin described in the literature that 
used calreticulin truncations lacking all or a subset of residues N- and C-terminal to the P 
domain (or truncation constructs containing only the regions N- or C-terminal to the P 
domain), may have to be re-interpreted in light of these findings. 
 The C terminal truncation mutant mCRT(%C) was not defective for tapasin binding 
(Figure 2.3B). However, mCRT(%C)  was less efficient at being recruited into the TAP 
complex, did not stabilize tapasin and MHC class I heavy chains as efficiently as did 
mCRT(WT), and did not induce MHC class I surface expression as efficiently as did 
mCRT(WT) (Figure 2.3A and 2.3C). Ineffective ER retention of mCRT(%C) (Figure 2.5) 
may help explain the phenotypes observed in K42 cells expressing mCRT(%C). Secretion 
of mCRT(%C) from the ER would diminish the calreticulin available for PLC 
stabilization in the ER. 
 Truncation and point mutations of calreticulin that disrupted glycan binding 
[mCRT(Y92A) and mCRT(W302A)] or ERp57 binding [mCRT(%P) and 
mCRT(W244A)] were defective for binding tapasin, being recruited into the TAP 
complex, stabilizing tapasin and MHC class I heavy chains, and inducing MHC class I 
surface expression. For the Y92A and W244A mutations, binding deficiencies were more 
strongly apparent in the anti-CRT immunoprecipitations than in the anti-TAP1 
immunoprecipitations, indicating that binding defects with these mutants may be partial 
rather than complete. Nevertheless, strong binding defects were apparent with these 
mutants as well as with mCRT(%P), mCRT(W302A), and mCRT(Y92A/W244A), 
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mutants for which tapasin or TAP binding were essentially undetectable. The Williams 
laboratory used a different set of mutants, Y111A for a glycan binding-deficient mutant, 
D241N for an ERp57 binding-deficient mutant (Y128A and D258N, respectively, in 
protein numbering that includes the signal sequence), and the double mutant 
Y111A/D241A, analyses of which suggested that calreticulin could be recruited into the 
PLC in the absence of interactions with both ERp57 and substrate oligosaccharides 
(Zhang et al., 2009). Previous studies have defined that trisaccharide interactions with 
calreticulin were essentially undetectable with the Y92F mutant (Y109F in mature 
protein numbering), whereas binding was detectable with Y111F (Y128F in mature 
protein numbering) (KB = 11.21 x 104 M-1 for Y128F compared with a KB of 58.8 x 104 
M-1 for mCRT(WT)) (Kapoor et al., 2004). Thus, it is likely that the choice of mutant 
impacts the extent of the binding deficiency and forms the basis for the discrepancies in 
conclusions from the two studies. Additionally, antibodies used in the interactions 
analyses and the levels of calreticulin expression achieved are likely to determine the 
sensitivity with which binding differences can be elucidated. 
 Our mutational data are strongly supportive of a model in which calreticulin-ERp57 
and calreticulin-glycan interactions are both important for the recruitment of calreticulin 
into the PLC and for the functional activity of calreticulin in stabilizing tapasin and MHC 
class I heavy chains. Although previous studies have suggested a role for MHC class I 
glycan-dependent interactions for the recruitment of calreticulin to the PLC, support for 
such a mode of binding comes from studies with glycosylation inhibitors, in vitro binding 
studies with purified MHC class I molecules and calreticulin, and glycan-deficient 
mutants of MHC class I molecules (Harris et al., 1998; Sadasivan et al., 1996; Wearsch et 
al., 2004). Support for an ERp57-dependent mode of calreticulin recruitment comes from 
the known tapasin-ERp57 interaction and its impact on calreticulin recruitment (Garbi et 
al., 2006; Peaper and Cresswell, 2008; Wearsch and Cresswell, 2007). The studies 
described here represent the first direct evidence for the involvement of the glycan and 
ERp57 binding sites of calreticulin for its recruitment into the PLC. Furthermore, based 
on the strong Tyr-92 and Trp-302 dependence of the tapasin-calreticulin binding (Figures 
2.7 and 2.8), it was an open question whether calreticulin recruitment to the PLC involves 
tapasin’s glycan, MHC class I’s glycan, or both (Figure 2.12). Two models for the 
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recruitment of calreticulin into the PLC are shown in Figure 2.12 that were both 
consistent with the Figures 2.7 and 2.8. In both models, the tip of the P domain of 
calreticulin engages the b’ domain of ERp57. In model A, glycans of MHC class I are 
bound by calreticulin, and a specific contact interface for tapasin binding is also present 
on calreticulin. This model is similar to that proposed following structural studies of 
tapasin-ERp57 complexes (Dong et al., 2009). Current support for model 2.12A comes 
from inhibitor-based data, which showed reduced calreticulin-MHC class I binding in 
castanospermine-treated cells, and from cells expressing mutant MHC class I molecules 
lacking an appropriate glycan, which displayed reduced calreticulin binding (Harris et al., 
1998; Sadasivan et al., 1996). The treatments or mutations also impacted MHC class I-
TAP binding, which leaves open the possibility of indirect impacts upon MHC class I-
calreticulin binding. Further support for model 2.12A comes from detection of MHC 
class I – calreticulin assembly intermediates (Wearsch et al., 2011). In the 
additional/alternate model 2.12B, which is favored by the data in Figure 2.7D, 













Figure 2.12. Modes of substrate recognition by calreticulin. A and B, two mechanisms to 
explain the central roles of tapasin, glycans, and ERp57 in calreticulin recruitment to the 
PLC and function within the PLC. In A, calreticulin binds to a MHC class I glycan, to 
ERp57 via the tip of its P domain, and to tapasin via a specific polypeptide binding site. 
In B, calreticulin binds to the glycan of tapasin, and to ERp57 via the tip of its P domain. 
A specific polypeptide-based interaction with MHC class I may also be relevant to this 
mode of recruitment. Interactions mediated by the acidic domain of calreticulin, which is 
also important for function, have to be further defined, and are not shown for simplicity. 
C and D, polypeptide binding sites on calreticulin are induced by mutations targeting 
distinct domains and residues on calreticulin, likely relating to the structural plasticity of 
calreticulin, which exposes single (C) or distinct hydrophobic sites (D) upon different 
truncations/mutations. Because mutations that induce the ability of calreticulin to 
suppress protein aggregation in vitro inhibit calreticulin recruitment to the PLC in cells, 
generic polypeptide binding sites per se are insufficient to recruit calreticulin to the PLC 
under non-stress conditions. 
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 To further elucidate whether one or both models (Figure 2.12A or 2.12B) are 
relevant, in a subsequent study (Rizvi et al., 2011) we compared calreticulin recruitment 
mediated by a tapasin glycan mutant (N233Q) compared to wild type tapasin and by a 
MHC class I glycan mutant HLA-A2 (N86Q) compared to wild type HLA-A2 in the 
tapasin-deficient M553 cell line. Our findings support the model that tapasin’s glycan is a 
relevant site that mediates calreticulin recruitment into the PLC.  
 Compared to wild type tapasin, the tapasin(N233Q) mutation significantly reduced 
the efficiency of calreticulin recruitment to tapasin under conditions where MHC class I 
heavy chain and !2m expression were low.  ERp57 recruitment efficiency to tapasin was 
also reduced in cells expressing the tapasin(N233Q) mutation compared to cells 
expressing wild type tapasin (Rizvi et al., 2011). Calreticulin deficiency in cells reduced 
ERp57 recruitment into the PLC as well (data not shown). These data suggest that 
calreticulin bound to tapasin’s glycan may initiate ERp57 recruitment into the PLC via a 
calreticulin P domain-ERp57 interaction. Once ERp57 is recruited to the PLC by the 
calreticulin P domain, ERp57 could bind and initiate conjugation with C95 of tapasin. 
Molecular modeling studies suggest that a calreticulin bound to tapasin’s glycan cannot 
simultaneously contact the ERp57 molecule present within the same tapasin–ERp57 
conjugate (S.J. Wijeyesakare and M. Raghavan, unpublished observations). Hence, we 
propose that once ERp57 forms a conjugate with tapasin, a conformational change is 
initiated that forces calreticulin to disengage from tapasin’s glycan (Figure 2.13A) and 
repositions calreticulin for P-domain mediated ERp57 binding (Figure 2.13B). 
Calreticulin may equilibrate between the two conformational states (Figure 2.13A " 
2.13B) where calreticulin recruitment is initially mediated by tapasin’s glycan and once 
tapasin bound calreticulin recruits ERp57, calreticulin is repositioned to interact primarily 
with ERp57 and disengages from tapasin’s glycan. The latter conformation (2.13B) 
appears to be the relevant one for recruitment of MHC class I molecules as the tapasin 
C95A mutant significantly affects the efficiency of MHC class I heavy chain and !2m 
recruitment to the PLC (Rizvi et al., 2011). 
 Experiments utilizing a deglycosylated heavy chain showed that the heavy chain 
glycan is not central to calreticulin recruitment into the PLC. This was suggested in 
experiments in murine cells (Figure 2.7), and confirmed in human cells (Rizvi et al., 
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2011). The heavy chain glycan impacted the efficiency of H chain recruitment to the 
PLC, but does not impact calreticulin recruitment (Rizvi et al., 2011). On the other hand, 
!2m deficiency strongly impaired calreticulin recruitment into the PLC (Figure 2.9). 
These findings suggested a model involving tapasin, ERp57, calreticulin and !2m as 
intermediate PLCs into which MHC class I heavy chains are recruited (Figure 2.13C). 
Whether the MHC class I glycan participates in recruitment remains to be elucidated, 
although a recent study (Wearsch et al., 2011) alludes to this possibility. 
 Calreticulin is able to interact with MHC class I molecules in a glycan-independent 
manner under conditions of ER stress both in cells and in vitro (Rizvi et al., 2004), but 
whether such interactions also occur under physiological non-stress conditions is unclear. 
Mutations targeting diverse regions of calreticulin induced its ability to suppress 
aggregation of a non-glycosylated polypeptide (Figure 2.11), likely by providing 
increased exposure (at 37 °C in 0.5 mM CaCl2) of either one or several hydrophobic 
surfaces that can participate in substrate binding (Figures 2.12, C and D), as suggested by 
the slight reduction in Tm values of the mutants (Figures 2.2, 2.6, and 2.8). However, 
calreticulin mutants with induced aggregation suppressive activities in vitro were 
impaired in their binding to tapasin and in their recruitment into the PLC under non-stress 
conditions (Figures 2.3, 2.7, 2.8, and 2.11). Thus, generic polypeptide-based associations 
involved in protein aggregation suppression mediated by calreticulin per se are 
insufficient for stable recruitment of calreticulin to PLC components in cells under non-
stress conditions. However, based on the model discussed in Figure 2.13, it is likely that 
P domain based interactions are relevant to stabilize interactions within the PLC. 
 In summary, the work here provides greater insight into the assembly of the PLC. 
We show that MHC class I incorporation into the PLC is reduced in cells deficient in 
calreticulin. We also provide evidence that calreticulin recruitment into the PLC is 
mediated by ERp57 and glycan-based interactions, and calreticulin mutations affecting 
either the ERp57 or glycan binding site of calreticulin negatively affect MHC class I 
recruitment into the PLC. Additionally, we show that ERp57 recruitment into the PLC is 
negatively affected by the absence of calreticulin within the PLC. Finally, we find that 
!2m deficiency reduced the recruitment of both ERp57 and calreticulin into the PLC. 
Based on this study and a recently published study (Rizvi et al., 2011), we have 
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developed a model for PLC assembly (Figure 2.13). We propose that calreticulin is first 
recruited to TAP/tapasin via tapasin’s glycan. ERp57 is then recruited into the PLC via 
the P domain of calreticulin. Once recruited by calreticulin, ERp57 forms a stable 
disulfide bond with tapasin. Lastly, !2m is recruited into the PLC intermediate. The PLC 
intermediate containing TAP, tapasin, ERp57, calreticulin and !2m functions to recruit 
MHC class I into the PLC. Details of the latter complex remain to be further clarified. 
Taken together, the findings here and in Rizvi et al. (2011) raise the possibility that 
although the glycan and ERp57 binding sites of calreticulin are important for its 
recruitment into the PLC or to components of the PLC, glycan-based and ERp57-based 




Figure 2.13. In a proposed model of the PLC, calreticulin equilibrates between tapasin 
glycan- and tapasin(C95)-associated forms. (A) Tapasin’s glycan contributes to the 
recruitment of calreticulin. Such a subcomplex may facilitate ERp57 recruitment by 
transient interaction of ERp57 with the tip of calreticulin’s P domain, thus bringing 
ERp57 into proximity to tapasin(C95). ERp57 becomes conjugated to tapasin(C95). This 
is shown to displace calreticulin from tapasin’s glycan, and link calreticulin to the PLC 
via P domain-mediated interactions with tapasin(C95)-associated ERp57. This complex is 
unstable, as calreticulin and ERp57 recruitment to tapasin is reduced in !2m-/- cells 
(Figure 2.9). (C) !2m is recruited into the PLC, and this intermediate associates with 
MHC class I heterodimers, resulting in !2m and peptide dissociation from incoming 






Materials and Methods 
DNA Constructs 
Expression of mCRT in Escherichia coli—Truncation mutants of mouse calreticulin 
(mCRT) were amplified from the pCMV-SPORT6 (ATCC, MGC-6209) vector using 
primers that allowed for subsequent ligation-independent cloning (LIC) into the pMCSG7 
vector (Stols et al., 2002). The following oligonucleotide primers were used to terminate 
CRT at the indicated C-terminal amino acid positions: 399, 5!-TTA TCC ACT TCC 
AAT GTT ACA GCT CAT CCT TGG CTT-3!; 362, 5’-TTA TCC ACT TCC AAT GTT 
ATT CCT CTT TAC GCT TCT TGT-3’; 339, 5’-TTA TCC ACT TCC AAT GTT ACT 
GCT TCT CGG CAG CCT TGG TTA CAC CCC-3’; and 318, 5’-TTA TCC ACT TCC 
AAT GTT AAT CAT TAG TGA TGA GGA AAT TGT C-3’. The following 
oligonucleotide primers were used to generate constructs at the N-terminal start sites: 1, 
5’-TAC TTC CAA TCC AAT GCT GCC GCA GAC CCT GCC ATC- 3’; and 33, 5’-
TAC TTC CAA TCC AAT GCT GTC CTC AGT TCT GGC AAG TTT TAC GGG-3’. 
Underlined bases represent those that are complementary to the sequence encoding 
mCRT, and additional 5’ sequences were introduced for LIC. 
 Deletion of the P domain amino acids 187–283 and insertion of two glycine 
residues (mCRT(%P)) was achieved with the Finnzymes Phusion site-directed 
mutagenesis kit (New England Biolabs). The following primers were used to generate 
mCRT(%P): forward, 5’-GGA CCC GAT GCA AAT ATC TAT GCC TAT-3’ and 
reverse, 5’-TCC CAG AAA GTC CCA ATC ATC CTC CAA-3’. 
 DNA constructs were sequenced and transformed into BL21 (DE3) cells for protein 
expression. All bacterially expressed mCRT constructs lacked the signal sequence and 
contained an N-terminal MHHHHHHSSGVDLGTENLYFQSNA fusion sequence for 
nickel affinity chromatography. 
Cloning of mCRT Truncation Mutants into Retroviral Vectors— mCRT mutants were 
cloned into pMSCV-ires-GFP and pMSCV-puro retroviral vectors. pMSCV-puro 
constructs were created by ligation-dependent cloning, and LIC was used to generate 
pMSCV-ires-GFP vectors. The mCRT templates used were the corresponding mCRT in 
the pMSCV-ires-GFP vector (for %C X pMSCV-puro) or pCMV-SPORT6 (all other con- 
structs). All constructs retained the mCRT signal sequence and KDEL ER retention 
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motifs. 
Generation of LIC-competent Version of pMSCV-ires-GFP— The plasmid pMCSV-ires-
GFP (Van Parijs et al., 2009) was used as the parent vector for construction of a LIC-
competent variant. This was accomplished by inserting a unique sequence with a PmeI 
restriction site. LIC overhangs were then generated by treatment of the linearized vector 
with T4 DNA polymerase exonuclease activity. The inserted sequence was constructed 
by annealing two oligonucleotides to generate a fragment with overhangs complimentary 
to an EcoRI restriction site. The oligonucleotide sequences used were 5’-
AATTAGAGAGTTTAAACTTCCAC-3’ and 5’-AATTGTGGAAGTTTAAACTC- 
TCT-3’. The lyophilized oligonucleotides were resuspended in distilled water at a 
concentration of 20 µM. Prior to annealing these were phosphorylated using T4 
polynucleotide kinase (New England Biolabs). The 20-µl reactions contained 2 µl of 10 
mM ATP, 12.5 µl of 20 µM oligonucleotide, 2 µl of 10x reaction buffer, 1 µl of enzyme, 
and 2.5 µl of distilled water. Reactions were incubated for 1 h at 37 °C then shifted to 95 
°C for an additional 10 min. The two oligonucleotide reactions were then mixed together 
at 95 °C and slow cooled to 37 °C. A 2.5-µl aliquot was then added to a 20-µl ligation 
reaction composed of 1 µl of 45 ng/µl EcoRI-cut pMCSV-ires-GFP, previously treated 
with calf intestinal phosphatase, 2 µl of 10x reaction buffer, and 13.5 µl of distilled water. 
The reaction was slow cooled from 37°C to 16°C, and 1 µl of 1 unit/µl of T4 DNA ligase 
(New England Biolabs) was added. Incubation was continued at 16 °C for ~16 h. 
 A 2-µl aliquot of the ligation reaction was used to transform 20 µl of competent 
XL1-Blue cells. These were plated on Lysogeny Broth (LB) agar with ampicillin (Amp) 
selection and incubated at 37 °C overnight. Colonies were picked and grown in 5 ml of 
LB-Amp, and plasmid DNA was isolated using Qiagen minispin columns. Positive 
clones were identified by restriction digestion with PmeI and ClaI and confirmed by 
DNA sequencing. 
Primers for LIC of mCRT(WT), mCRT(!C) and mCRT(!P) into pMSCV-ires-GFP—The 
following primers were used: forward, 5’-GAA TTA GAG AGT TTC ACC ATG CTC 
CTT TCG GTG CCG CTC CTG CTT GGC-3’, reverse for WT and %P: 5’-GG AAT 
TGT GGA AGT TTC TTA CAG CTC ATC CTT GGC TTG GCC AGG GGA TTC-3’, 
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and reverse for %C, 5’-GG AAT TGT GGA AGT TTC TTA CAG CTC ATC CTT CG 
CTT CTC TGC AGC CTT GGT A-3’. 
Procedures for LIC—LIC was performed to introduce mCRT sequences into the 
pMCSG7 and pMSCV-ires-GFP vectors. Overhangs of 15 bp were generated in the insert 
DNA by processing 0.2 pmol of the PCR product with 0.5 unit of LIC-qualified T4 DNA 
polymerase (Novagen) in the presence of 4 mM dCTP (for ligation with pMCSG7) or 4 
mM dGTP (for ligation with pMSCV-ires-GFP) and 5 mM dithiothreitol, at 20-µl final 
reaction volume. Reactions were incubated for 30 min at 22 °C followed by 20 min at 75 
°C. The pMCSG7 or pMSCV-ires-GFP vectors were linearized by restriction digestion 
with SspI (for pMCSG7) or PmeI (for pMSCV-ires-GFP) (New England Biolabs) at a 
concentration of 5 units/µg of DNA at 37 °C for 1.5 h. The protein was removed using a 
Qiagen PCR minispin kit. Linearized vector DNA was then processed by T4 DNA 
polymerase to yield single-stranded ends for annealing. Reactions, 60-µl total, were set 
up with 1.6 –2.0 µg of linear DNA and 3.75 units of LIC-qualified T4 polymerase 
(Novagen) in the presence of 4 mM dGTP (for pMCSG7) or 4 mM dCTP (for pMSCV-
ires- GFP) and 5 mM dithiothreitol. Reactions were mixed on ice and incubated as 
described above for inserts. Insert and vector DNA were annealed in 96-well plates by 
combining 1 µl of processed vector and 2 µl of processed insert per well, followed by 
incubation in a PCR machine at 22 °C for 15 min with addition of 1 µl of 25 mM EDTA 
after 10 min of incubation. Annealed DNA was used to transform competent XL1-Blue 
cells. Positive clones were identified by PCR analysis. DNA sequences were verified at 
the University of Michigan DNA sequencing core. Purified plasmid DNA from positive 
clones was used to transform competent Rosetta cells (Novagen) or BL21 (DE3) cells for 
protein expression. 
Primers for Cloning mCRT into pMSCV-puro—The following primers were used to 
clone untagged mCRT into the pMSCV-puro vector: forward, 5’-GA CTC GAG ATG 
CTC CTT TCG GTG-3; and reverse, 5’-GA GTT AAC CTA CAG CTC ATC CTT-3’, 
which introduce 5’ XhoI and 3’ HpaI restriction sites. A FLAG-tagged CRT containing a 
C-terminal FLAG epitope tag was also generated in pMSCV-puro. The following primers 
were used: forward, 5’-GA CTC GAG ATG CTC CTT TCG GTG-3’ and reverse 5’-GA 
GTT AAC CTA CAG CTC ATC CTT CTT ATC ATC GTC ATC CTT ATA ATC GGC 
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TTG GCC AGG GGA TTC TTC-3’. Underlined bases represent those that are 
complementary to the sequence encoding mCRT, with additional 5’ sequences added to 
insert an XhoI restriction site upstream of the protein sequence, and a FLAG epitope tag 
inserted before the KDEL ER retention motif, and finally an HpaI restriction site 
downstream of the protein sequence. Following amplifications from appropriate 
templates, PCR products were digested with XhoI and HpaI (New England Biolabs). 
PCR reactions were cleaned using MinElute 96 UF PCR purification kits by Qiagen. The 
digested products were ligated into the pMSCV-puro vector digested with the same 
enzymes. Both mCRT retroviral constructs retained the mCRT signal sequence and 
KDEL ER retention motif. 
Generation of Y92A, W244A, W302A, and Y92A/W244A Mutants of mCRT—
mCRT(W244A) was obtained by site-directed mutagenesis of mCRT(WT) in pMSCV-
puro (Finnzymes Phusion, New England Biolabs). mCRT(Y92A) and mCRT(Y92A/ 
W244A) were obtained by site-directed ligation-independent mutagenesis (Chiu et al., 
2004) of mCRT(WT) and mCRT(W244A) constructs in pMSCV-puro. mCRT(W302A) 
was obtained by site-directed mutagenesis of mCRT in pCMV-SPORT6 (QuikChange II 
site-directed mutagenesis kit, Stratagene). mCRT(W302A) in pMSCV-puro was 
subsequently cloned using a 3’ primer that introduced a FLAG epitope tag as described 
above. A corresponding FLAG-tagged mCRT(WT) was also generated. mCRT(Y92A), 
mCRT(W244A), mCRT(Y92A/W244A), and mCRT(W302A) were inserted into 
pMCSG7 from pMSCV-puro or pCMV- SPORT6 templates by LIC using the primers for 
an N-terminal start site at residue 1, and C-terminal end site at residue 399. 
Site-directed Ligation-independent Mutagenesis to Create mCRT(Y92A) and 
mCRT(Y92A/W244A)—Procedures for site-directed ligation-independent mutagenesis 
were similar to those described in (Chiu et al., 2004). To create Y92A, full-length mCRT 
in the retroviral vector pMSCV-puro was used as a template for the following primers in 
two separate PCR reactions to create DNA fragments with complementary 5’ overhangs, 
which are underlined: forward tailed, 5’-GGG GGC GGC GCC GTG AAG CTG TTT 
CCG AGT GGC TTG-3’; reverse short, 5’-ACA GTC GAT ATT CTG CTC ATG CTT 
CAC CG-3’; reverse tailed, 5’-CTT CAC GGC GCC GCC CCC ACA GTC GAT ATT 
CTG CTC-3’; and forward short, 5’-CTG TTT CCG AGT GGC TTG GAC CAG AAG-
! '%!
3’. The PCR products were then incubated with DpnI (New England Biolabs) to digest 
template DNA, and this reaction was quenched with the addition of the following 2x site-
directed ligation-independent mutagenesis buffer: 50 mM Tris, pH 8.8, 300 mM NaCl, 20 
mM EDTA. The two products were then mixed and incubated for two cycles of 65 °C for 
5 min and 30 °C for 15 min to hybridize the two fragments, and the product was 
transformed into competent XLI-Blue cells. Positive clones were identified through 
sequencing performed by the University of Michigan DNA Sequencing Core. The 
Y92A/W244A mutant was created with the same method as Y92A, except that the 
original template used was full-length mCRT containing the W244A mutation in 
pMSCV-puro. 
Generation of mCRT(W244A) by Finnzymes Phusion Site-directed Mutagenesis Kit—The 
following primers were used to generate mCRT(W244A): forward, 5’-GCT GAA CCA 
CCA GTG ATT CAA AAT CCT GAA TAC-3’ and reverse, 5’-CTC TCC ATC CAT 
CTC TTC ATC CCA GTC CTC-3’. 
Generation of the W302A Mutant Using the QuikChange II Site-directed Mutagenesis 
Kit—The following primers were used to generate mCRT(W302A): forward, 5’-G GGC 
CTA GAT CTC GCG CAG GTC AAG TCC GG-3’ and reverse, 5’-CC GGA CTT GAC 
CTG CGC GAG ATC TAG GCC C-3’. 
Cloning Human ERp57 into pET33b—ERp57 was PCR-amplified from the pVL1392 
vector (Silvennoinen et al., 2004) using primers that introduced 5’ NcoI and 3’ XhoI sites 
and deleted the signal sequence. The vector pET33b, which allows for insertion of a C-
terminal His tag, and ERp57 inserts were both prepared by XhoI and NcoI digestion and 
ligated (Invitrogen). The following primers were used: forward, 5’-A TCC ATG GCC 
TCC GAC GTG CTA GAA CTC-3’ and reverse, 5’-AT CTC GAG GAG ATC CTC 
CTG TGC CTT C-3’.  
Expression of LLO in E. coli—A listeriolysin O (LLO) W492A mutant LLO, which is 
described to have reduced cytotoxic activity (Michel et al., 1990), was used as a non-
glycosylated calreticulin substrate. Wild-type LLO with a C-terminal histidine tag was 
mutated by PCR using the primer 5’-GCG AGA ACG GTA ATT GAT GAC C-3’ 
(Integrated DNA Technologies, Coralville, IA) to change Trp-492 to Ala. The PCR 
product was ligated into the pET29b plasmid (Novagen, WI), sequenced, transformed 
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into BL21 (DE3, Novagen), and purified as described below. 
Generation of C95A, N33Q, C95A/N233A mutants of tapasin–The construction of 
retroviral vectors encoding wild-type and C95A human tapasin has been previously 
described (Rizvi and Raghavan, 2010). The N233Q mutants on the wild-type and 
tapasin(C95A) backgrounds were generated using the QuikChange site-directed 
mutagenesis kit (Stratagene). The MSCV-puro vector expressing wild-type or C95A 




Purification of Calreticulin—Glycerol stocks of BL21 (DE3) cells expressing the 
calreticulin constructs were inoculated into a 25-ml terrific broth culture (with 50 µg/ml 
ampicillin) and incubated at 37 °C overnight. The starter culture was added to 1 liter of 
terrific broth with 50 µg/ml ampicillin and incubated at 37 °C until cell density measured 
by A600 was 0.8–0.9. Cultures were then incubated at room temperature for 1 h before 
inducing calreticulin protein expression with 200 µM isopropyl 1-thio-!-D-
galactopyranoside. Bacterial cultures were incubated at room temperature for 16 –20 h 
before harvesting cells by centrifugation. Cell pellets were resuspended in 50 ml of 50 
mM Tris with 0.33 mg/ml lysozyme and EDTA-free complete protease inhibitors (Roche 
Applied Science). Cells were lysed by sonication. Subsequently, 10 µg/ml DNase, 1% 
Triton X-100, 10 mM MgCl2, and 1 mM CaCl2 were added, and the cell lysis suspension 
was incubated at room temperature for 30 min. Cell debris was removed from samples by 
centrifugation, followed by vacuum filtration of the supernatant with a Steriflip having a 
0.22-µm pore membrane (Millipore). The filtrate was then incubated with nickel-
nitrilotriacetic acid-agarose beads (Qiagen) for 2– 4 h at 4 °C. The beads were washed 
with 10 mM imidazole in wash buffer (50 mM Tris, 150 mM NaCl, 1 mM CaCl2, pH 
7.5). Murine calreticulin was eluted from beads with 75 and 100 mM imidazole in wash 
buffer. Protein was concentrated to 0.5– 4.0 ml, by centrifugation using Centriplus 
centrifugal filter devices (Millipore) with molecular weight cut-offs of 10 or 30 kDa, and 
analyzed by gel-filtration chromatography. 
Gel-filtration Analyses of Calreticulin—Purified concentrated calreticulin constructs 
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were analyzed by gel filtration at 4 °C using a Superdex 200 10/300 GL column or 
Highload 16/60 Superdex 200 (Amersham Biosciences). Buffer used was 20 mM Hepes, 
150 mM NaCl, 10% glycerol, 1 mM CaCl2, pH 7.5. Following gel filtration, fractions 
corresponding to the various monomeric and oligomeric calreticulin species for each 
construct were pooled and concentrated by centrifugation using Centricon centrifugal 
filter devices (Millipore) with molecular weight cut-offs of 10 or 30 kDa. Protein 
concentration was determined measuring absorbance at 280 nm. Extinction coefficients 
were calculated from the protein amino acid sequence using ProtParam (www.expasy.ch) 
and are as follows (units are in M-1 cm-1): mCRT1–399, 82,975; mCRT1–362, 82,975; 
mCRT1–339(%C), 82,975; mCRT1–318, 75,985; mCRT33–362, 70,485; and mCRT(%P), 
44,015. 
Purification of LLO—BL21 E. coli cells expressing LLO were inoculated into LB broth 
with 60 µg/ml kanamycin. Cell cultures were expanded to log phase (A600 = 0.8–0.9), 
induced with 1 mM isopropyl 1-thio-!-D-galactopyranoside for 16 –20 h at room 
temperature, and the recombinant LLO was purified from bacterial lysates by nickel 
affinity chromatography. Buffers used throughout the purification procedure were pH 8.0 
and contained 10% glycerol to minimize LLO aggregation. LLO was eluted from the 
nickel beads with 250 mM imidazole in wash buffer, and then stored in aliquots at -80 
°C. Relative purity was consistently >95% by SDS-PAGE and SYPRO Red gel staining 
(Invitrogen). Prior to aggregation assays (described below), small aliquots of LLO were 
further purified by gel-filtration chromatography using a Superdex 200 10/300 column. 
Buffer used was 50 mM Hepes, 140 mM NaCl, 10% glycerol, pH 8.0. LLO concentration 
and extinction coefficient (77,240 M-1 cm-1) were calculated as described above for 
mCRT. 
Purification of ERp57—LB broth containing 50 µg/ml kanamycin was inoculated with 
BL21 E. coli cells expressing His-tagged ERp57. Cell cultures were expanded to log 
phase, induced with 250 µM isopropyl 1-thio- ! -D-galactopyranoside for 3 h at 37 °C. 
ERp57 was purified by resuspending bacterial pellets in lysis buffer containing: 50 mM 
NaH2PO4, 150 mM NaCl, 0.2 mg/ml lysozyme, 0.1% Triton X-100, 10 mM !-
mercaptoethanol, 2.7 mM benzamidine, 5 µg/ml leupeptin, 7 µg/ml pepstatin, and 1.5 
mM phenylmethylsulfonyl fluoride, pH 8.0. Cells were disrupted by sonication in lysis 
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buffer. Cell debris was removed from samples by centrifugation, followed by vacuum 
filtration of the supernatant with a Steriflip having a 0.22-µm pore membrane (Millipore). 
The filtrate was then incubated with nickel-nitrilotriacetic acid-agarose beads (Qiagen) 
for 3 h at 4 °C. The beads were washed with wash buffer (50 mM Tris, 300 mM NaCl, 
pH 8.0). ERp57 was eluted from beads with 10 and 20 mM imidazole in wash buffer. 
Protein was concentrated to ~6.5 ml, by centrifugation using Centriplus centrifugal filter 
devices (Millipore) with molecular weight cut-offs of 10 or 30 kDa, and further purified 
by Mono Q ion-exchange chromatography. A linear gradient from 150 mM to 1 M NaCl 
in 50 mM Tris (pH 7.4) was used to elute ERp57 from the column. The fractions of 
eluted protein containing ERp57 were dialyzed into 10 mM Tris, 150, mM NaCl (pH 
7.4), concentrated, and stored at -80 °C after adding 10% glycerol. 
Thermostability Analyses by Sypro Orange Binding 
These analyses were undertaken as previously described (Lo et al., 2004; Malawski et al., 
2006). Proteins (16 µM) were incubated in buffer (20 mM Hepes, 150 mM NaCl, and 1 
mM CaCl2, pH 7.5) and 1x Sypro Orange Stain (Invitrogen) diluted from a 5000! stock 
solution in the presence or absence of 48 µM Glc"1–3Man"1–2Man"1– 2Man-OH 
(G1M3, Alberta Research Council) in a total reaction volume of 10 µl. Thermal scans 
were performed using an ABI PRISM 7900HT Sequence Detection System using 
temperature increments of 1 °C starting at 25 °C. Within an experiment, each condition 
was analyzed in triplicate wells. Fluorescence emission was measured across different 
wavelength bins, and the bin with maximum fluorescence was chosen for further 
analysis. Fluorescence was normalized within wells as percent maximum fluorescence 
((Fobs - Fmin)/(Fmax - Fmin)*100) and plotted against the sample temperature.  
Biacore-based Assays 
CRT-ERp57 binding was assayed by surface plasmon resonance-based assays using a 
Biacore 2000 instrument, as previously described (Martin et al., 2006). Briefly, 
mCRT(WT) or mutants or the control protein bovine serum albumin were coupled to a 
Biacore CM5 chip (Amersham Biosciences) using amine-based coupling chemistry. 
ERp57 binding to each surface was monitored in 10 mM Hepes, 150 mM NaCl, 0.5 mM 
CaCl2, 0.005% surfactant P-20, pH 7.5, at a flow rate of 5 µl/min at 25 °C over a 30-min 
period. Signals obtained from the bovine serum albumin surface were subtracted from 
! ')!
corresponding signals for each mCRT surface. Specific signals for mCRT binding were 
plotted as a function of ERp57 concentration, and non-linear curve fitting (1:1 specific 
binding model) was performed to derive KD values using PRISM software. 
Aggregation Assays 
In gel-based assays, 2 or 4 µM LLO were incubated with purified mCRT constructs (4 –
32 µM), or OVA as a negative control, at 37 °C for 1 h. Assays were conducted in the 
presence of 0.2– 0.5 mM CaCl2 with or without 5 mM EDTA or 3 mM ATP. Following 
incubation, aggregated proteins were separated from solution by microcentrifugation at 
maximum speed for 30 min at 4 °C. Supernatants containing non-aggregated protein were 
removed, and the pellets containing the aggregated protein were re-suspended in an equal 
volume of buffer. Proteins present in the supernatants and pellets were separated by SDS- 
PAGE and visualized with Coomassie Blue stain. Protein band intensity was quantified 
using ImageQuant (Amersham Biosciences) and used as a measure of aggregation 
suppression activity of calreticulin. A light scattering assay was also performed to 
compare the aggregation suppression activities of different calreticulin mutants. In this 
assay, 1 µM LLO was incubated in a 96-well plate with 1–16 µM of different mCRT in 
the presence of 0.5 mM CaCl2. Plates were incubated in a BIO-TEK spectrophotometer 
pre-heated to 37 °C, and absorbance at 360 nm was monitored over a 60-min period 
(KC4 software). The absorbance signal for LLO alone was set to 100%. 
Cell Cultures 
Bosc cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) 
containing 4.5 g/liter glucose, L-glutamine, and 110 mg/liter sodium pyruvate, 
supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 100 µg/ml streptomycin, 
and 100 units/ml penicillin (Invitrogen). Calreticulin-deficient (K42) cells (Gao et al., 
2002) and a melanoma cell line M553 (Belicha-Villanueva et al., 2008) (obtained from 
N. Bangia, Roswell Park Cancer Institute) were maintained in RPMI medium 1640 
(Invitrogen) supplemented with 10% (v/v) fetal bovine serum, 100 µg/ml streptomycin, 
and 100 units/ml penicillin. 
Generation of Retroviral Supernatants 
5.5 µg of pMSCV-ires-GFP or pMSCV-puro vector (encoding different mCRT or control 
vector lacking mCRT) DNA was mixed with 4 µg of pCL-EcoDNA and 0.5 µg of VSV-
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G encoding plasmid, and added to a mixture of Opti-MEM (Invitrogen) and FuGENE 6 
(Roche Applied Science). Following incubation for 20 min at room temperature, the 
mixture was added to Bosc cells that had been grown to 70% confluency in a 10-cm 
tissue culture dish. Medium was changed after 24 h, and after 48 h, supernatants 
containing retroviruses were harvested and used to infect K42 cells. 
Mice 
C57BL/6 and !2m-/- mice were purchased from The Jackson Laboratory. All mice were 
maintained in a specific pathogen-free mouse facility. The mice were cared for according 
to the guidelines set by the University of Michigan Committee on Use and Care of 
Animals. 
Flow Cytometry 
For MHC class I surface analysis by flow cytometry, infected K42 cells were 
resuspended and washed in phosphate-buffered saline containing 1% fetal bovine serum 
(flow cytometry buffer). 2 x 105 cells were resuspended in 100 µl of flow cytometry 
buffer containing the MHC class I ascites fluid Y3 (1:100, anti-H2-Kb, ATCC HB-176), 
AF6 (anti-H2-Kb, ATCC HB-158, 1:50), 28-14-8S (1:50, anti-H2-Db, ATCC HB-27), 
W6/32 (1:250), or anti-HA (Covance, 1:250) and incubated for 30 min to 1 hour on ice. 
Cells were washed once with buffer, then resuspended in 100 µl of buffer containing goat 
anti-mouse antibody conjugated to phycoerythrin (1:500) or to FITC (1:250), and 
incubated for 15 min to 1 hour on ice. Cells were washed three times, and data for each 
sample were collected on the FACSCanto flow cytometer (BD Biosciences). For 
pMSCV-ires-GFP-infected cells, levels of mCRT expression were normalized by gating 
on a subset of the GFP-positive population. For pMSCV-ires-GFP-derived cells, flow 
cytometric analyses were undertaken 37 and 71 h post-infection. For pMSCV-puro-
derived cells, following selection and maintenance in media containing 1–2.5 µg/ml 
puromycin, cells were analyzed no earlier than 3 weeks post-infection. Analyses were 
performed using WinMDI version 2.8. 
Immunoprecipitations 
Splenocytes from wild-type (C57BL/6) and !2m-/- mice were isolated, and the RBCs 
were lysed using red cell lysis buffer (Sigma-Aldrich R7757). The remaining 
splenocytes, K42 cells or K42 cells expressing mCRT constructs were harvested and 
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lysed in digitonin lysis buffer (10 mM Na2HPO4, 10 mM Tris, 130 mM NaCl, 1% 
digitonin, complete EDTA-free protease inhibitors, pH 7.5). Indicated 
immunoprecipitations additionally contained 20 mM N-ethylmaleimide in the lysis 
buffer. In some analyses, cells were incubated with 10 µg/ml tunicamycin to induce 
accumulation of de-glycosylated tapasin. Cells were lysed on ice for 1 h, followed by a 
30-min centrifugation to remove cell debris. Supernatants of lysed cells or supernatance 
of medium collected from tissue culture plates were incubated with or without antibodies 
overnight at 4 °C. Samples were then centrifuged to remove precipitated proteins and 
incubated for 2 h with Protein G beads (Amersham Biosciences). Beads were washed 
three times with lysis buffer containing 0.1% digitonin. Samples were separated by 10% 
SDS-PAGE and transferred to Immobilon membranes (Millipore) for immunoblotting. 
Membranes were blocked in 5% milk in TBS for 1 h at room temperature, followed by an 
overnight incubation with primary antibody in TBS plus 0.05% Tween 20 (TTBS) at 4 
°C. Membranes were washed for 2 h in TTBS, incubated for 30 min with secondary 
antibody, and washed again for 2 h at room temperature. Chemiluminescence was 
detected using the Amersham Biosciences ECL Plus kit. 
The following antibodies were used to immunoisolate relevant proteins: rabbit 
anti-mouse TAP1 serum (1:15, kindly provided by Dr. Ted Hansen), rabbit anti-mCRT 
antibody (1:400, Abcam, catalog number ab2907), and rabbit anti-Kb antiserum (EX8, 
1:100, kindly provided by Dr. Jonathan Yewdell). The following antibodies were used in 
immunoblotting analyses: goat anti-TAP1 antibody (1:2000, Santa Cruz Biotechnology, 
Inc., catalog number sc-11465), goat antibody specific to the N terminus of mCRT 
(1:2000, Santa Cruz Biotechnology, Inc., catalog number sc-7431), Hamster tapasin-
specific Ab and rabbit anti-!2m serum were also obtained from T. Hansen and used at 
1:3000 dilutions to detect murine tapasin and !2m, respectively, EX8 (1:7500), and 
rabbit anti-ERp57 (1:3000, Santa Cruz Biotechnology, Inc., catalog number 28823). 
Secondary antibodies (Jackson ImmunoResearch) were all conjugated to horseradish 




Influences of calreticulin, antigen uptake pathways, and innate signaling upon 
antigen cross-presentation 
Abstract 
Antigen cross-presentation involves the uptake and processing of exogenously derived 
soluble and cell-associated antigens by APCs via MHC class I. APCs load peptides 
derived from the exogenous antigens onto MHC class I molecules for presentation to 
CD8 T cells. Calreticulin has been suggested to mediate the cross-presentation of both 
soluble and cell-associated antigen. In this study, we examined roles for calreticulin in 
antigen cross-presentation using a number of models. Our findings indicate that soluble 
calreticulin does not enhance the cross-presentation of a peptide, fused, or bead 
associated antigen. Additionally, in a subcutaneous immunization context, cell-surface 
calreticulin of pre-apoptotic cells (induced by the drug thapsigargin) does not impact 
CD8 T cell proliferation or cytotoxicity in response to cell-associated antigen. Finally, 
although the ability of calreticulin to enhance intracellular MHC class I assembly does 
translate to induced transfer of MHC class I-peptide complexes from antigen donor cells 
to APC in vitro, this mode of antigen transfer is not relevant for the in vivo activation of 
naive CD8 T cells. Our findings indicate that known interactions between calreticulin and 
calreticulin-specific receptors are not sufficient to impact CD8 T cell activation against 
soluble or particulate antigens in association with calreticulin. Additionally, the ability of 
cell-surface calreticulin to facilitate phagocytic uptake of antigen donor cells does not 
translate to enhanced CD8 T cell activation against cell-associated antigen in 
subcutaneous immunizations of pre-apoptotic cells.  Importantly, this study points to the 
redundancy of pathways for uptake of soluble and cell-associated antigen. Lastly, 
independent of calreticulin, we show that LPS or high doses of thapsigargin inhibits 
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the proliferation of CD8 T cells in response to cell-associated antigen. Overall, this study 
provides insight into mechanisms of cross-priming of CD8 T cells, particularly as relating 
to modes of antigen transfer and effects of innate stimuli.  
Introduction 
APCs present peptides bound to MHC class I or class II molecules to T cells; this process 
facilitates T cell development, homeostasis, peripheral tolerance and activation of antigen 
specific T cells. Typically, MHC class I molecules present peptides derived from 
endogenous antigens to CD8 T cells. However, exogenous antigens can also be presented 
by MHC class I molecules of professional APCs such as DCs by a process termed cross-
presentation. APCs internalize extracellular soluble or cell-associated antigens and traffic 
the material to intracellular compartments that facilitate MHC class I presentation of the 
exogenously derived antigens [reviewed in (Amigorena and Savina, 2010)]. Cross-
presentation is suggested to be critical for the maintenance of CD8 T cell peripheral 
tolerance and for generation of cytotoxic T cell responses against intracellular pathogens 
and tumor cells [reviewed in!(Amigorena and Savina, 2010)].   
 Calreticulin is an ER-localized chaperone that aids in the intracellular assembly of 
nascent MHC class I molecules and other newly synthesized glycoproteins [reviewed in 
(Rutkevich and Williams, 2011)]. HSPs, like calreticulin, bind antigens. HSP-antigen 
complexes can be taken up by APCs and re-presented by APCs to CD8 T cells in vitro 
and in vivo (Basu et al., 2001; Basu and Srivastava, 1999; Binder and Srivastava, 2005; 
Nair et al., 1999). Furthermore, mice immunized with calreticulin derived from tumor 
cell lysates are protected against subsequent live tumor challenges (Basu and Srivastava, 
1999). The protection is attributed to the ability of calreticulin to efficiently cross-present 
associated tumor peptides. Calreticulin cross-presents associated peptides more 
efficiently compared to the peptides alone in vitro and in vivo (Basu et al., 2001; Basu 
and Srivastava, 1999). Receptors that bind calreticulin such as CD91, scavenger receptor-
A (SR-A) and scavenger receptor expressed by endothelial cells-1 (SREC-1) are thought 
to specifically bind to and endocytose calreticulin and associated cargo (Basu et al., 2001; 
Berwin et al., 2004; Berwin et al., 2003). These receptors are not exclusive to calreticulin 
as they bind other HSPs such as gp96, HSP90 and HSP70 (Basu et al., 2001; Berwin et 
al., 2003; Binder and Srivastava, 2004). Cross-presentation of soluble OVA is also 
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dependent on a receptor-specific interaction. Endocytosis and trafficking of OVA to a 
sub-cellular compartment that favors its cross-presentation is facilitated by the mannose 
receptor (Burgdorf et al., 2006). However, the idea that the mannose receptor is required 
for the efficient cross-presentation of OVA has been recently challenged (Segura et al., 
2009), which highlights the possibility of redundancy in receptors that mediate uptake of 
soluble proteins for cross-presentation. 
Calreticulin is also upregulated on the surface of apoptotic and pre-apoptotic 
cells; calreticulin acts as an “eat-me” signal on the cell surface (Gardai et al., 2005; 
Kuraishi et al., 2007; Obeid et al., 2007b). Cell-surface calreticulin, like soluble 
calreticulin, also binds CD91, facilitating the phagocytosis of cell-associated antigens 
(Gardai et al., 2005; Kuraishi et al., 2007; Obeid et al., 2007a). Recent studies show that 
cell-surface localized calreticulin contributes to the immunogenicity of tumor cells 
treated with specific chemotherapeutic drugs (Obeid et al., 2007b). Drug-induced surface 
calreticulin on pre-apoptotic tumor cells facilitates phagocytosis of treated tumor cells 
(Obeid et al., 2007b). Hence, calreticulin-dependent phagocytosis is hypothesized to play 
a role in developing the anti-tumor immune response (CD8 and CD4 T cell activation) 
[reviewed in (Kepp et al., 2011)]. Although calreticulin-mediated phagocytosis of pre-
apoptotic and apoptotic cells is described by a number of groups (Gardai et al., 2005; 
Kuraishi et al., 2007; Obeid et al., 2007b), the direct association between calreticulin-
mediated phagocytosis and enhanced proliferation or cytotoxicity of antigen-specific 
CD8 T cells has not been shown.  
 In this study, we examined the role of calreticulin in the cross-presentation of 
soluble and cell-associated antigens. To accomplish this, we formed OVA peptide-
calreticulin complexes as well as fused full length OVA to calreticulin and examined the 
ability of calreticulin-specific receptors to enhance the cross-presentation of OVA peptide 
or OVA. Additionally, we used a calreticulin-deficient MEF cell line to examine the role 
played by calreticulin in the cross-presentation of cell-associated antigens. Thapsigargin 
treatment is known to induce cell surface calreticulin and phagocytosis of cells. 
Phagocytic uptake of MEFs by BMDC is partially facilitated by calreticulin (Peters and 
Raghavan, 2011). We used thapsigargin treated cells to assess whether enhanced 
calreticulin-dependant phagocytosis of antigen donor cells translates to enhanced CD8 T 
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cell proliferation and cytotoxcity. Finally, calreticulin deficient cells express a lower 
MHC class I levels compared to calreticulin sufficient cells because calreticulin helps 
facilitate MHC class I assembly (Gao et al., 2002). Thus, the calreticulin-deficient 
fibroblasts also allowed us to assess the contribution of trogocytosis [cell-cell MHC class 
I transfer (Dolan et al., 2006; Harshyne et al., 2001)] to in vivo priming of naïve CD8 T 
cells. In sum, this study sheds light into mechanisms of antigen transfer utilized for cross-
priming naïve CD8 T cell responses against soluble and cell-associated antigens in vitro 
and in vivo.  
RESULTS 
Effects of calreticulin association upon the cross-presentation of a peptide 
Calreticulin-peptide complexes form when peptides and calreticulin are mixed and heat 
shocked to 50 °C (Basu and Srivastava, 1999). To examine whether calreticulin-specific 
receptors enhance the cross-presentation of a calreticulin-associated peptide (Figure 
3.1A), we heated calreticulin or bovine serum albumin (BSA) with a FITC labeled 
peptide derived from the model antigen OVA (amino acids 255-267: QLESIINFEKLTE-
FITC) at 50 °C for 1 hour. Free peptide was removed using a centrifugal filter device, 
and the amount of peptide bound to calreticulin and BSA was examined.  We observed 
that the peptide bound equally to both calreticulin and BSA (Figure 3.2A, left panel).  We 
next incubated C57BL/6 BMDC with the peptide complexes or peptide alone, and then 
added to the culture a T cell hybridoma line (B3Z) whose TCR ligand is the OVA258-265  
epitope (SIINFEKL) bound to the murine MHC class I allele H2-Kb (Karttunen et al., 
1992). We observed equal IL-2 levels in the culture supernatants when comparing 
responses to calreticulin-associated or BSA-associated peptide (Figure 3.2A, right panel) 
and equal IL-2 levels when comparing calreticulin-associated peptide to free peptide 
(Figure 3.2B).  We also incubated the calreticulin- or BSA-peptide complexes with bone 
marrow-derived M$ (BM M$), as M$ express a different set of receptors than DCs.  
Similar to the results seen with BMDC, calreticulin did not enhance the cross-
presentation of a peptide-associated antigen compared to BSA when BM M$ were used 
as the APC (Figure 3.2C).  Thus, the calreticulin-specific receptors that have been 
reported (Basu et al., 2001; Berwin et al., 2004; Berwin et al., 2003) are not sufficient to 




Figure 3.1: Hypothetical pathways by which calreticulin could enhance proliferation of 
naïve CD8 T cells. The figure depicts an APC displaying a MHC class I molecule loaded 
with an exogenously acquired OVA-derived peptide. Enhanced display of the OVA-
derived peptide will lead to enhanced proliferation of naïve OT-I T cells, which are 
specific for H2-Kb complexes with the OVA-derived SIINFEKL peptide. The APC could 
generate or acquire H2-Kb-SIINFEKL complexes via three potential calreticulin-
dependent mechanisms, which were tested in this study. (A) In the first pathway, 
calreticulin complexes with OVA might be cross-presented with higher efficiency 
compared to OVA alone; an OVA-calreticulin fusion protein and a peptide-calreticulin 
complex were generated in this study to test this possibility. (B) In the second pathway, 
cell-surface expression of calreticulin could enhance phagocytic uptake by APC of cells 
expressing OVA, thereby over-riding anti-phagocytic signals (“don’t eat me” signals 
such as CD47), and leading to increased generation and display of the H2-Kb-SIINFEKL 
peptide. (C) In the third pathway, expression of calreticulin in a cell expressing OVA is 
expected to result in increased formation of H2-Kb-SIINFEKL complexes within the cell. 
Increased levels of H2-Kb-SIINFEKL complexes could then be transferred to the APC 
via trogocytocis (or could function in trans along with APC-derived co-stimulatory 




Figure 3.2. Calreticulin does not enhance cross-presentation of a peptide antigen. (A) 10 
µM calreticulin (CRT) or bovine serum albumin (BSA) were incubated with 10 µM 
peptide (QLESIINFEKLTE-FITC).  Free peptide was removed using a centrifugal filter 
device at 4 °C, and peptide still in complex with CRT or BSA was measured (left panel).  
CRT- or BSA-peptide complexes were incubated with BMDC and B3Z cells. IL-2 
production was determined by ELISA of the supernatants after 24 hours (right).  Peptide 
concentration is indicated; CRT or BSA were present at a final concentration of 1 µM.  
(B) Cross-presentation of free peptide or CRT-peptide complexes was measured as in A. 
(C) Cross-presentation of CRT- or BSA-peptide complexes was measured as in A, except 
that BM M& were used as APCs. Data are representative of two independent analyses for 
A (right panel), B and C. For C, peptide binding to CRT and BSA was not measured. 
Mean ± s.e.m. are shown.     
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Effects of calreticulin fusion and TLR4-deficiency upon the cross-presentation of 
OVA 
The extended peptide used in Figure 3.2 does not have a high affinity for calreticulin, as 
similar amounts of peptide were recovered following heat shock with calreticulin or BSA 
(Figure 3.2A, left panel).  The peptide-binding site of calreticulin and specificity of 
peptides that bind to calreticulin are poorly understood and defined. Hence, to assess the 
possibility that calreticulin could quantitatively enhance the cross-presentation of an 
associated soluble antigen (Figure 3.1A), we generated a fusion protein between full-
length OVA and calreticulin [that linked OVA to the N-terminus of calreticulin (OVA-
CRT)]. Both OVA-CRT and OVA were expressed in E. coli and contained a histidine tag 
for purification. Proteins were first purified over a nickel column and then further 
purified and analyzed on a size-exclusion column. OVA-CRT and OVA were both 
isolated predominantly as single peaks, results indicative of the homogeneity and stability 
of both proteins. The major peak of both proteins was isolated and used for subsequent 
experiments (Figure 3.3A).  
To assess the cross-presentation efficiency of OVA-CRT compared to OVA, 
OVA-CRT or OVA were incubated with BMDC and CFSE labeled OT-I T cells 
[obtained from a transgenic mouse whose CD8 T cells express a TCR that recognizes the 
OVA257-264 epitope (SIINFEKL) bound to the murine MHC class I allele H2-Kb!(Hogquist 
et al., 1994)]. Levels of IL-2 in the supernatant were measured after 24 hours and OT-I T 
cell proliferation was measured after 3 days. No significant differences were observed in 
levels of IL-2 produced by the OT-I T cells in response to OVA or OVA-CRT, and 
proliferation of the OT-I T cells was found to be very similar (Figure 3.3B). To assess 
binding of OVA and OVA-CRT to BMDC, both proteins were labeled with 
allophycocyanin. Higher level of fluorescence incorporation was observed for OVA-CRT 
compared to OVA, and correspondingly, binding to BMDC was enhanced for OVA-CRT 
compared to OVA (Figure 3.3C and 3.3D). Due to the difficulty in achieving equivalent 
labeling of OVA-CRT and OVA, it remains unclear whether calreticulin fusion to OVA 
confers a specific BMDC uptake advantage.  
To evaluate the in vivo response to the soluble proteins, CFSE labeled OT-I T 
cells were injected intravenously (i.v.) into wild-type (WT) recipient mice. Twenty-four 
! ()!
hours later, mice were immunized subcutaneously (s. c.) with equimolar amounts of E. 
coli derived OVA or OVA-CRT. Three days after the immunization, proliferation of the 
OT-I T cells from the draining lymph node (dLN) was assessed. Percentages of 
proliferating OT-I T cells (Figure 3.3E) and percentages of OT-I T cells recovered 
(Figure 3.3F) were similar in response to OVA, whether or not OVA was fused to 
calreticulin  
In the experiments described thus far, lipopolysaccharide (LPS) contamination 
was of concern because the recombinant proteins used in these experiments are of E. coli 
origin. LPS is an agonist for TLR4 (Poltorak et al., 1998). It was conceivable that LPS 
contamination could mask potentiating effects of calreticulin. To address this concern, 
TLR4-/- recipient mice (Hoshino et al., 1999) were used, previously characterized for their 
inability to respond to LPS. OVA-CRT did not induce a greater CD8 T cell response 
compared to OVA alone even when TLR4-/- mice were used as recipients (Figure 3.3E, 
left panel and 3.3F). We concluded that there was no specific advantage for OT-I T cell 
proliferation when OVA was fused to calreticulin compared to OVA alone, even in the 
absence of LPS signaling. It is however noteworthy that percentages of OT-I T cells 
recovered in response to OVA and OVA-CRT were somewhat reduced in TLR4-/- mice 
compared to WT mice (Figure 3.3F). This reduction was not surprising as TLR4 
engagement can provide signal 2 (Figure 1.3), which enhances CD8 T cell activation. 
These results are also consistent with previous findings that TLR signaling enhances in 
vitro cross-presentation of soluble antigen (Burgdorf et al., 2008). However, the 
difference in OT-I T cell recovery is small at the tested antigen doses, indicating that 





Figure 3.3: Calreticulin fusion does not enhance cross-presentation of OVA. 
(A) Gel-filtration chromatogram of E. coli-derived OVA or the OVA-calreticulin (OVA-
CRT) fusion protein (left). SDS-PAGE analysis of pooled fractions from left panel; 
proteins were loaded in equimolar amounts (right) and coomassie stained. (B) Indicated 
proteins were incubated with BMDC for 3 hours. BMDC were fixed and CFSE labeled 
OT-I T cells were added. IL-2 levels in supernatants were determined by ELISA (left 
panel; 24 hour time point). OT-I T cell proliferation was measured at 72 hours in 
response to 44 µM OVA or OVA-CRT. The solid grey profile indicates the condition 
where no antigen (no Ag) was added. Data are representative of two independent 
analyses. (C, D) OVA-CRT and OVA were labeled with allophycocyanin. (C) Labeling 
intensity was determined by fluorescence imaging of the proteins after separation by 
SDS-PAGE (inset). Fluorescence intensity was quantified for the indicated proteins. (D) 
Binding of fluorescent proteins to BMDC was assessed by flow cytometry. BMDC were 
incubated with labeled proteins on ice before being analyzed by flow cytometry. BMDC 
not incubated with proteins are depicted as a grey filled (unlab). Representative of two 
independent experiments performed with the same labeled proteins. (E, F) WT or TLR4-/- 
recipient mice were injected i.v. with CFSE labeled OT-I T cells. Twenty-four hours 
later, mice received s.c. injections of the indicated antigen (100 µl of a 220 nM solution). 
OT-I T cell proliferation was measured 3 days later in the dLN (inguinal). (E) The % of 
proliferating OT-I T cells averaged from the mice of one experiment is shown in the left 
panel. Two to three mice were used in all groups. The right panel depicts proliferation in 
WT recipient mice. (F) Quantification of the percentage of OT-I T cells of all CD8 T 
cells recovered in E. Data for E and F are representative of three out of four independent 
analyses for WT recipients and a single analysis with TLR4-/- recipients. Similar results 
were obtained in comparisons of OVA and OVA-CRT-induced OT-I proliferation in WT 
and TLR2/4-/- recipient mice (data not shown). (G) Compilation of the % of proliferating 
OT-I T cells (left panel) and of the % of OT-I T cells as a function of all CD8 T cells 
(right panel) from 4 independent experiments performed with WT recipient mice. Two 
experiments contained 2 doses of antigen and two experiments contained 1 antigen dose. 
Antigen doses ranged from 0.22 µM – 22 µM, using 100 µl. Each point represents the 
mean of 2-3 mice for that condition. Mean ± s.e.m. are shown. A two-tailed pair-wise 
student t-test was used for statistical analyses in G. Analyses shown in Figure 3.3E-G 








Cross-presentation efficiencies of glycosylated and non-glycosylated OVA 
Cross-presentation of soluble OVA is suggested to be facilitated by the mannose receptor 
(Burgdorf et al., 2006). OVA purified from E. coli is not glycosylated, as E. coli lack 
eukaryotic glycosylation machinery. However, we found that non-glycosylated OVA 
isolated from E. coli was cross-presented in vivo (Figure 3.3), indicating that the mannose 
receptor may not be essential for the cross-presentation of soluble OVA. This result 
prompted us to assess the cross-presentation efficiency of OVA purified from E. coli and 
OVA obtained from Sigma [OVA (Sigma)], which is glycosylated as it is isolated from 
chicken eggs. This comparison would allow us to further determine the importance of 
OVA uptake through the mannose receptor upon the cross-priming of OT-I T cells.    
To assess the cross-presentation efficiency of OVA purified from E. coli [OVA 
(E. coli)] compared to OVA (Sigma), OVA (E. coli) and OVA (Sigma) were incubated 
with BMDC for 3 hours. After 3 hours, the cells were fixed and B3Z cells (a T cell line 
that is specific for the same OVA epitope for which OT-I T cells are specific (Karttunen 
et al., 1992)) were added to the cultures. IL-2 levels induced by OVA (Sigma) were 
similar compared to IL-2 levels induced by OVA (E. coli) at a number of OVA doses 
tested (Figure 3.4A). However, at an OVA dose of 0.9-2.6 mg, we observed a significant 
(p=0.0018) increase in IL-2 levels produced in response to OVA (Sigma) compared to 
OVA (E. coli) (Figure 3.4A). We next assessed the ability of s.c. delivered OVA (E. coli) 
and OVA (Sigma) to induce proliferation of CFSE labeled OT-I T cells in vivo. Using 
WT mice as recipients, the percentages of proliferating OT-I T cells were similar in 
response to OVA (Sigma) compared to OVA (E. coli) (Figure 3.4B; p=0.8583). We 
concluded that glycosylated OVA does have a slight cross-presentation advantage 
compared to non-glycosylated OVA in vitro using BMDC as APC, as at one OVA dose 
range, OVA (Sigma) was cross-presentated more efficiently than OVA (E. coli) (Figure 
3.4A). However, glycosylated OVA does not have a cross-presentation advantage 
compared to non-glycosylated OVA in vivo. Taken together, the data in Figure 3.4 
suggest that the mannose receptor is non-essential for the cross-presentation of soluble 





Figure 3.4: Glycosylated and non-glycosylated OVA are cross-presented with the same 
efficiency. (A) Indicated proteins were incubated with BMDC for 3 hours. BMDC were 
fixed B3Z cells were added. IL-2 levels in supernatants were determined by ELISA (24 
hour time point). Within one experiment, each condition was performed in triplicate and 
averaged. Reported here is the average of two, three, six, eight and five independent 
experiments performed with 15, 5.7-8.3, 3-4, 0.9-2.6, and 0.43-0.7 mg OVA, 
respectively, and each experiment contained one to two doses within a dose range. 
*p=0.0018. (B) WT recipient mice were injected i.v. with CFSE labeled OT-I T cells. 
Twenty-four hours later, mice received s.c. injections of the indicated antigen (2.5-100 
µg). OT-I T cell proliferation was measured 3-5 days later in the dLN (inguinal). Left 
panel: A representative proliferation profile is presented in response to 2.5 µg OVA.  
Middle and right panels: Two to three mice are averaged to generate each data point, 
which represents the % of proliferating OT-I T cells (middle) or the % of OT-I T cells as 
a function of all CD8 T cells recovered (right). Three independent experiments are 
represented. In one experiment, 2 different OVA (E. coli) preps were used in 2 different 
groups of mice. In another experiment, two doses (10 µg and 100 µg) of OVA were used 
in 2 different groups of mice. Mean ± s.e.m. is shown in A. A two-tailed pair-wise student 
t-test was used for statistical analysis in A and B. Analyses shown in Figure 3.4B were 





Effects of calreticulin upon the cross-presentation of bead-associated OVA 
We next hypothesized that calreticulin may have a role in inducing the cross-presentation 
of a particulate antigen as calreticulin has been shown to function as an “eat-me” signal 
when present on the surface of cells (Gardai et al., 2005; Kuraishi et al., 2007; Obeid et 
al., 2007b; Peters and Raghavan, 2011). Additionally, it is possible that the soluble 
antigens tested thus far (calreticulin-peptide complex and OVA-calreticulin fusion 
protein) may lack the avidity needed bind to and be efficiently internalized by calreticulin 
specific receptors. To test the effect of calreticulin on a particulate antigen, OVA or an 
equimolar mixture of OVA and calreticulin (OVA+CRT) were conjugated to 1.5 µm iron 
oxide beads, and cross-presentation efficiencies were assessed in vitro and in vivo. Levels 
of OVA conjugated to beads were quantified with a fluorescent Ab. Comparable amounts 
of OVA were conjugated in the OVA and OVA+CRT bead preparations (Figure 3.5A). 
Similar to Figure 3.3B, OVA or OVA+CRT beads were next incubated with BMDC and 
CFSE labeled OT-I T cells. Again, there was no difference in the levels of IL-2 generated 
or in the proliferation of the OT-I T cells induced in response to OVA or OVA+CRT 
beads (Figure 3.5B). Similar results were obtained in vivo with WT or TLR2/4-/- recipient 
mice (Takeuchi et al., 1999) (Figure 3.5C). These results echoed our findings using the 
soluble OVA-CRT fusion protein. Taken together, we concluded that extracellular 
calreticulin, in a soluble or particulate context, does not enhance the cross-presentation of 














Figure 3.5: Calreticulin on the surface of a particulate antigen does not influence CD8 T 
cell proliferation. (A) OVA alone or with calreticulin (OVA+CRT) were conjugated to 
iron-oxide beads. Levels of OVA conjugated to the beads were quantified using a 
fluorescence-based assay. (B) The indicated beads were incubated with BMDC for 3 
hours. BMDC were fixed and CFSE labeled OT-I T cells were added. IL-2 production 
was determined by ELISA of the supernatants at 24 hours (left panel). OT-I T cell 
proliferation was measured after 72 hours in response to 10 µl OVA or OVA+CRT 
beads. The solid grey profile indicates the condition where no antigen (no Ag) was added 
(right panel). Data are representative of three independent analyses. Comparing 
proliferation of OT-I T cells in response to 10 µl OVA or OVA+CRT, a p-value of 
0.3105 was obtained using a two-tailed pair-wise student t-test. (C, D) OT-I T cell 
proliferation and recovery were measured in WT or TLR2/4-/- mice in response to 50 µl 
beads on day 3. (C) Average proliferation values for 2-3 mice per group (except PBS, 
where 1 mouse was used) are shown in the left panel. A representative proliferation 
prolife from WT recipients in response to OVA beads, OVA+CRT beads or PBS (filled 
in grey) is shown on the right panel. (D) Quantification of the percentage of OT-I T cells 
of all CD8 T cells recovered in C. Data are representative of two independent analysesfor 
C. Mean ± s.e.m. are shown. Analyses shown in Figure 3.5C and 3.5D were performed 










Calreticulin expression in thapsigargin-treated cells cells does not enhance the cross-
presentation of cell-associated OVA in vitro  
We next tested the ability of cell-surface calreticulin to enhance the cross-presentation of 
a cell-associated antigen, via the induction of cellular phagocytic uptake (Figure 3.1B). 
The drug thapsigargin depletes ER calcium by inhibiting the sarco-ER Ca2+-ATPase 
pumps (Thastrup et al., 1990). We showed recently that short treatments of MEF with 
thapsigargin induce cell surface expression of calreticulin, and phagocytosis of treated 
MEF was enhanced in a manner that was partially dependent on calreticulin (Jeffery et 
al., 2010; Peters and Raghavan, 2011). To test whether thapsigargin-induced cell surface 
calreticulin could thereby quantitatively enhance CD8 T cell proliferation in response to a 
cell-associated antigen, a MEF cell line (K42) derived from a calreticulin-deficient mouse 
embryo (Gao et al., 2002; Mesaeli et al., 1999) was used. K42 cells were infected with a 
retrovirus encoding WT calreticulin or one lacking calreticulin [to generate K42(WT 
CRT) and K42(CRT-/-) cells, respectively (Del Cid et al., 2010).] Calreticulin protein 
expression was confirmed by immunoblotting analyses (Figure 3.6A, inset). To assess the 
ability of thapsigargin to induce surface calreticulin, K42(WT CRT) and K42(CRT-/-) (as 
a specificity control) cells were incubated with either 200 nM or 5 µM thapsigargin for 5 
hours. The cells then harvested and triple stained for analysis by flow cytometry. The 
cells were stained with anti-calreticulin (in the presense or absence of the calreticulin 
peptide used as the immunogen to generate the calreticulin-specific antibody in order to 
account for any non-specific binding of the antibody), annexin V (AnnV) and 7-
aminoactinomycin D (7AAD). Annexin V binds PS, a surface marker of apoptotic cells. 
7AAD is not permeable to live or early apoptotic cells. However, 7AAD does stain late 
apoptotic/secondary necrotic cells and thus allows us to assess surface calreticulin 
expression only on cells that have maintained membrane integrity. Cell-surface 
calreticulin was significantly up-regulated in response to both 200 nM or 5 µM 
thapsigargin on pre-apoptotic K42(WT CRT) cells (AnnV-7AAD-) (Figure 3.6A). 
Staining was specific for calreticulin, as surface calreticulin was not detectable on 
K42(CRT-/-) cells. Both cell types were largely pre-apoptotic immediately after treatment, 
and most cells reached secondary necrosis by 30 hours post treatment [Figure 3.6B and 
(Peters and Raghavan, 2011)].   
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K42(WT CRT) and K42(CRT-/-) cells were infected with a retrovirus encoding a 
truncated, cytosolically-expressed form of OVA and GFP utilizing a bicistronic IRES-
GFP element in the retroviral vector (Van Parijs et al., 2009). The OVA/GFP expressing 
K42(WT CRT) and K42(CRT-/-) cells were sorted to match the two cell types for GFP 
intensity (Figure 3.7A), and GFP expression was found to be stably maintained thereafter 
(and assessed prior to each experiment). Thapsigargin-treated OVA-expressing 
K42(CRT-/-) or K42(WT CRT) cells were used as an antigen source for in vitro 
experiments with BMDC as the APC. Five hours after thapsigargin treatment, cells were 
washed and then mixed with BMDC and CFSE labeled OT-I T cells. The five-hour time 
point was used because cell-surface calreticulin is significantly detectable only in pre-
apoptotic thapsigargin-treated cells (Peters and Raghavan, 2011), and the majority of 
MEFs are pre-apoptotic at this time point (Figure 3.6B). Levels of IFN# and OT-I T cell 
proliferation were measured after 5 days. The OT-I T cells did not produce IFN# or 
proliferate in presence of antigen donor cells alone when no BMDC were present (Figure 
3.7B; K42 + OT-I alone and 3.7C; grey fills). This finding indicates that the cells 
expressing OVA were not able to directly activate the OT-I T cells. BMDC are necessary 
for OT-I T cell activation in a primary response, likely due to the requirement for co-
stimulatory molecules that are provided by BMDC. In the samples containing both 
BMDC and thapsigargin-treated cells, slightly higher levels of IFN# were detected in 
response to OVA derived from thapsigargin-treated K42(WT CRT) cells compared to 
thapsigargin-treated K42(CRT-/-) cells at the higher of the two target cell doses tested 
(Figure 3.7B). However, we observed no significant difference in proliferation of the OT-
I T cells in response to OVA derived from thapsigargin-treated K42(WT CRT) cells 
compared to thapsigargin-treated K42(CRT-/-) cells (Figures 3.7C and 3.7D). As an 
alternative protocol, thapsigargin-treated OVA-expressing K42(CRT-/-) or K42(WT 
CRT) cells were incubated with BMDC for 60 min, a time point at which calreticulin-
dependent phagocytic uptake of thapsigargin treated cells was observed (Peters and 
Raghavan, 2011). CD11c+ cells were subsequently purified and added to OT-I T cells; 
proliferation was then assessed. The result did not change based on the altered protocol 
(Figure 3.7E). The use of purified CD11c+ cells eliminates possible activation of OT-I 
cells in trans (by antigen donor cell derived MHC-peptide signals in combination with 
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APC derived co-stimulation). Thus, thapsigargin-induced surface calreticulin on pre-
apoptotic cells enhances phagocytosis of cells (Peters and Raghavan, 2011), but the 
enhancement in phagocytosis does not translate to enhanced cross-presentation of cell-



















Figure 3.6: 200 nM and 5 µM thapsigargin induce cell-surface calreticulin in MEF. 
Calreticulin-/- MEF (K42) were infected with a retrovirus expressing wild-type 
calreticulin or empty vector [K42(WT CRT) and K42(CRT-/-), respectively]. (A) 
Immunoblotting analyses of indicated cell lysates were undertaken with an antibody 
directed against calreticulin [inset; wild-type MEF (K41) were used as a positive control]. 
K42(WT CRT) or K42(CRT-/-) cells were treated with 200 nM or 5 µM thapsigargin 
(THP) for 5 hrs. Cells were then stained with anti-calreticulin or anti-calreticulin pre-
incubated with the calreticulin-derived peptide used as the immunogen and used to 
affinity purify the Ab (KEQFLDGDAWTNRWVESKHK). All cells were also stained 
with annexinV (AnnV) and 7-aminoactinomycin D (7AAD) to measure PS exposure and 
cell membrane permeability, respectively; the cells were then analyzed by flow 
cytometry. The ratio of the mean fluorescence (MF) of the samples in the absence over 
the presence of the peptide is reported here for the AnnV-7AAD- population (right panel) 
and a representative histogram of cells treated with 200 nM thapsigargin is shown (left 
panel). Cells were gated on the AnnV-7AAD- population for the histogram. Untreated 
cells are shown in filled grey. (B) K42(WT CRT) or K42(CRT-/-) cells were treated with 
200 nM THP. At the indicated time points post-treatment, the cells were labeled with 
AnnV and 7AAD. The percentage AnnV single positive (apoptotic), AnnV/7AAD double 
positive (secondary necrotic) and double negative (live/pre-apoptotic) cells are shown. 
Data are a compilation of 7 and 6 experiments for 200 nM and 5 mM thapsigargin 
treatments, respectively for A. For B, the 0 time point is a compilation of 4 independent 
experiments and the rest of the time points are from a single experiment. A two-tailed 
pair-wise student t-test was used for statistical analysis. Mean ± s.e.m. are shown.
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Figure 3.7: Calreticulin expression in thapsigargin-treated cells does not enhance CD8 T 
cell proliferation in vitro. K42(WT CRT) or K42(CRT-/-) cells were infected with a 
retrovirus expressing cytosolic OVA and GFP, and GFP-positive cells were sorted and 
stably maintained. (A) K42(WT CRT) or K42(CRT-/-) cells expressing OVA were 
analyzed for GFP expression. (B, C) K42(WT CRT) or K42(CRT-/-) cells expressing 
OVA were treated with 200 nM THP for 5 hrs. The K42 cells were washed three times 
and incubated with BMDC and CFSE labeled OT-I T cells. Five days later, IFN# 
production was determined by ELISA of the supernatants (B), and proliferation of OT-I T 
cells was measured (C). For the IFN# ELISA, K42 + OT-I alone indicates samples in 
which BMDC were not added. SIINFEKL indicates samples containing BMDC + OT-I 
and the OVA-derived peptide, SIINFEKL. BMDC + OT-I alone indicates samples in 
which no target cells or peptide was added. Data are representative of 2 independent 
experiments. For the proliferation analysis, THP-treated K42(WT CRT) cells expressing 
OVA incubated with OT-I T cells alone (no BMDC) are shown in grey (filled in). Data 
are representative of 2 replicates per condition. (D) Compilation of four independent 
experiments comparing the proliferation of OT-I T cells in response to K42(WT CRT) or 
K42(CRT-/-) cells expressing OVA and treated with 200 nM THP. Each point represents 
the average proliferation of 2 replicates per condition and is an independent experiment. 
(E) K42(WT CRT) or K42(CRT-/-) cells expressing OVA were treated with 200 nM THP 
for 5 hrs. The K42 cells were washed three times and incubated with BMDC for 1 hour. 
CD11c+ cells were MACS purified and incubated with CFSE labeled OT-I T cells. 
Proliferation of OT-I T cells was measured 5 days later. Data are representative of 2 
replicates per condition and of 2 independent experiments. A two-tailed pair-wise student 






















Calreticulin expression in antigen donor cells does not enhance the proliferation or 
cytotoxicity of CD8 T cells in vivo in response to cell-associated antigen 
The in vivo counterpart of the cell-associated antigen experiment was undertaken as 
described above for the fusion protein, following injection of thapsigargin-treated OVA-
expressing K42(WT CRT) or K42(CRT-/-) cells s.c. into the flank of the recipient mice. 
Four days after the injection of antigen donor cells, proliferation of the adoptively 
transferred CFSE labeled OT-I T cells was measured by flow cytometry. At a dose of 200 
nM thapsigargin, there was no difference in proliferation in response to OVA from 
K42(WT CRT) or K42(CRT-/-) cells (Figures 3.8A and 3.8B). Surprisingly however, OT-
I T cell proliferation was strongly inhibited when the K42 cells [both K42(WT CRT) and 
K42(CRT-/-)] were treated with 5 µM thapsigargin [Figures 3.8A and 3.8B; data not 
shown for K42(CRT-/-)]. We have recently shown that conditioned media from MEFs 
treated with 5 µM thapsigargin induces IL-6 production in BMDC in the absense of any 
other stimuli. The sterile induction of IL-6 is not observed in response to conditioned 
media from MEFs treated with 200 nM thapsigargin. Direct treatment of BMDC with 
thapsigargin was also able to induce sterile IL-6 production in BMDC. Sterile IL-6 
production by BMDC in response to the conditioned media was attributed to the direct 
effects of thapsigargin sequestered within the treated cell membranes and subsequently 
partitioned into the conditioned media (Peters and Raghavan, 2011). Hence, drug 
sequestered in K42 cells treated with 5 µM thapsigargin may have directly activated APC 
in vivo, inducing inhibition of OT-I T cells. Further studies are needed to understand the 
inhibition of OT-I T cells in response to K42 cells treated with 5 µM thapsigargin. 
Nevertheless, similar levels of OT-I T cell proliferation was observed in response to 
K42(WT CRT) and K42(CRT-/-) cells expressing OVA treated with 200 nM thapsigargin 
(Figure 3.8B, left panel). Similar percentages of OT-I T cells were recovered from mice 
immunized with K42(WT CRT) and K42(CRT-/-) thapsigargin treated cells as well 
(Figure 3.8B, right panel).   
 The in vivo experiments described thus far measure proliferation of OT-I T cells 
in response to soluble, bead-associated and cell-associated OVA. However, proliferation 
may not be indicative of effector function. Additionally, although widely used, the OT-I 
cell adoptive transfer protocol could represent a non-physiological mode of expansion of 
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CD8 T cells (in the absence of adequate CD4 T cell help). To evaluate the effector 
function of endogenous CD8 T cells in response to different forms of cell-associated 
antigen, an in vivo cytotoxicity assay was performed. Recipient WT mice were 
immunized s.c. with PBS, or 200 nM thapsigargin-treated K42(WT CRT) or K42(CRT-/-) 
cells expressing OVA. Seven days later, two different groups of target splenocytes 
labeled with two different dilutions of CFSE dye were simultaneously injected i.v. into 
the recipient mice. One group of target cells was pulsed with the OVA-derived 
SIINFEKL peptide, and these target cells were labeled with a high concentration of 
CFSE. The second group of target cells was pulsed with a non-specific peptide that, 
similar to SIINFEKL, binds the mouse MHC class I allele H2-Kb and is derived from 
listeriolysin O (LLO; a protein expressed by the bacterium Listeria monocytogenes) 
(Goldszmid et al., 2009). This second group of target cells was labeled with a low 
concentration of CFSE. The two populations of target cells were injected at a 1:1 ratio 
into the immunized mice, with a total of 3.6x106 target cells injected. The spleens of the 
recipient mice were harvested and analyzed by flow cytometry for persistence of labeled 
cells 18 hours after the injection of the target cells. The percentage of SIINFKEL pulsed 
target cells recovered from the mouse that was immunized with PBS remained about 50. 
However, target cells isolated from mice immunized with 5x105 K42(WT CRT) or 
K42(CRT-/-) cells showed a reduction in the percentage of SIINFEKL pulsed target cells 
(Figure 3.8C). Thus, effector cells specific to the OVA-derived peptide (and not the LLO-
derived peptide) were generated in mice that had been immunized with K42 cells 
expressing OVA. Reduction of the SIINFEKL pulsed target cells was not observed at the 
lower immunizing cells dose of 5x104 K42 cells (Figure 3.8C). The reduction of 
SIINFEKL pulsed target cells was similar between mice immunized with 5x105 K42(WT 
CRT) or K42(CRT-/-) cells (Figure 3.8C).  
The draining lymph nodes of the recipient mice were also harvested (at the same 
time as the spleens) to assess the activation of the endogenous antigen specific CD8 T 
cells. The cells of the lymph nodes were incubated with SIINFEKL peptide for 48 hours. 
IFN# production was then measured from the supernatants. The levels of IFN# produced 
by CD8 T cells was similar between mice immunized with 5x105 K42(WT CRT) or 
K42(CRT-/-) cells expressing OVA (Figure 3.8D). These findings indicate that 
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thapsigargin-induced cell-surface calreticulin on K42 cells (Figure 3.6) does not lead to 































Figure 3.8: Calreticulin expression in thapsigargin-treated cells does not enhance CD8 T 
cell proliferation or cytotoxicity in vivo. (A) Recipient WT mice were injected i.v. with 
CFSE labeled OT-I T cells. Twenty-four hours later, the mice received PBS, 5x105 THP-
treated K42(WT CRT) and K42(CRT-/-) (left panel; 200 nM THP) or THP-treated 
K42(WT CRT) (right panel; 5 µM THP) OVA expressing cells s.c. Proliferation was 
measured 4 days later in the dLN (inguinal). The control immunization with PBS is 
depicted in filled grey. Data are representative of 2-3 mice per group. (B) Quantification 
of proliferating OT-I T cells and the percentage of OT-I T cells as a function of all CD8 T 
cells recovered in response to 200 nM and 5 µM THP. Panels comparing K42(WT CRT) 
to K42(CRT-/-): For both panels, each point represents the average OT-I T cell 
proliferation from 2-3 mice and is an independent experiment. Three independent 
experiments are represented; mice received 2.5-5x105 THP-treated antigen donor cells. 
One experiments contained 2 cell doses, and two experiments contained 1 cell dose. 
Panels comparing 200 nM to 5 µM THP: In the left panel, each point represents the 
average OT-I T cell proliferation from 2-3 mice and is an independent experiment. Five 
independent experiments are represented; mice received 0.1-50x105 THP-treated antigen 
donor cells. Only two experiments compared 200 nM to 5 µM THP. In the right panel, 
four independent experiments are represented; mice received 2.5-10x105 THP-treated 
antigen donor cells. Only two experiments compared 200 nM to 5 µM THP. (C) 
Recipient WT mice were injected s.c. with PBS, or 200 nM THP-treated K42(WT CRT) 
and K42(CRT-/-) cells expressing OVA. Seven days post-immunization, mice were 
injected i.v. with PKH26 labeled target cells pulsed with the OVA-derived SIINFEKL 
peptide (high CFSE labeling) or the listeriolysin O derived VAYGRQVYL non-specific 
peptide (low CFSE labeling). Spleens were recovered 18 hours later to assess killing of 
target cells by flow cytometry; the PKH26 dye and a congenic marker (CD45.1) 
identified the target cells. The percentage of SIINFEKL loaded target cells recovered is 
depicted in the graph. Each circle is representative of the percentage of target cells 
recovered from one mouse. Representative of two independent experiments. (D) Draining 
lymph nodes (inguinal) were harvested at the same time as spleens and incubated in vitro 
with 10 µM SIINFEKL for 72 hours. IFN# production was determined by ELISA of the 
supernatants. Representative of two independent experiments. For B, A two-tailed pair-
wise student t-test was used for statistical analysis. Mean ± s.e.m. are shown in C and D. 







Calreticulin expression in antigen donor cells enhances CD8 T cell proliferation in 
vitro  
We considered the possibility that pre-assembled MHC class I molecules of antigen 
donor cells could contribute to CD8 T cell proliferation (Figure 3.1C), thus accounting 
for the non-critical role of cell-surface calreticulin in inducing CD8 T cell proliferation 
(Figures 3.7 and 3.8).  Calreticulin facilitates intracellular assembly of MHC class I 
molecules (Gao et al., 2002), and correspondingly, K42(WT CRT) cells expressing OVA 
have higher levels of H2-Kb and H2-Kb-SIINFEKL complexes compared to K42(CRT-/-) 
cells expressing OVA (Figure 3.9A and 3.9B). If pre-assembled MHC class I molecules 
of antigen donor cells contribute to CD8 T cell proliferation in vitro or in vivo, we would 
expect to see some enhancement in proliferation in response to antigen derived from WT 
cells compared to calreticulin-deficient cells. This effect may not have been apparent 
with thapsigargin-treated cells as thapsigargin treatment abrogates the calreticulin-
dependent optimization of MHC class I assembly (Jeffery et al., 2010). 
To further address possible contributions of pre-assembled MHC class I to CD8 T 
cell proliferation, MEFs were UV-irradiated immediately prior to use in OT-I T cell 
assays [in order to prevent their uncontrolled proliferation; cell death progression in UV-
treated cells had comparable kinetics to that for thapsigargin-treated cells (Figure 3.10A 
compared to Figure 3.6B)].  In contrast to findings with thapsigargin treated MEF (Figure 
3.7D), OT-I T cells proliferated to a greater extent and secreted more IFN# in response to 
OVA-expressing UV-treated K42(WT CRT) cells compared to OVA-expressing UV 
treated K42(CRT-/-) cells in vitro (Figures 3.11A; first panel and 3.11B & 3.11C; top 
panels). The difference in proliferation was significant at the higher of the two cell doses 
assessed (Figure 3.11D).  
We showed recently that UV-treated MEF do not induce cell-surface calreticulin 
at a level detectable by flow cytometry and that calreticulin does not enhance phagocytic 
uptake of UV-treated MEF (Peters and Raghavan, 2011). These findings were confirmed 
in the present study by measuring cell-surface calreticulin at various time points post UV-
treatment. It is noteworthy that these analyses were undertaken in the absence of calcium. 
Cell-surface calreticulin induction was not detectable by flow cytometry at any of the 
time-points that were tested (Figure 3.10B).  Calreticulin is reported to bind PS in a 
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calcium dependant manner (Paidassi et al., 2011; Tarr et al., 2010), and it is possible that 
use of AnnexinV in our staining protocol or the absence of calcium during staining 
interfered with expression or detection of calreticulin. Under these conditions, phagocytic 
uptake of K42(WT CRT) or K42(CRT-/-) cells was also very similar at multiple time-
points tested (Figure 3.10C-3.10E; phagocytic uptake was measured 17 hours post UV-
treatment). Although conditions used for OT-I T cell proliferation and phagocytosis were 
different (MEFs were irradiated immediately or 17 hours prior to the assay, respectively), 
these findings suggested that the observed calreticulin-dependent increase in OT-I T cell 
proliferation (Figure 3.11D) could not be attributed mainly to increased calreticulin-
dependent phagocytic uptake of antigen donor cells.  
To further test for possible involvement of intracellular calreticulin-dependent 
enhancement of MHC class I assembly, we examined the ability of MHC-mismatched 
BMDC (Balb/c mice-derived) to activate OT-I T cells. In this setting, Balb/c BMDC 
cannot cross-present OVA from the apoptotic donor cell to OT-I T cells because Balb/c 
BMDC lack the appropriate MHC class I allele (H2-Kb). Thus, the primary mechanism of 
OT-I T cell activation by Balb/c BMDC would involve the trogocytic transfer of H2-Kb-
SIINFEKL complexes from the antigen donor cell to Balb/c BMDC, or activation in 
trans mediated by MEF-derived H2-Kb-SIINFEKL together with BMDC-derived co-
stimulatory molecules. Indeed, when Balb/c BMDC were used as APC, differences in 
IFN# secreted by OT-I T cells and OT-I T cell proliferation induced by OVA-expressing 
UV-treated K42(WT CRT) and K42(CRT-/-) cells persisted (Figure 3.11A; middle panel 
and Figure 3.11B; lower panel). Proliferation of OT-I T cells was also examined using 
BMDC from !2m-/- mice (B6 background) and similar results were obtained (Figure 
3.11C, lower panel). The analyses of Figure 3.11C used K42(WT CRT) and K42(CRT-/-) 
cells from a different OVA-GFP-expressing virus infection compared to that shown in 
Figure 3.11B. GFP and MHC class I expression profiles for antigen donor cells used in 
3.11B are shown in Figures 3.7A and Figure 3.8A, respectively. MHC class I and GFP 
expression profiles for antigen donor cells used for the experiment shown in Figure 3.11C 
are depicted in Figures 3.9B and 3.9C, respectively.  
Two experiments were performed comparing Balb/c to B6 BMDC, and two 
experiments were performed comparing B6(!2m-/-) and B6(WT) BMDC. Combining 
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these four experiments to perform statistical analyses, we found that OT-I T cells 
proliferated to a significantly higher extent in response to UV-treated OVA-expressing 
K42(WT CRT) cells compared to K42(CRT-/-) cells when either B6 BMDC or Balb/c and 
B6(!2m-/-) BMDC were used (Figure 3.11E). Although OT-I T cells secreted less IL-2 in 
response to K42 cells using BMDC from Balb/c mice compared to B6 mice, there was no 
statistically significant difference in OT-I T cell proliferation in response to OVA derived 
from K42(WT CRT) cells using B6 BMDC compared to Balb/c and B6(!2m-/-) BMDC 
(Figure 3.11E). The same result was observed when comparing K42(CRT-/-) antigen 
donor cells incubated with the different BMDC preparations (Figure 3.11E). Notably, 
OT-I T cells did not proliferate in response to K42 cells expressing OVA when BMDC 
were not present (Figure 3.11B and 3.11C, grey filled profiles). These findings suggested 
that 1) the positive effect of calreticulin on OT-I T cell proliferation in the UV-treated 
antigen donor cell context was attributable to the ability of intracellular calreticulin of 
K42(WT CRT) cells to facilitate MHC class I assembly and 2) OT-I T cell proliferation 
observed in a syngeneic in vitro experimental set-up (using B6 BMDC) largely derives 
from pre-assembled H2-Kb-SIINFEKL complexes rather than de novo assembly of MHC 













Figure 3.9: MHC class I or GFP expression in antigen donor cells used in the analyses of 
Figures 3.11. (A) and (B, left panel) OVA-expressing K42(WT CRT) or K42(CRT-/-) 
cells were labeled with an Ab against H2-Kb, or secondary alone (filled grey). Analyses 
shown in A and B are data from separate infections of K42(WT CRT) or K42(CRT-/-) 
cells with retroviruses encoding GFP and OVA. Cells characterized in panel A were used 
for experiments shown in Figure 3.11A and 3.11B. Cells characterized in panels B and C 
were used for the experiment shown in 3.11C. (B, right panel) Cells were labeled with an 
Ab against H2-Kb-SIINFEKL [non-OVA expressing cells are shown as controls; 
K42(WT CRT) in filled grey and K42(CRT-/-) as a dotted line]. (C) GFP expression was 






















Figure 3.10: UV treatment of WT MEF does not induce cell-surface calreticulin or 
enhanced phagocytosis compared to calreticulin-deficient MEF. (A) K42(WT CRT) cells 
were exposed to UV. At the indicated time points post-treatment, the cells were labeled 
with AnnV and 7AAD. The percentage AnnV single positive (apoptotic), AnnV/7AAD 
double positive (secondary necrotic) and double negative (live/pre-apoptotic) cells are 
shown. (B) K42(WT CRT) or K42(CRT-/-) cells were exposed to UV and allowed to 
progress through apoptosis for the indicated time points. Cells were harvested and stained 
with anti-calreticulin or anti-calreticulin pre-incubated with the calreticulin-derived 
peptide used as the immunogen and used to affinity purify the Ab. All cells were also 
stained with AnnV and 7AAD; the cells were then analyzed by flow cytometry. The ratio 
of the mean fluorescence (MF) of the samples in the absence over the presence of the 
peptide is reported here. (C) K42(WT CRT) or K42(CRT-/-) cells were labeled with 
CellTracker Green CMFDA.  Fluorescence intensity of the labeled cells was measured 
using the FITC channel. (D) K42(WT CRT) or K42(CRT-/-) cells were exposed to UV 
and allowed to undergo apoptosis for 17 hrs. AnnV and 7AAD binding was measured 
after this time. (E) Labeled apoptotic cells were incubated with BMDC for the indicated 
time points at either 37 °C or 4 °C. The acquisition of K42 cells by CD11c+ cells was 
measured and plotted as a function of time. These experiments were performed in the 
absence of calcium. For (A), the 0 time point is a compilation of 3 independent 
experiments and the rest of the time points are from a single experiment. Data are 
representative of 4 experiments for (B). Three to six independent analyses are averaged 




Figure 3.11: Calreticulin expression in antigen donor cells enhances CD8 T cell 
proliferation in vitro (A, B) K42(WT CRT) or K42(CRT-/-) OVA-expressing cells were 
exposed to UV light, following which cells were immediately incubated with CFSE 
labeled OT-I T cells and either B6 or Balb/c BMDC. Levels of IL-2 were measured 24 
hours later (A) and proliferation of OT-I T cells was measured 5 days later (B). In A, K42 
+ OT-I alone indicated samples that did not contain BMDC. Data are representative of 2 
independent experiments. In B, UV-treated K42(WT CRT) OVA-expressing cells 
incubated with OT-I T cells alone (no BMDC) are shown in grey (filled). Data are 
representative of 2 replicates per condition. (C) Analyses similar to B, but comparing OT-
I T cell proliferation induced in the presence of B6 or B6(!2m-/-) BMDC. Data are 
representative of 2 replicates per condition. (D, E) Compilation of four independent 
experiments comparing the proliferation of OT-I T cells in response to OVA-expressing, 
UV-treated K42(WT CRT) or K42(CRT-/-) cells using (D) B6 BMDC or (E) B6, Balb/c 
and !2m-/- BMDC (0.4-0.6x104 antigen donor cells were used in E). Each point 
represents the average proliferation of 2 replicates per condition and is an independent 
experiment within the group. For E, a similar analysis was performed at the 0.05-
0.08x104 target cell dose comparing OT-I T cell proliferation in response to K42(WT 
CRT) to K42(CRT-/-) cells using Balb/c and !2m-/- BMDC. This analysis yielded a p 
value of 0.0033. Two-tailed pair-wise student t-tests were used for all statistical analysis. 









MHC class I molecules of subcutaneously delivered antigen donor cells are non-
essential for CD8 T cell proliferation in vivo 
We next examined whether pre-assembled MHC class I of antigen donor cells also 
contribute significantly to CD8 T cell proliferation in vivo, which could account for the 
non-critical role of cell-surface calreticulin in inducing CD8 T cell proliferation (Figures 
3.7 and 3.8). CFSE labeled OT-I T cells were adoptively transferred into B6 recipient 
mice. Twenty-four hours later, we immunized the mice s.c. with K42(WT CRT) or 
K42(CRT-/-) cells expressing OVA that had been UV-treated immediately prior to 
immunizations. There was no statistical difference in the proliferation of the OT-I T cells 
in the two groups of mice (Figures 3.12A and 3.12B). Similar percentages of OT-I T cells 
were recovered from mice immunized with K42(WT CRT) and K42(CRT-/-) UV treated 
cells as well (Figure 3.12B, right panel).  These findings suggested that unlike the in vitro 
situation with BMDC, during a primary response, pre-assembled MHC class I molecules 
did not contribute significantly to CD8 T cell proliferation in vivo in response to cell-
associated antigen. To extend and verify the latter possibility, OT-I T cell proliferation 
efficiencies were compared following immunizations with WT MEF or MEF deficient in 
H2-Kb, H2-Db and !2m (3KO) (Lybarger et al., 2003). 3KO cells lack H2-Kb (Figure 
3.12C, left panel). Therefore, trogocytic transfer or direct activation by MEFs (in trans 
with APC) cannot contribute to the CD8 T cell response. WT and 3KO MEF were 
infected with the retrovirus encoding OVA and GFP, and sorted cells expressing similar 
levels of GFP were obtained (Figure 3.12C, right panel). If trogocytosis or direct 
activation by MEFs contributes significantly to antigen transfer in vivo, we would expect 
impaired OT-I T cell proliferation in response to OVA derived from UV-treated 3KO 
cells compared to WT cells. Interestingly, we found that OT-I T cells responded similarly 
to OVA derived from WT and 3KO cells (Figures 3.12D and 3.12E). These findings 
suggest that trogocytosis or activation in trans are not significant mechanisms of CD8 T 
cell activation in vivo in a primary response to s.c. antigen, or that other redundant 





Figure 3.12: MHC class I molecules of subcutaneously delivered antigen donor cells are 
non-essential for in vivo proliferation of CD8 T cells. (A) Recipient B6 mice were 
injected i.v. with CFSE labeled OT-I T cells. Twenty-four hours later, the mice received 
s.c. immunization of UV-treated K42(WT CRT) or K42(CRT-/-) cells expressing OVA. 
Proliferation was measured 4 days later in the dLN. PBS control is depicted in filled grey. 
Data are representative of 2-4 mice per group. (B) Left panel: quantification of 
proliferating OT-I T cells in response to 1-2.5 x105, 5-10 x105, or 50-100 x105 UV-
treated antigen donor cells. Two experiments are reported for the 50-100 x105 dose range. 
Each point represents the average proliferation of 2-4 mice per group. Six independent 
experiments are shown, with multiple doses performed within an experiment. Right 
panel: the percentage of OT-I T cells as a function of all CD8 T cells. (C-E) WT or 3KO 
cells were infected with a retrovirus expressing cytosolic OVA and GFP. MHC class I (C, 
left panel) or GFP expression (C, right panel) were compared on sorted cells. (D) OT-I T 
cell proliferation was assessed in vivo as described in A, with the difference that recipient 
mice received s.c. immunizations of 0.6x106 UV-treated WT or 3KO OVA-expressing 
cells. Data are representative of 3 mice per group, except the PBS condition, where 1 
mouse was used. (E) Quantification of proliferating OT-I T cells in response to 0.5-
0.6x106 UV-treated antigen donor cells. Each point represents the proliferation of OT-I T 
cells from an individual mouse and 2 independent experiments are depicted. Two-tailed 
pair-wise student t-tests were used for all statistical analysis. Mean ± s.e.m. are shown. 




















LPS treatment of antigen donor cells inhibits CD8 T cell proliferation against cell-
associated antigen in vivo 
As noted above, we have recently shown that thapsigargin induces the secretion of sterile 
IL-6 by BMDC in vitro. Thus, observed inhibition of CD8 T cell proliferation in vivo in 
response to antigen donor cells treated with 5 µM thapsigargin (Figure 3.8) prompted us 
to further investigate the role of innate signaling in CD8 T cell proliferation. To 
investigate the possibility that innate signaling could inhibit CD8 T cell proliferation in 
response to s.c. delivered cell-associated antigen, we examined the effects of LPS 
treatment of antigen donor cells on CD8 T cell proliferation in vivo. K42(WT CRT) cells 
expressing OVA were exposed to UV-irradiation and subsequently mixed with 0, 1, 10 or 
100 ng LPS. The UV-treated cells and the varying amounts of LPS were injected s.c. into 
WT recipient mice that had received CFSE labeled OT-I T cells 24 hours prior. 
Proliferation was then assessed. Similar to the 5 µM thapsigargin treatment of antigen 
donor cells, LPS inhibited proliferation of the OT-I T cells in a dose-dependent manner. 
LPS was inhibitory at levels as low as 1 ng per mouse (Figures 3.13A and 3.13B).  
 In this set of experiments, insufficient CD4 T cell help may be available for the 
OT-I CD8 T cells due to the large numbers of OT-I T cells transferred in the adoptive 
transfer experiment. It is possible that the LPS-induced inhibition of CD8 T cell 
proliferation resulted from the lack of sufficient CD4 T cell help. Therefore, a similar 
experiment was undertaken as described above with the addition of OT-II T cells 
[obtained from a transgenic mouse whose CD4 T cells express a TCR that recognizes the 
OVA323-399 epitope ISQAVHAAHAEINEAGR bound to the murine MHC class II allele 
I-Ad (Barnden et al., 1998)]. OT-I T cell proliferation was inhibited by 10 ng LPS (Figure 
3.13C), as previously observed (Figure 3.13B), in the absence of OT-II T cells in 
response to antigen donor cells treated with UV. When unlabeled OT-II T cells were 
injected along with the CFSE labeled OT-I T cells at a CD8:CD4 T cell ratio of 1:2, LPS 
induced inhibition of OT-I T cell proliferation in response to antigen donor cells was still 
observed (Figure 3.13C). The observed inhibition of CD8 T cells proliferation indicates 
that LPS interferes with CD8 T cell responses against cell-associated antigen even when 
CD4 T cell help is present. We also assessed the percentage of OT-I T cells recovered of 
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all CD8 T cells recovered. This type of analysis revealed the extent of LPS induced 
inhibition of OT-I T cells (Figure 3.13D). Also, in the absence of LPS, OT-I T cells 
proliferated to a lower extent in the presence of OT-II T cells (Figure 3.13C). 
Accordingly, a lower percentage of OT-I T cells were recovered from mice that received 
both OT-I and OT-II T cells (Figure 3.13D). The reduction may be explained by 
competition for lymph node space or antigen. Compared to mice that receive only OT-I T 
cells, OT-II T cells may compete with OT-I T cells in mice that receive both cell types. 
Nevertheless, our findings indicate that antigen donor cells treated with inducers of innate 
signaling (5 µM thapsigargin or LPS) inhibit the proliferation of CD8 T cells in vivo 
































Figure 3.13: LPS inhibits OT-I T cell proliferation in vivo against a cell-associated 
antigen in the presence or absence of CD4 T cell help. (A) Recipient mice were injected 
i.v. with CFSE labeled OT-I T cells. Twenty-four hours later, the mice received s.c. 
immunizations of 2.5x105 UV-treated K42(WT CRT) cells expressing OVA mixed with 
0, 1, 10 or 100 ng LPS. Proliferation was measured 4 days later in the dLN. PBS control 
is depicted in filled grey. Data are representative of 2-3 mice per treatment. (B) 
Quantification of OT-I T cell proliferation in response to UV, UV + 1-10 ng LPS and UV 
+ 40 µg LPS treatments of antigen donor cells. Each point represents the average OT-I T 
cell proliferation from 2-6 mice (except for one experiment, which had 1 mouse in the 
PBS group) and is an independent experiment. Four independent experiments are 
represented; mice received 2.5-5x105 antigen donor cells. Two experiments compared 
UV treatment of cells to UV + 1-10 ng LPS (unfilled and filled triangles), one experiment 
compared UV treatment of cells to UV + 40 µg LPS (unfilled squares), and one 
experiment contained all three conditions (unfilled circles). (C) Recipient mice were 
injected i.v. with CFSE labeled OT-I T cells alone or a 1:2 ratio of CFSE labeled OT-I T 
cells and unlabeled OT-II T cells (the same number of OT-I T cells were injected in both 
groups of mice). Twenty-four hours later, the mice received s.c. immunizations of 5x105 
UV-treated K42(WT CRT) cells expressing OVA mixed with 0 or 10 ng LPS (no LPS 
and + LPS, respectively). Proliferation was measured 4 days later in the dLN. PBS 
control is depicted in filled grey. Data are representative of 2-3 mice per treatment. 
Quantification of the percentage of proliferating OT-I T cells is depicted in the right 
panel; each circle represents the proliferation of OT-I T cells from an individual mouse. 
(D) Quantification of the percentage of OT-I T cells of all CD8 T cells recovered in C. 
Each circle represents the proliferation of OT-I T cells from an individual mouse. (C, D) 
One experiment was performed. A two-tailed pair-wise student t-test was used for 










In this study, we set out to examine three different pathways by which calreticulin could 
have an impact on CD8 T cell proliferation. The first pathway involves the ability of 
extracellular, soluble calreticulin to enhance the cross-presentation of an associated 
antigen (Figure 3.1A). We imagine a scenario where calreticulin in complex with an 
antigen (pathogen derived or self) escapes a cell in response to calcium perturbations 
(Peters and Raghavan, 2011) or pathogen-induced cell lysis, thus gaining access to the 
extracellular environment. Using a M$ cell line as the APC, a previous study has shown 
that calreticulin enhances the cross-presentation of an associated peptide to a T cell line 
compared to the peptide alone (Basu et al., 2001). We were not able to replicate this 
finding using a different peptide and BMDC as the APC (Figure 3.2). This discrepancy 
maybe due to differences in peptide affinity for calreticulin. The polypeptide- and 
peptide-binding site of calreticulin and specificity of peptides that bind to CRT are poorly 
understood and defined. Hence, to bypass the need to identify a high affinity calreticulin-
specific peptide, we generated a fusion protein containing calreticulin and OVA. We 
show that calreticulin was not able to enhance the cross-presentation of the fused OVA in 
vitro or in vivo (Figure 3.3). We concluded that calreticulin-specific receptors such as 
CD91 did not target calreticulin to sub-cellular compartments favorable for cross-
presentation or that calreticulin receptors are absent on BMDC.  
In the in vivo experiments, we injected the soluble antigens subcutaneously in the 
flanks of the recipient mice. It remains possible that CD91 expression is low on relevant 
APCs in the draining lymph node examined (inguinal lymph node). Peritoneal cells and 
the RAW264.7 M$ cell line express high levels of CD91 (Basu et al., 2001; Pawaria and 
Binder, 2011). The expression of CD91 enables peritoneal M$ and RAW264.7 cells to 
cross-present HSP-associated peptides to CD8 T cells by engaging the HSPs directly 
(Basu et al., 2001). Thus, if CD91 expression were low on APC residing in the inguinal 
lymph node, we would not expect calreticulin to enhance the cross-presentation of a 
fused antigen. Interestingly, gp96-chaperoned peptide is cross-presented with a higher 
efficiency compared to peptide alone or albumin-chaperoned peptide when administered 
intradermally in mice. In this study, 6 hours after the administration of antigen, axillary 
and inguinal draining lymph nodes were harvested, and CD11c+ cells were isolated for 
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an in vitro activation assay of B3Z cells (Binder and Srivastava, 2004). The ability of 
gp96 to efficiently chaperone the peptide was shown to be dependant on the CD91 
receptor, indicating that it is possible that APCs in the inguinal lymph node express 
sufficient levels of CD91 to mediate HSP uptake and re-presentation. The caveat to the 
experiments is that the axillary and inguinal lymph nodes described above were mixed. 
Thus, the observed effect could have been due primarily to APCs in the axillary lymph 
node. Further studies are necessary to assess CD91 expression on the relevant cross-
presenting APCs in the inguinal lymph node to better understand the results obtained in 
this study concerning the cross-presentation of soluble calreticulin associated OVA.     
We hypothesized that calreticulin associated antigens are cross-presented 
efficiently because the antigens are targeted to APCs via calreticulin-specific receptors. 
However, it may be possible that calreticulin has a role in protecting unstable peptides or 
proteins from degradation in vivo. The protection would allow more time for the peptide 
or protein to be phagocytosed by an APC before it degrades. The relatively high stability 
of OVA may have rendered calreticulin non-critical for antigen stability in our study. It 
may also be possible that calreticulin enhances cross-presentation by altering the cytokine 
milieu. Calreticulin is reported to induce CD91 phosphorylation, which results in the 
activation of a number of NF-'B-dependent and –independent cytokines (Pawaria and 
Binder, 2011). However, if inflammatory cytokines were induced in vivo by calreticulin-
CD91 interactions in response to the OVA-CRT immunization, the presence of the 
cytokines did not lead to greater CD8 T cell proliferation in response to OVA-CRT 
compared to OVA (Figure 3.3). However, the cytokines produced in response to the 
calreticulin-CD91 interaction may have a more significant role in shaping the T-helper 
response, as has been recently assessed (Pawaria and Binder, 2011). The T-helper 
response may in turn affect the CD8 T cell response. The impact of CD4 T cell help on 
CD8 T cell proliferation was untested in our study using soluble proteins.  
 OVA-CRT and OVA are taken up by BMDCs through pinocytosis or receptor-
mediated endocytosis. Figure 3.3 indicates that either pinocytosis is dominant over 
receptor-mediated endocytosis, or that there exist other receptors that mediate the uptake 
of OVA which render calreticulin-specific receptors non-essential. The mannose receptor 
is reported to be critical for the phagocytosis and trafficking of glycosylated OVA to 
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early endosomes conducive for cross-presentation (Burgdorf et al., 2007). However, this 
model was called into question by findings demonstrating that steady state DC are able to 
cross-present glycosylated OVA independently of the mannose receptor (Segura et al., 
2009). The latter finding was subsequently also refuted due to the non-physiologically 
high levels of antigen used in the study (Burgdorf et al., 2010). OVA used in Figure 3.3 is 
not expected to be taken up by the mannose receptor (as it is isolated from E. coli and 
non-glycosylated). However, we show that non-glycosylated OVA (E. coli) and 
glycosylated OVA (Sigma) induce similar levels of OT-I T cell proliferation in vivo. We 
used 2.5-100 µg OVA per mouse; this amount is well below the amount used to show a 
dependence on the mannose receptor in vivo (500 µg) (Burgdorf et al., 2010). Our data 
suggest that the mannose receptor is non-essential for the cross-presentation of soluble 
OVA in vivo in the context of a s.c. administration of antigen. Notably, OVA was 
injected i.v. in the studies described above (Burgdorf et al., 2010; Segura et al., 2009). 
Ours is the first study to examine the impact of glycosylation upon the cross-presentation 
of a soluble antigen. Taken together, Figure 3.3 and Figure 3.4 demonstrate that there are 
redundant receptor pathways for soluble antigen uptake that render calreticulin-specific 
receptors and the mannose receptor non-essential for the cross-presentation of 
calreticulin-OVA or OVA, respectively. However, a closer examination of mannose 
receptor expression on APCs in the inguinal lymph node is warranted.  
It remains possible that the soluble OVA-CRT construct may not have been able 
to bind calreticulin-specific receptors with a high enough avidity to impact the cross-
presentation of OVA. Alternatively, OVA may have masked the calreticulin-receptor 
binding site on calreticulin. To address this issue, CRT and OVA or OVA alone were 
conjugated to iron oxide beads and cross-presentation efficiencies were assessed. OVA 
and CRT are not fused in this system. Thus, CRT-receptor interactions should not be 
inhibited.  We show that CRT was not able to enhance the cross-presentation of the bead-
associated OVA compared to beads with OVA alone, both in vitro and in vivo (Figure 
3.5). CRT has been reported to be an “eat me” signal on the surface of apoptotic cells 
(Gardai et al., 2005; Kuraishi et al., 2007). The findings of Figure 3.5 suggest that CRT 
does not work independently in a phagocytic context, but rather might work with one or 
more “eat me” signals such as PS. Hence, CRT in isolation is not sufficient to enhance 
! ""$!
cross-presentation of a particulate antigen. However, it is also possible that phagocytic 
uptake of the iron oxide beads was instrinsically high in the absence of calreticulin, 
rendering calreticulin ineffective at uptake.   
The second pathway we examined involves the ability of cell surface calreticulin 
to enhance the uptake of cell-associated antigens (calreticulin is an “eat-me” signal in this 
scenario; Figure 3.1B). Calreticulin is upregulated on apoptotic and pre-apoptotic cells 
(Gardai et al., 2005; Kuraishi et al., 2007; Obeid et al., 2007b) and has been identified as 
an “eat-me” signal (Gardai et al., 2005; Kuraishi et al., 2007; Peters and Raghavan, 
2011). It is hypothesized that the pro-phagocytic property of calreticulin contributes 
towards the immunogenicity of tumor cells treated with cell-surface calreticulin inducing 
chemotherapeutic agents [reviewed in (Chaput et al., 2007; Martins et al., 2010)]. Ours is 
the first study to examine whether cell-surface calreticulin on antigen donor cells is able 
to quantitatively impact CD8 T cell proliferation. Increased CD8 T cell proliferation 
would be expected if surface-calreticulin positively impacted the phagocytosis of antigen 
donor cells by APC and phagocytic transfer were the dominant mode of antigen transfer 
to APCs. We show that even though thapsigargin-induced surface calreticulin plays a role 
in the phagocytosis of pre-apoptotic cells (Peters and Raghavan, 2011), enhanced 
phagocytosis does not influence the proliferation or cytotoxicity of CD8 T cells in vitro 
or in vivo in response to pre-apoptotic antigen donor MEFs treated with thapsigargin 
(Figure 3.7 and 3.8). Studies examining the immunogenicity of drug-treated tumor cells 
attribute immunogenicity to HMGB1 and ATP release from the tumor cells and to the 
phagocytic role of calreticulin [reviewed in (Kepp et al., 2011)]. Thapsigargin treated 
cells do not release either ATP or HMGB1 (Peters and Raghavan, 2011). Thus, it is 
possible that calreticulin-mediated phagocytosis of antigen donor cells in the absence of 
HMGB1 or ATP release does not have an effect on the immunogenicity of the antigen 
donor cells (CD8 T cell activation against cell-associated antigens), as previously 
suggested (Kepp et al., 2011). Additionally, uptake of apoptotic cells delivered s.c. is 
mediated by CD169+ M$ via uptake through PS on the apoptotic cell in draining lymph 
nodes (Asano et al., 2011). The cells we used were largely pre-apoptotic at the time of 
immunization, but became apoptotic 20 hours post treatment (Figure 3.6). It is thus 
possible that PS, and not calreticulin, mediated the uptake of the drug-treated antigen 
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donor cells as they progressed through apoptosis. The phagocytic kinetics of pre-
apoptotic MEFs treated with thapsigargin are not characterized in vivo, but may warrant 
further studies. We conclude that enhanced calreticulin mediated uptake of antigen donor 
cells (Peters and Raghavan, 2011) is not sufficient to enhance the cross-priming of CD8 
T cells in the context of thapsigargin drug treatment of antigen donor cells. As noted 
above, cytokines induced by calreticulin-mediated CD91 signaling (Pawaria and Binder, 
2011) may impact the CD4 T cell response, which was not examined. The CD4 T cell 
response may in turn mediate the anti-tumor response observed against tumor cells 
treated with surface calreticulin-inducing chemotherapeutic drugs. Alternatively, the CD4 
T cells may help in shaping an effective anti-tumor CD8 T cell response. Neither 
possibility was examined in this study, but both warrant further investigation.     
Calreticulin helps facilitate endogenous assembly of MHC class I (Del Cid et al., 
2010; Gao et al., 2002). Hence, the third pathway we examined by which calreticulin 
could impact CD8 T cell proliferation involved the cell-cell transfer of MHC class I 
molecules from antigen donor cell to APC (trogocytosis; Figure 3.1C). Increased transfer, 
and thus increased activation of CD8 T cells, is expected to be induced by calreticulin as 
calreticulin expressing cells express a higher level of surface MHC class I compared to 
calreticulin-deficient cells (Del Cid et al., 2010; Gao et al., 2002). Trogocytic transfer 
contributes to CD8 T cell proliferation in response to s.c. delivered dead cells (Dolan et 
al., 2006). Trogocytosis has also been shown to be important in activating memory CD8 
T cells in a viral infection (Wakim and Bevan, 2011). Interestingly, the same study was 
not able to find a role for trogocytosis in the activation of naïve CD8 T cells. If trogocytic 
transfer were the dominant form of antigen transfer in our system, calreticulin-dependant 
phagocytosis might not significantly impact CD8 T cell proliferation (Figure 3.7 and 3.8). 
We show that trogocytic transfer (and/or activation by MEF and BMDC in trans) is the 
dominant form of antigen transfer in vitro (Figure 3.11). However, trogocytic transfer 
does not contribute to the proliferation of naïve CD8 T cells in vivo (Figure 3.12), 
consistent with published findings (Wakim and Bevan, 2011). We conclude that 
trogocytic transfer of antigen is not relevant for the proliferation of naïve CD8 T cells in 
response to s.c. delivered UV-treated cells. Additionally, trogocytic transfer can explain 
the non-essential role of calreticulin-mediated phagocytosis in vitro but not in vivo. 
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Interestingly, treatment of antigen donor cells with 5 µM thapsigargin inhibited 
CD8 T cell proliferation in vivo (Figure 3.8B), an unexpected finding. LPS treatment of 
antigen donor cells also inhibited CD8 T cell proliferation in a dose-dependant manner 
(Figure 3.13B). The secreted endogenous factor HMGB1, proposed to be a TLR4 ligand 
(Park et al., 2004), is suggested to contribute to the immunogenic cell death of drug-
treated tumor cells (Apetoh et al., 2007). Additionally, TLR4-deficiency impairs the 
ability of chemotherapeutic drugs to induce immunogenic forms of cell death (Apetoh et 
al., 2007; Tesniere et al., 2010). Thus, it was surprising that LPS inhibited the cross-
priming of CD8 T cells in vivo in response to cell-associated antigen. However, HMGB1 
and LPS have different mechanisms for activating cells (Park et al., 2003; Park et al., 
2004), which could explain the discrepancy of the effects of TLR4. APC are known to 
secrete immunosuppressive factors when exposed to a combination of apoptotic cells and 
LPS. The immunosuppressive factors are thought to be a mechanism to regulate 
inflammation and inflammatory cytokine production (Byrne and Reen, 2002). Monocytes 
stimulated with LPS secrete significantly more IL-10 and TFG! in response to apoptotic 
neutrophils compared to unstimulated monocytes (Byrne and Reen, 2002). BMDC 
exposed to LPS-coated apoptotic cells secrete higher levels of TGF-! compared to 
BMDC exposed to uncoated apoptotic cells (Torchinsky et al., 2009). Hence, an 
immunoinhibitory cytokine milieu produced by APC in response to a combination of 
innate signaling [thapsigargin (Peters and Raghavan, 2011) or LPS] and dying antigen 
donor cells may have resulted in the inhibition of CD8 T cell proliferation (Figure 3.8 and 
3.13). LPS-mediated inhibition of antigen-specific CD8 T cell proliferation appears to be 
unique to CD8 T cell responses against cell-associated antigen. First, we did not observe 
a significant decrease in CD8 T cell proliferation in response to soluble, bacterially 
derived recombinant OVA in WT mice compared to TLR4-/- mice (Figure 3.3). Inhibition 
would be expected in WT mice if LPS signaling negatively affected CD8 T cell responses 
against soluble antigen. Second, similar findings have been published using Poly(I:C) as 
the innate ligand (Frleta et al., 2009); Poly(I:C) inhibited the cross-priming of CD8 T 
cells against dead cell-associated antigens but not soluble antigen. In that study, CD4 T 
cell help was not able to rescue the observed inhibition of CD8 T cell proliferation, which 
is supported by data in our study (Figure 3.13C and 3.13D).  
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However, it is also possible that we observed the inhibition in CD8 T cell 
proliferation because the relevant APC became depleted in vivo in response to LPS (or 5 
µM thapsigargin), as has been previously observed in response to i.v. LPS (Qiu et al., 
2009). Alternatively, the relevant APC may have matured in response to the LPS prior to 
the arrival of the cell-associated antigen into the dLN. The maturation of APC would 
inhibit the cross-presentation of cell-associated antigen, as mature APC have a 
diminished capacity for phagocytosis compared to immature APCs. Delayed cross-
presentation kinetics is observed when antigen donor cells are injected intradermally 
(i.d.) compared to intravenous (i.v.) injection (days vs. hours). Furthermore, the 
administration of Poly I:C one day after the injection of antigen donor cells inhibits cross-
priming if the antigen donor cells are administered i.d. but enhances cross-priming if the 
antigen donor cells are administered i.v (Bouvier et al. 2011). In our study, it is possible 
that APCs in the dLN matured in response to the LPS before the arrival of antigen donor 
cells. However, apoptotic cells injected s.c. in the footpads of mice drain to the popliteal 
lymph nodes within hours (Asano et al., 2011). Further studies are needed to fully 
understand the kinetics of antigen-uptake of thapsigargin treated cells when administered 
s.c. in the flanks of mice (as was performed in our in vivo studies) and the mechanism of 
inhibition of CD8 T cell proliferation in response to cell-associated antigen in the 
presence of innate stimuli. Lastly, it is also possible that thapsigargin or LPS induced OT-
I T cell proliferation earlier than on day 4 (proliferation was assessed on day 4) by 
activating relevant APCs. The OT-I T cell population may have expanded and contracted 
within 4 days. Indeed, the level of inflammation present influences the contraction of 
CD8 T cells (Badovinac et al., 2004). Thus, assessing CD8 T cell proliferation at earlier 
time points may help elucidate the effects of innate stimuli on CD8 T cell activation. 
 In summary, we have examined three pathways by which calreticulin could 
influence CD8 T cell responses against cell-associated antigen. First, we show that 
calreticulin-specific receptors are non-essential for the cross-presentation of a stable 
calreticulin-associated soluble antigen. Second, we show that thapsigargin induced 
surface calreticulin on antigen donor cells does not impact CD8 T cell proliferation. 
Third, the ability of calreticulin to facilitate surface MHC class I assembly on antigen 
donor cells leads to enhanced CD8 T cell proliferation in vitro (either due to activation in 
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trans or to trogocytic transfer of MHC class I-peptide complexes). However, MHC class 
I transfer does not have a role in vivo in activating naïve CD8 T cells. Finally, 
independent of calreticulin, LPS and high dose thapsigargin treatments of antigen donor 
cells inhibit CD8 T cell proliferation in response to cell-associated antigens. Further 
studies are needed to understand the mechanisms underlying this inhibition, which has 
relevance in understanding mechanisms of peripheral tolerance in the context of an 
infection or inflammatory setting.  
Materials and Methods 
Mice 
C57BL/6J (WT or B6 in text; CD45.2), B6.SJL-Ptprca Pepcb/BoyJ (WT or B6 in text; 
CD45.1), Balb/cJ (Balb/c in text), B6.129P2-B2mtm1Unc/J [B6(!2m-/-) or !2m-/- in text], 
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I in text), and ,&(-./'0123145614578%#&,79/: 
(OT-II in text) mice were purchased from The Jackson Laboratory. OT-I transgenic mice 
were used directly (CD45.2) or bred with B6.SJL-Ptprca Pep3b/Boy mice (The Jackson 
Laboratory) to yield CD45.1 T cells. TLR2–/– and TLR4–/– mice (Hoshino et al., 1999; 
Takeuchi et al., 1999) were provided by Dr. S. Akira at the Laboratory of Host Defense, 
Osaka University, Osaka, Japan. TLR2/4–/– mice were generated by crossing TLR2–/– 
with TLR4–/– mice. TLR4-/- mice were backcrossed onto the B6 background six times 
before being bred with TLR2–/– mice. All mice were maintained in specific pathogen-free 
conditions at the University of Michigan or the University of Massachusetts Medical 
School mouse facilities. The mice were cared for according to the guidelines set by the 
University Committee on Use and Care of Animals (UCUCA). Recipient mice for in vivo 
experiments were used at 5 to 10 weeks of age. 
Cell culture, purification and labeling 
Cell lines 
The B3Z hybridoma T cell line (Karttunen et al., 1992) and calreticulin-deficient MEF 
(K42), WT MEF (K41) and 3KO (H2-Kb, H2-Db and !2m deficient) MEF cell lines (Gao 
et al., 2002; Lybarger et al., 2003; Mesaeli et al., 1999) were maintained in RPMI+ 
[RPMI medium 1640 (Invitrogen) supplemented with 10% (v/v) fetal bovine serum, 100 
!g/ml streptomycin, and 100 units/ml penicillin (Invitrogen)]. L-cells were maintained in 
MEM (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (Gibco), non-
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essential amino acids, 1 mM sodium pyruvate, and 100 !g/ml streptomycin, 100 units/ml 
penicillin (Invitrogen). Cells were maintained in an incubator kept at 37 °C with 5% CO2. 
BMDC 
DCs were generated from the bone marrow of B6, Balb/c or B6(!2m-/-) mice. Bone 
marrow was flushed from the femur and tibia with RPMI+. The red blood cells were 
lysed using red cell lysis buffer (Sigma), and the cells were re-suspended in RPMI 
medium supplemented with 10% (v/v) fetal bovine serum (Gibco), 100 !g/ml 
streptomycin, 100 units/ml penicillin (Invitrogen), 1 mM HEPES (Gibco), 0.1 mM MEM 
Non-Essential Amino Acids (Gibco), 1 mM Sodium pyruvate, 50 !M !-mercaptoethanol 
and granulocyte M$ colony-stimulating factor (GM-CSF). The bone marrow obtained 
from one mouse was plated into two 24-well plates (Corning). The medium was replaced 
on days 2 and 4, and the cells were harvested for in vitro experiments on day 5 or 6.   
BM M" 
M$ were generated from the bone marrow of B6 mice. Bone marrow was flushed from 
the femur and tibia with RPMI+. The red blood cells were lysed using red cell lysis 
buffer (Sigma), and the cells were resuspended in DMEM (Invitrogen) medium 
supplemented with 20% (v/v) fetal bovine serum (Gibco), 30% (v/v) L-cell conditioned 
medium, 100 !g/ml streptomycin, 100 units/ml penicillin (Invitrogen), 2 mM GlutaMAX 
(Gibco), and 50 !M !-mercaptoethanol. The bone marrow obtained from one mouse was 
plated into x5 150 mm plates. The medium was replaced on days 2, 4 and 6. On day 7, 
medium without L-cell conditioned medium was added and M$ were harvested for 
assays on day 8 with ice-cold PBS.     
Purification of CD8+ and CD4+ T cells  
Spleens were extracted from OT-I or OT-II transgenic mice. The red blood cells were 
lysed using red cell lysis buffer (Sigma), and the CD8+ or CD4+ cells were isolated by 
positive selection using anti-CD8a (Ly-2) or anti-CD4 (L3T4) microbeads (MACS, 
Miltenyi Biotec), respectively, following the manufacturer’s suggested protocol.  
CFSE labeling 
MACS purified CD8+ T cells from OT-I transgenic mice were labeled with CFSE for 
proliferation analyses. CD8+ T cells were washed once with PBS, centrifuged, and re-
suspended in PBS + 5 µM CFSE. The cells were incubated at 37 °C for 10 min. The cells 
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were washed once with medium, re-suspended in RPMI+ and incubated at 37 °C, 5% 
CO2 for 1 hour. The cells were then centrifuged and re-suspended in an appropriate 
volume of RPMI+ for in vitro experiments or PBS for in vivo experiments. On average, 
3-5x106 live, CFSE labeled, CD8+ OT-I T cells were recovered from one spleen, where 
trypan blue staining assessed viability. 
PKH26 labeling 
Splenocytes were labeled with PKH26 (Sigma) for in vivo cytoxicity analysis. 
Splenocytes were extracted from B6 CD45.1 mice. The red blood cells were lysed using 
red cell lysis buffer (Sigma). Splenocytes were washed in PBS and labeled with 2-4 µM 
PKH26 according to the manufacturer’s instructions. After cells were washed, they were 
labeled with 1 or 0.1 µM CFSE as described above.   
DNA constructs 
Expression of calreticulin, OVA, and OVA-calreticulin in Escherichia coli 
Mouse calreticulin (accession number BC003453) was amplified from the 
pCMV-SPORT6 (ATCC, MGC-6209) vector using primers that allowed for subsequent 
ligation-independent cloning (LIC) into the pMCSG7 vector (Stols et al., 2002). The 
following primers were used: forward, 5’ TAC TTC CAA TCC AAT GCT GCC GCA 
CAT CCT TGG CTT 3’ and reverse, 5’ TTA TCC ACT TCC AAT GTT ACA GCT 
CAT CCT TGG CTT 3’. Underlined bases represent those that are complementary to the 
sequence encoding calreticulin, and additional 5’ sequences were introduced for LIC.  
Chicken egg OVA (accession number V00383) was amplified for LIC. The 
following primers were used: forward: 5’ TAC TTC CAA TCC AAT GCT ATG GGC 
TCC ATC GGC G 3’ and reverse, 5’ TTA TCC ACT TCC AAT GTT AAG GGG AAA 
CAC ATC TGC 3’. Underlined bases represent those that are complementary to the 
sequence encoding OVA, and additional 5’ sequences were introduced for LIC.  
The OVA-calreticulin fusion protein was constructed using a 2-step amplification 
process resulting in a full length OVA molecule fused to the N-terminus of full length 
calreticulin by a flexible linker (gly-gly-ser-gly-gly). The reverse OVA primer was 
complementary to the forward calreticulin primer, allowing for the fusion of the two PCR 
products in a second PCR reaction. OVA was amplified using the following primers: 5’ 
TAC TTC CAA TCC AAT GCT ATG GGC TCC ATC GGC G 3’ and reverse, 5’ GGC 
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AGG GTC TGC GGC TCC TCC TGA TCC ACC AGG GGA AAC ACA TCT 3’. 
Calreticulin was amplified using the following primers: forward, 5’ AGA TGT GTT TCC 
CCT GGT GGA TCA GGA GGA GCC GCA GAC CCT GCC 3’ and reverse, 5’ TTA 
TCC ACT TCC AAT GTT ACA GCT CAT CCT TGG CTT 3’. Underlined bases 
represent those that are complementary to the sequence encoding OVA, bold bases 
represent the introduced linker sequences (gly-gly-ser-gly-gly), italicized bases represent 
those that are complementary to calreticulin, and additional sequences were introduced 
for LIC. Both PCR products were run on a 0.8% agarose gel and gel-purified (Qiagen). 
Both products were then used together as templates in a second PCR reaction using the 
forward OVA primer and reverse calreticulin primer, which allowed for subsequent LIC 
of the OVA-calreticulin fusion into the pMCSG7 vector.  
LIC was performed to introduce calreticulin, OVA, and OVA-calreticulin 
sequences into the pMCSG7 vector as described in Chapter 2.  
DNA constructs were sequenced and transformed into BL21 (DE3) cells for 
protein expression. All bacterially expressed constructs lacked their signal sequence and 
contained an N-terminal MHHHHHHSSGVDLGTENLYFGSNA fusion sequence for 
nickel affinity chromatography.  
Cloning WT calreticulin into pMSCV-puro  
This was performed as described in Chapter 2. 
pMSCV-IRES-GFP encoding OVA 
The pMSCV-IRES-GFP retroviral vector was created as previously described (Van Parijs 
et al., 1999) and was modified to express OVA upstream of the IRES-GFP reporter. 
Briefly, OVA contains a secretion signal sequence beginning at amino acid 21 and ending 
at residue 47 (Robinson et al., 1986). Linker primers (5’ OVA BglII-del 50 and 3’ OVA 
EcoRI) were designed to truncate the amino terminus and delete the secretion signal 
sequence from OVA as well as introduce an in-frame start codon at amino acid position 
50 of the protein. Linker primers were engineered with BglII and EcoRI sites for cloning 
the truncated OVA into pMSCV-IRES-GFP upstream of the IRES-GFP reporter. 
Resultant clones from ligation of OVA into pMSCV-IRES-GFP were confirmed through 
DNA sequencing. 
Linker Primer sequences: 
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5’ OVA BglII-del 50: 5’-GGAGATCTACCATGCAGGACACAGATAAATAAGG-3’ 
3’ OVA EcoRI: 5’-GCGAATTCTTAAGGGGAAACACATCTGCCAAA-3’ 
Protein purification 
OVA, and OVA-calreticulin were all purified as previously described for calreticulin in 
Chapter 2. Gel-filtration analyses were performed as described in Chapter 2. Extinction 
coefficients were calculated from the protein amino acid sequence using ProtParam 
(www.expasy.ch) and are as follows (units are M-1 cm-1): OVA, 33,265; OVA-
calreticulin, 114,750. 
Generation of calreticulin-peptide and BSA-peptide complexes 
10 µM calreticulin or BSA were incubated with 10 or 100 µM peptide 
(QLESIINFEKLTE-FITC; University of Michigan Protein Structure Facility) for 1 hour 
at 50 °C. Free peptide was removed by centrifugal filter (Centricon-30, Millipore). 
Peptide bound to calreticulin or BSA was measured using a VICTOR plate reader 
(fluorimeter; PerkinElmer) against a peptide standard.  
OVA and OVA-CRT allophycocyanin conjugation 
Allophycocyanin was conjugated to OVA and OVA-CRT following manufacturer’s 
instructions at a 1:1 molar ratio (Lightning-Link Conjugation Kit, Innova Biosciences). 
To measure fluorescence intensity, OVA and OVA-CRT were separated by SDS-PAGE 
and fluorescence was measured using a fluorescence imager (Typhoon TRIO, GE 
Healthcare). Quantification was performed using ImageQuant5.2 software.   
Generation of retroviral supernatants and infections  
This was performed as described in Chapter 2.  
Flow Cytometry 
OVA and OVA-CRT binding to BMDC 
1x105 BMDC were incubated with 1.3 µg OVA-CRT or 0.6 µg OVA that were 
allophycocyanin labeled in a total reaction volume of 100 µl for 30 minutes on ice. Cells 
were washed twice with flow cytometry buffer and analyzed by flow cytometry.  
Detection of cell-surface calreticulin and MHC class I 
The presence of cell-surface calreticulin was analyzed and performed as previously 
described (Jeffery et al., 2010; Peters and Raghavan, 2011). The staining of surface MHC 
! "##!
class I was carried out as described in Chapter 2. In addition, an allophycocyanin labeled 
anti-mouse H2-Kb-SIINFEKL Ab (1:300, eBioscience) was used in this study. 
Detection of proliferating OT-I T cells 
dLN (inguinal) were harvested; a single cell suspension was obtained and plated in a 96-
well plate. Cells were lysed in red cell lysis buffer (Sigma). These cells were washed 
once with flow cytometry buffer (2% FBS in PBS) and then incubated for 10 min with 
unconjugated murine IgG (Jackson ImmunoResearch) to bind and block Fc receptors. 
Cells from draining lymph nodes or from in vitro cell cultures were stained with a rat 
anti-mouse CD8a Ab conjugated to allophycocyanin (BD Pharmingen, 1:400) or anti-
CD8a Ab conjugated to PerCP (eBioscience) and mouse anti-mouse CD45.1 or CD45.2 
Ab conjugated to PE or allophycocyanin for in vivo experiments (BD Pharmingen, 1:300 
and eBioscience). Either CD45.1 or CD45.2 OT-I mice were utilized for in vivo adoptive 
transfers into WT strains (CD45.2 or CD45.1, respectively); the appropriate antibody was 
used to discriminate between donor and recipient cells. The cells were incubated with the 
Ab for 20 min, washed twice with flow cytometry buffer and then analyzed by flow 
cytometry. CFSE labeled OT-I T cells were analyzed in the FITC channel. All 
centrifugations in the 96-well plate were performed for 1 minute at 2,000 rpm.  
Detection of PKH26 labeled target splenocytes 
Spleens were harvested and processed as described for dLN above. Cells were stained 
with anti-CD45.1 conjugated to allophycocyanin as described for dLN above. PKH26 
labeling was analyzed in the PE channel.   
Phagocytosis assay 
K42(WT CRT) and K42(CRT-/-) cells were labeled with CellTracker™ Green CMFDA 
(5-chloromethylfluorescein diacetate) according to the manufacturer’s instructions 
(Invitrogen). Cells were harvested with PBS + 5 mM EDTA and 2x105 cells were plated 
per well in a 96-well plate in RPMI+. The plate was exposed to a UV light box for 3 min 
and incubated at 37 °C for 17 hours. 1x105 B6 BMDC were added to the wells, incubated 
at 37 °C or on ice and then harvested at various time points with PBS + 5 mM EDTA. 
Samples were fixed with 1% formaldehyde for 7 min at room temperature at various 
indicated time points. Once the last time point was collected and fixed, cells were washed 
with flow cytometry buffer. Cells were incubated with a hamster anti-mouse CD11c Ab 
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conjugated to allophycocyanin (BD Pharmingen, 1:400) for 20 min on ice, washed 2 
times with flow cytometry buffer and then analyzed by flow cytometry. !
All samples were read on the FACSCanto flow cytometer (BD Biosciences). Analysis 
was performed using FlowJo 8.8.6 (Treestar Inc.). 
In vitro antigen cross-presentation assays  
Assays using peptide antigen 
3-5x104 BMDC and 2-3x104 B3Z cells were plated in a 96 well plate. Calreticulin-peptide 
complexes, BSA-peptide complexes, or peptide alone were added to the wells. At 24 
hours, supernatant IL-2 levels were measured by ELISA.   
Assays using soluble or bead-associated antigen  
4-5x105 BMDC were plated in a 96 well plate. Soluble proteins were then added to the 
wells. The cells were incubated at 37 °C for 3 hours. BMDC were fixed with 1% 
formaldehyde for 7 min at room temperature. The wells were then washed two times with 
200 µl PBS and once with RPMI+. Medium was aspirated from the wells, and a 
suspension of 4-5x105 B3Z or 1-3x105 CFSE labeled OT-I T cells in 250 µl RPMI+ was 
added to the wells. At 24 hours, supernatant IL-2 levels were measured by ELISA, and 
proliferation of OT-I T cells was measured at 72 hours by flow cytometry. OVA (Sigma) 
was obtained from Sigma (A5503).  
Assays using cell-associated antigen 
Target cell fibroblasts expressing OVA were either exposed to UV-irradiation or treated 
with thapsigargin. For thapsigargin treatments, cells in 10 cm plates were incubated with 
7 ml of 200 nM or 5 µM thapsigargin in RPMI+ for 5 hours. The cells were washed 3 
times with 7 ml PBS and harvested with PBS + 5 mM EDTA. Untreated or thapsigargin-
treated cells were plated in a 96-well plate. Apoptosis was induced in the untreated cells 
by exposing the 96-well plate to UV on a UV-box for 3 min. 2x105 BMDC and 0.4-
0.7x105 CFSE labeled OT-I T cells were added to the wells immediately after the 
treatments. For assays with MACS-purified cells, target cells were incubated with BMDC 
in the 96-well plate at 37 °C for 1 hour. The cells were then harvested with 5 mM EDTA 
+ PBS and CD11c+ cells were isolated by positive selection using anti-CD11c Ab 
according to the manufacturer’s instructions (MACS, Miltenyi Biotec). 0.7x105 CD11c+ 
cells were incubated with 0.4-0.7x105 CFSE labeled OT-I T cells. The OT-I T cells were 
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analyzed by flow cytometry on day 5 post incubation. At 24 hours, supernatant IL-2 
levels were measured by ELISA. Where indicated, IFN# was measured on day 5 by 
ELISA. 
In vivo antigen cross-presentation assays using OT-I T cells 
CD8+ OT-I T cells were MACS purified from CD45.1 or CD45.2 mice and transferred 
i.v. into CD45.2 or CD45.1 recipient mice, respectively. Where indicated, unlabeled OT-
II CD4+ T cells were co-administered with OT-I T cells. One day later, mice were 
immunized s.c. in either the left or right flank with the indicated concentration/number of 
soluble or cell-associated antigen in 100 µL PBS. Three to four days later, dLN (inguinal) 
were harvested and analyzed as described above. For cell-associated antigen 
immunizations, UV-irradiated or thapsigargin-treated cells (as described above) were 
harvested immediately after treatment with 5 mM EDTA + PBS. Cells were washed 3 
times with PBS and counted. The indicated numbers of target cells were re-suspended in 
100 µl PBS (LPS was added where indicated) and used for the immunizations. 
In vivo cytotoxicity of endogenous CD8 T cells 
WT mice were immunized s.c. in the right flank with the indicated number of antigen 
donor cells in 100 µL PBS. Seven days post-immunization, mice were injected i.v. with 
PKH26 (Sigma) labeled target cells pulsed with SIINFEKL (1 µM CFSE labeled cells) or 
VAYGRQVYL (0.1 µM CFSE labeled cells). Spleens were recovered 18 hours later to 
assess killing of target cells by flow cytometry. dLN were also recovered and incubated 
with SIINFEKL. IFN# was measured 48 hours later by ELISA. 
ELISA 
IL-2 and IFN#  
96-well plates were coated with purified anti-mouse IL-2 Ab (BD Pharmingen, catalog # 
554424) or anti-mouse IFN# (b (BD Pharmingen, catalog # 551216) overnight at room 
temperature. After blocking with 10% calf serum for 3 hours, cell culture supernatants 
were incubated in the plate for 1 hour at 37 °C. The plates were washed 3 times with 
0.05% Tween-20 in PBS and a biotinylated anti-mouse IL-2 Ab (BD Pharmingen, catalog 
# 554426) or anti-mouse IFN# Ab (BD Pharmingen, catalog # 554410) was added for an 
overnight incubation at room temperature. The plates were washed 3 times, and 
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streptavidin conjugated to HRP (BD Pharmingen, catalog # 554066) was added to the 
plates for 20 min at room temperature. The plates were again washed 3 times, and the 





The studies undertaken in this thesis explored the role of calreticulin in the 
context of MHC class I assembly and cross-presentation. In Chapter 2, we examined 
specific interactions required for calreticulin recruitment into the MHC class I PLC. We 
also documented the effects of calreticulin deficiency on MHC class I heavy chain and 
tapasin stability. In Chapter 3, we examined roles of calreticulin in the cross-priming of 
CD8 T cell responses against peptide, soluble, bead-associated, and cell-associated 
antigen. Data from both chapters further our understanding of MHC class I assembly and 
antigen presentation. 
Interactions between calreticulin and components of the PLC 
In Chapter 2, calreticulin was shown to require ERp57 and glycan based 
interactions for recruitment into the PLC and stabilization of the PLC. We proposed a 
model for calreticulin recruitment into the PLC that involves glycan- and ERp57-based 
interactions, where the glycan-based interaction is mediated at least in part by the glycan 
of tapasin (Figure 2.13). Our study reinforced the proposed model for calreticulin 
recruitment into the PLC involving glycan- and ERp57-based interactions (Dong et al., 
2009) and demonstrated critical roles for the glycan and ERp57 binding sites in the 
formation of the PLC. However, in our model, the glycan of tapasin rather than that of 
the MHC class I heavy chain impacted the recruitment of calreticulin into the PLC (Dong 
et al., 2009). Our study enabled us to put forth a new model for interactions that mediate 
MHC class I assembly in the PLC (Figure 2.13).  
When components of the PLC (tapasin, calreticulin, ERp57, and MHC class I) 
were reconstituted in vitro, calreticulin–glycan and calreticulin–Erp57 based interactions 
were found to be crucial for tapasin-mediated peptide loading onto MHC class I, and 
MHC class I glycans were suggested to be important for the functional effects of 
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calreticulin (Wearsch et al., 2011). Soluble MHC class I purified from baculovirus-
infected insect cell lysates was used in these assays. However, the glycosylation status of 
MHC class I was not directly tested. The same glycan-binding mutant of calreticulin used 
in our study (Y92A) and a mutant of ERp57 that is deficient in calreticulin binding were 
used in the assay. A model for PLC assembly was proposed that involved the formation 
of a calreticulin–MHC class I complex independent of the PLC, via glycan-based 
interactions. The calreticulin–MHC class I complex was suggested to be subsequently 
recruited into the PLC via calreticulin–Erp57 mediated interactions. The model for 
calreticulin-mediated MHC class I recruitment into the PLC is partially based on results 
utilizing a transient siRNA transfection to knock-down !2m in cells. Upon siRNA knock 
down of !2m, calreticulin and MHC class I decreased their association with TAP as a 
function of time, whereas tapasin did not (Wearsch et al., 2011). The dissociation of 
calreticulin from TAP suggested that calreticulin is not recruited into the PLC in the 
absence of MHC class I heterodimers. We have similarly reported that calreticulin is not 
recruited into the PLC in !2m-deficient cells (Figure 2.9). However, calreticulin and !2m 
(but not MHC class I heavy chains) are recruited into the PLC in cells that lack heavy 
chain expression and in cells that express a deglycosylated MHC class I heavy chain, 
although with a lower efficiency than cells expressing wild-type heavy chains (Rizvi et 
al., 2011). Hence, the siRNA knock down of !2m may negatively affect the recruitment 
of MHC class I heavy chains and calreticulin into the PLC independently, as !2m 
expression and recruitment into the PLC (but not MHC class I heavy chain) facilitates 
calreticulin recruitment into the PLC. Further studies are needed to fully understand the 
sequence of events that result in the formation of the PLC. One of the most interesting 
questions our study raises is: what is the role of MHC class I heavy chain independent 
recruitment of !2m into the PLC? Understanding the interactions within the proposed 
(Figure 2.13) PLC intermediate (consisting of TAP, tapasin, ERp57, calreticulin and 
!2m) and the role of this intermediate may help in elucidating the mechanism by which 
the PLC facilitates the generation and export of stable MHC class I molecules to the cell 
surface.  
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The effects of calreticulin deficiency on tapasin stability and PLC assembly are 
quite striking. Within the PLC, the MHC class I heterodimer was previously the only 
recognized substrate for calreticulin. Calreticulin is proposed to bind MHC class I via 
glycan-based interactions, and in the absence of calreticulin, MHC class I steady state 
levels are reduced [(Figure 2.3C) and reviewed in (Wearsch and Cresswell, 2008)]. In 
this thesis, we have shown that calreticulin also preferentially interacts with glycosylated 
rather than deglycosylated tapasin in cells (Figure 2.7D). Additionally, similar to MHC 
class I, steady-state levels of tapasin are substantially diminished in cells that lack 
calreticulin or that express a glycan binding deficient mutant of calreticulin (Figure 2.7B, 
tapasin lysates). Thus, as tapasin is highly dependant on calreticulin for its stability, we 
propose that tapasin is a second substrate of calreticulin within the PLC, a novel role for 
calreticulin. Additionally, in contrast to the previous model that newly synthesized MHC 
class I molecules can bind to TAP in calreticulin-deficient cells (Gao et al., 2002), our 
data suggest that MHC class I recruitment into the PLC is strongly impaired in 
calreticulin deficient cells (Figure 2.3C and 2.7C). Thus, calreticulin is key to the overall 
stability of the PLC.  
Role of the calreticulin P domain in substrate binding 
 In Chapter 2, we assessed the interactions that mediated calreticulin recruitment 
into the PLC. To demonstrate the critical role of the ERp57 binding site of calreticulin, 
two constructs were examined: mCRT(%P) and mCRT(W244A). The entire P domain of 
calreticulin is removed in mCRT(%P) and a single residue in calreticulin critical for 
calreticulin binding to ERp57 is mutated in mCRT(W244A). Calreticulin binding to 
ERp57 is strongly reduced with both constructs (Figures 2.2N and 2.2D). However, there 
are notable differences between cells expressing mCRT(%P) and mCRT(W244A). In 
anti-TAP immunoprecipitations, mCRT(%P) co-immunoprecipitation is not detected 
whereas mCRT(W244A) is detected, albeit at a lower level than mCRT(WT) (Figure 
2.3C compared to 2.7C). Surface MHC class I induction appears lower in cells expressing 
mCRT(%P) compared to mCRT(W244A) as well. The fold increase of surface MHC 
class I in cells expression mCRT(%P) compared to mCRT(CRT-/-) is close to 1 whereas 
the fold increase is closer to 1.5 in cells expressing mCRT(W244A) (Figure 2.3A 
compared to 2.7A). Additionally, the level of surface MHC class I induction in cells 
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expressing the calreticulin double mutant deficient in glycan and ERp57 binding 
mCRT(Y92A/W244A) is lower than the induction in cells expressing mCRT(W244A), 
suggesting that the mCRT(W244A) mutant is not entirely impaired for MHC class I 
assembly (Figure 2.7A). Taken together, the enhanced activity of mCRT(W244A) 
compared to mCRT(%P) suggests that in addition to recruiting ERp57 into the PLC, the P 
domain of calreticulin may have another role within the MHC class I assembly complex.  
Whereas mCRT(W244A) displayed enhanced aggregation suppression activity 
against a polypeptide substrate compared to mCRT(WT), the data with mCRT(%P) were 
variable (Figure 2.11). Additionally, the P domains of calnexin and calreticulin facilitate 
suppression of aggregation of polypeptide substrates (Brockmeier et al., 2009; Pocanschi 
et al., 2011), supporting the hypothesis that the calreticulin P domain may have a role in 
polypeptide-based substrate binding within the PLC, a role independent of ERp57 
recruitment. Calreticulin binds ERp57 via residues in the b’ domain of ERp57 (Russell et 
al., 2004) (Figure 4.1). Based on data in Chapter 2, we hypothesized that calreticulin also 
interacts with the glycan of tapasin. However, docking of calreticulin onto the solved 
crystal structure of ERp57-tapasin revealed that calreticulin could not simultaneously 
bind both the glycan of tapasin and the b’ domain of ERp57. Thus, association of 
calreticulin with the glycan and ERp57 of the tapasin-ERp57 complex may be sequential 
rather than simultaneous. MHC class I molecules are preferentially recruited to the 
ERp57 associated form of tapasin (Rizvi et al., 2011). A number of orientations of 
calreticulin relative to tapasin-ERp57 were possible. This is further compounded by the 
possibility of multiple relative orientations of the globular domain of calreticulin relative 
to its P domain. Further studies are needed to understand how calreticulin and MHC class 
I are oriented upon the tapasin-ERp57 complex. It is likely that the P domain has a role in 
tethering together this complex. Based on the finding that MHC class I-deficient cells 
recruit !2m into an intermediate PLC (Rizvi et al., 2011), it is possible that the P domain 
interacts with the !2m component of MHC class I heterodimers. Further studies are 
needed to better understand modes of PLC construction. We propose a model in which 
the flexible P domain wraps around a substrate during calreticulin interaction with the 
PLC, and that the P domain interaction with !2m is important for the stabilization of PLC 
intermediates consisting of TAP, ERp57, tapasin, !2m and calreticulin. The P domain 
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may also wrap around MHC class I heterodimers upon their recruitment, which could 
have a small, but significant role in the overall stability of the PLC.    
 
 
Figure 4.1. Tapasin-ERp57 crystal structure and depiction of calreticulin binding site on 
ERp57. A. Crystal structure of ERp57 (yellow) and tapasin (green) (PDB ID 3F8U) 
(Dong et al., 2009). Residues in ERp57 that mediate calreticulin binding are depicted in 
red (Russell et al., 2004). Asn233, the glycosylation site in tapasin, is depicted in blue. 
Docking of calreticulin onto this structure reveals that calreticulin cannot simultaneously 
contact its ERp57 binding site (red) and the glycan of tapasin (blue). Thus, we predict 
that interactions involving calreticulin binding the glycan of tapasin and the tapasin-
associated ERp57 must involve distinct steps of PLC formation. MHC class I molecules 
are predominantly recruited to the ERp57 associated form of tapasin, and how 
calreticulin orients itself in this complex remains to be further elucidated. Docking of 





Role for the acidic domain in the ER retention of calreticulin 
Expression of mCRT(%C) resulted in the secretion of calreticulin from cells 
(Figure2.5). The mCRT(%C) construct contained the KDEL retrieval motif of full length 
calreticulin, suggesting that the KDEL motif is not sufficient for the ER localization of 
calreticulin, consistent with published findings (Sonnichsen et al., 1994). Interestingly, a 
KDEL retrieval motif was insufficient to prevent the secretion of IL-6 from human 
hepatoma cells (Rose-John et al., 1993). However, appending the 14 C-terminal residues 
(including KDEL) of PDI to the C-terminus of cytosolic IL-6 resulted in complete ER 
retention.  Notably, there was a string of 5 acidic amino acids in the sequence appended 
to IL-6. The ability of the acidic residues of PDI to aid in the retention of IL-6 suggests 
that ER retention mediated by acidic residues may not be unique to calreticulin.  Indeed, 
the removal of the KDEL motif from PDI does not drastically affect the ER retention of 
PDI (Mazzarella et al., 1990). A matrix of interactions between ER proteins mediated by 
acidic residues is suggested to retain soluble proteins in the ER (Sonnichsen et al., 1994).  
Higher order plants express two distinct families of calreticulin isoforms: a 
calreticulin1/calreticulin2 group and a calreticulin3 group (Persson et al., 2003). 
Calreticulin1 and calreticulin2 isoforms share a higher sequence homology with each 
other compared to calreticulin3. All three isoforms are upregulated in response to ER 
stress. Notably, the C terminal domains of calreticulin1 and calreticulin2 contain a large 
number of acidic residues, suggesting these isoforms have a role in ER calcium 
homeostasis. However, the C terminal domain calreituclin3 contains a high number of 
positively charged residues. The globular and P domains of all three isoforms are not 
significantly different. Recently, calreticulin3, UGGT and a putative HDEL retrieval 
receptor ERD2b were implicated in the quality control of EFR, a plant innate immune 
receptor (Li et al., 2009). The gene that encodes ERD2b is a homolog of the (H/K)DEL 
receptor in yeast, ERD2. The second homolog for ERD2 in Arabidopsis, ERD2a, has 
been shown to function as an ER retrieval receptor in yeast expressing a non-functional 
mutant of ERD2 (Lee et al., 1993). However, ERD2b had not previously been assessed 
for its function as an ER retrieval receptor. Calreticulin1 and calreticulin2 played a small 
role in quality control, but could not substitute for calreticulin3 in the folding of EFR. 
Interestingly, mutations in ERD2b affect ER retention of calreticulin3 but not of 
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calreticulin1 or calreticulin2. It is surprising that ER retention of calreticulin1 and 
calreticulin2 are not affected by mutations in ERD2b, as both isoforms also express a 
HDEL retrieval motif similar to calreticulin3. We speculate that in addition to the HDEL 
retrieval motif, the acidic domains of calreticulin1 and calreticulin2 play a role in the ER 
retention of these two isoforms of calreticulin either directly or via interactions with 
factors distinct from ERD2b. However, as the C domain of calreticulin3 is positively 
charged, calreticulin3 is dependant on HDEL receptor mediated retrieval for its ER 
localization. Thus, data accumulated in the literature as well as our data (Figure 2.5) all 
point to a poorly described novel mechanism for the ER retention of soluble ER proteins 
that contain positively charged residues in their C terminus. This mode of retention likely 
functions cooperatively with (K/H)DEL retrieval mechanisms, ensuring the proper ER 
localization of the protein.  
Although substrate binding may be highly redundant between the three isoforms 
of plant calreticulin, the C domain has been shown to play a crucial role in ER quality 
control mediated by calreticulin towards some substrates. As mentioned above, 
calreticulin3, but not calreticulin1 or calreticulin2, was able to chaperone EFR, a plant 
innate immune receptor (Li et al., 2009). In another study of Arabidopsis, calreticulin2 
was shown to be a regulator of a different component of plant innate immunity (Qiu et 
al., 2012). In a third study, calreticulin3, but not calreticulin1 or calreticulin2 was shown 
to mediate the retention of a mutant surface receptor (Jin et al., 2009). Additionally, 
swapping the acidic C domain of calreticulin1 for the positively charged C domain of 
calreticulin3 enabled calreticulin1 to retain the mutant receptor. Calreticulin3 with the C 
domain of calreticulin1 lost its ability to mediate retention. Thus, the C domain of 
calreticulin3 was crucial in conferring substrate specificity (Jin et al., 2009). The different 
substrate specificities of the plant calreticulin isoforms suggest that the C terminal 
domain of calreticulin is able to influence calreticulin targeting to specific substrates. 
Substrate specificities of calnexin and calreticulin 
Different substrates display varying dependence on calreticulin or calnexin 
(Molinari et al., 2004). The molecular basis for these differences is incompletely 
understood since both proteins have identical glycan binding specificities and similar 
ERp57 interacting characteristics. One factor that is suggested to influence substrate 
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specificity is the topological environment of calnexin and calreticulin. A calreticulin 
construct engineered to contain a transmembrane domain was shown to associate with 
substrates with a pattern that matched the pattern seen for calnexin. Conversely, a soluble 
version of calnexin associated with substrates that were normally calreticulin-associated 
(Danilczyk et al., 2000). However, soluble calnexin was not able to induce MHC class I 
assembly in calreticulin deficient cells [data not shown and (Gao et al., 2002)], 
suggesting that the membrane bound constraint of calnexin is not the only factor that 
inhibits the ability of calnexin to mediate PLC assembly. However, the soluble calnexin 
construct used in Gao et al. 2002 partially truncates the P domain of calnexin. Thus, the 
finding that soluble calnexin was not able to induce MHC class I assembly needs to be re-
examined in the context of a correct soluble calnexin construct. The length of the 
calreticulin P domain is shorter than the calnexin P domain (Figure 4.2). If one role of the 
P domain is to encompass a substrate bound to calreticulin or calnexin, having a longer or 
shorter P domain could drastically alter substrate specificities. Finally, although calnexin 
has a C terminal acidic domain, it is located in the cytosol. The luminal location of the 
calreticulin acidic domain may determine calreticulin substrate specificity in a manner 




Figure 4.2. Structural models of calreticulin and calnexin. A. Model of calreticulin 
(described in Figure 1.6). B. Crystal structure of the luminal domains of calnexin (PDB 
ID IJHN) (Schrag et al., 2001). Putative glycan-binging residues of calreticulin and 
calnexin are depicted in yellow. The longer P domain of calnexin, the luminal location of 
the acidic domain of calreticulin, or the presence of a transmembrane domain in calnexin 
may account for the differing substrate specificities of the two proteins.  
 
A role for calreticulin in MHC class I quality control outside the PLC 
The calreticulin mutants generated in this thesis provide insight into functions of 
calreticulin outside the PLC. Calreticulin lacking the KDEL motif [mCRT(%KDEL)] was 
recently shown to be both recruited into the PLC and secreted from cells (Howe et al., 
2009). Additionally, mCRT(%KDEL) did not restore surface expression of MHC class I 
at a level induced by mCRT(WT) (Howe et al., 2009). Reduced surface expression of 
MHC class I was attributed to a novel role for calreticulin in MHC class I assembly that 
is independent of the PLC. Calreticulin was shown to have a role in the retrieval of sub-
optimally loaded MHC class I molecules from the golgi back to the ER. In this thesis, we 
show that mCRT(%C) is recruited into the PLC (Figure 2.3C). However, cells expressing 
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mCRT(%C) have low levels of surface MHC class I (Figure 2.3A) and are unable to 
reduce the acquisition rate of EndoH resistance by MHC class I heavy chains to levels 
seen in cells expressing mCRT(WT) (data not shown). The phenotype of mCRT(%C) is 
likely due to the inability of mCRT(%C) to retrieve sub-optimally folded MHC class I 
molecules from the golgi, as mCRT(%C) itself is defective in being retained in the ER 
[(Figure 2.5) and (Sonnichsen et al., 1994)]. Hence, we provide further evidence for a 
secondary role for calreticulin outside of PLC formation and related to retrieval of MHC 
class I molecules from post-ER compartments.  
Although the mode of the calreticulin-MHC class I interaction relevant for 
retrieval was only speculated upon in Howe et al. (2009), data from our group suggest 
that glycan based interactions are relevant. In Chapter 2, we showed that cells expressing 
glycan binding-deficient mutants of calreticulin [mCRT(Y92A) or mCRT(W302A)] did 
not rescue  MHC class I surface expression to levels in cells expressing mCRT(WT) 
(Figure 2.7 and 2.8). Both mutants of calreticulin displayed enhanced in vitro aggregation 
suppression activities of a polypeptide substrate (Figure 2.11). Additionally, 
mCRT(W302A) was unable to reduce the rate of EndoH resistance acquisition by MHC 
class I heavy chains when expressed in calreticulin deficient cells (Jeffery et al., 2010). 
However, a calreticulin mutant deficient in suppressing the aggregation of a polypeptide 
substrate in vitro [mCRT(L139A)] was able to restore surface levels of MHC class I and 
reduce the acquisition rate of EndoH resistance by MHC class I heavy chains to the same 
level as cells expressing mCRT(WT) (Jeffery et al., 2010).  
We speculate that under steady state conditions, the glycan binding site of 
calreticulin is involved two aspects of MHC class I heavy chain quality control. The first 
is recruitment of calreticulin into the PLC for stabilization of tapasin and MHC class I. 
The second is the retrieval of MHC class I molecules loaded with sub-optimal peptides 
from the golgi into the ER. This retrieval is mediated via the KDEL motif of calreticulin 
(Howe et al., 2009). Although tapasin has been dubbed the “peptide editor” of the PLC 
[reviewed in (Peaper and Cresswell, 2008)], our data blur the lines of whether or not 
calreticulin could also be included in that category. Tapasin displaces low affinity 
peptides bound to the MHC class I peptide binding groove and facilitates the exchange 
for high affinity peptides (Howarth et al., 2004). Tapasin is also believed to have the 
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ability to detect the presence of empty MHC class I heterodimers or those loaded with 
sub-optimal peptides and prevent the export of these unstable MHC class I molecules 
from the ER. Calreticulin has not been shown to displace peptides within the MHC class I 
peptide binding groove, but calreticulin does slow the rate of transport of MHC class I 
molecules out of the ER and prevents the export of MHC class I molecules loaded with 
sub-optimal peptides. Thus, calreticulin and tapasin may have redundant roles, with both 
being important in maintaining complete quality control of MHC class I assembly. 
Additionally, the redundant roles may be spatially distinct – ER retention of MHC class I 
molecules by tapasin and golgi retrieval of MHC class I molecules by calreticulin.  
Insights into the calreticulin/calnexin cycle 
ERp57, an oxidoreductase that is a member of the PDI family, aids in the folding 
of nascent proteins. However, unlike other members of the PDI family, ERp57 shows a 
preference for glycoprotein substrates [reviewed in (Rutkevich and Williams, 2011)]. 
This preference is thought to be due to the ability of ERp57 to interact with the P domain 
of calreticulin and calnexin, both of which contain binding sites for glycoprotein 
substrates. Inhibiting the formation of monoglucosylated glycoproteins in cells reduced 
the ability of ERp57 to aid in the isomerization of some, but not all, of its substrates. 
Some ERp57 substrates are not dependant on the calreticulin/calnexin cycle (Jessop et al., 
2007). In our proposed model for calreticulin recruitment into the PLC, calreticulin 
recruits ERp57 to its substrate (tapasin) by first binding to tapasin via glycan-based 
interactions [(Figure 2.13) and (Rizvi et al., 2011)]. This model was partially based on 
our observation of reduced ERp57 recruitment to TAP/tapasin in calreticulin deficient 
cells (data now shown). Hence, to our knowledge, ours is the first study to demonstrate 
the unique requirement for calreticulin for ERp57 binding to a known ERp57 substrate, 
tapasin. Although calnexin also contains a glycan-binding site similar to calreticulin, 
calnexin expression is not sufficient to recruit ERp57 to tapasin in calreticulin deficient 
cells (data not shown).  
Our studies also open the possibility of other requirements for the efficient folding 
of glycoprotein substrates by calreticulin and ERp57. A PLC intermediate containing 
TAP, tapasin, ERp57, calreticulin and !2m is detected in cells devoid of detectable MHC 
class I heavy chain (Rizvi et al., 2011). Additionally, calreticulin and ERp57 recruitment 
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into the PLC are undetectable and reduced, respectively, in !2m-/- cells (Figure 2.9). The 
impaired recruitment of calreticulin and ERp57 suggest that !2m is necessary to stabilize 
the tapasin-ERp57-calreticulin complex. Hence, it is possible that polypeptide based 
binding between calreticulin and !2m contribute to stability of the sub-complex of the 
PLC.  
Relevance of aggregation assays as a measure of polypeptide binding by calreticulin 
 Aggregation assays were used to measure polypeptide binding by calreticulin in 
Chapter 2. In these assays, calcium depletion of calreticulin dramatically enhances 
activity (Figure 2.10), and correspondingly calcium depletion induces calreticulin 
oligomerization [Figure 2.2D and (Rizvi et al., 2004)]. Under physiological non-stress 
conditions however calreticulin is largely monomeric (Rizvi et al., 2004). Thus, it is 
possible that aggregation assays reflect the use of polypeptide binding sites of calreticulin 
that are stress-induced rather than constitutive. Further studies are needed to understand 
locations and functions of polypeptide binding sites of calreticulin under non-stress 
conditions.  
Immune implications of calcium depletion induced secretion of calreticulin 
It is interesting that calreticulin and PDI are also secreted in response to ER 
calcium depletion (Peters and Raghavan, 2011), a finding that also indicates calcium 
sensitivity of ER retention. The secretion of specific ER proteins in response to forms of 
ER stress that induce calcium perturbations in the ER may be one mechanism of immune 
marking cells under ER stress. For example, cell-surface calreticulin appears to be a 
marker for the phagocytic uptake of viable cells under conditions of ER stress mediated 
by perturbations in ER calcium (Peters and Raghavan, 2011). The clearance of cells 
under ER stress may be one mechanism of suppressing steady-state levels of 
inflammation, as ER stress induction in cells results in the secretion of factors that induce 
ER stress, activation and secretion of IL-6 in M$ (Mahadevan et al., 2011).  
As mCRT(%C) is secreted under steady-state conditions, it would be interesting to 
ask whether mCRT(%C) is expressed on the cell surface. Such analyses would indicate 
whether surface receptor(s) for calreticulin are present on the cell-surface during steady-
state conditions. Additionally, if mCRT(%C) is partially localized on the surface of cells 
under steady-state conditions, the phagocytic uptake of cells expressing mCRT(WT 
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CRT) or mCRT(%C) can be compared to determine whether calreticulin, independent of 
any other apoptotic-associated pro-phagocytic markers, is sufficient to mediate the uptake 
of cells. The calreticulin “eat me” signal could be countered by “don’t eat me” signals on 
viable cells (such as CD47) (Gardai et al., 2005). However, it is also possible that surface 
levels and/or clustering of CD47 are altered on cells, following ER stress induction. 
Future directions may include investigating the role of surface calreticulin in the context 
of ER stress. Based on our current knowledge about the pro-phagocytic role of cell-
surface calreticulin (Gardai et al., 2005; Kuraishi et al., 2007; Obeid et al., 2007b; Peters 
and Raghavan, 2011) and ER stress associated inflammation (Mahadevan et al., 2011), 
we hypothesize that calreticulin upregulation on the surface of cells under ER stress 
mediates the removal of the cells to suppress ER stress associated inflammation.  
Effect of thapsigargin and LPS treatments on the cross-presentation of cell-
associated antigen 
In Chapter 3, we examined the role that calreticulin plays in the cross-presentation 
of associated antigen. We showed that calreticulin does not enhance the cross-
presentation of a fused or bead-associated antigen. Additionally, enhancement in 
phagocytic uptake of cells treated with thapsigargin that is partially dependant on 
calreticulin does not translate to induced cross-priming of CD8 T cell responses against 
cell-associated antigen. CD8 T cells proliferated and were activated to similar levels in 
response to antigen derived from wild-type or calreticulin-deficient thapsigargin treated 
cells. Although we did not find a positive role for calreticulin in the various cross-
presentation models examined, our work contributes to the understanding of various 
aspects of CD8 T cell activation driven by cell-derived antigen. 
 We have previously shown that conditioned media from MEFs treated with 
thapsigargin induces sterile IL-6 production and synergizes with LPS to induce a greater 
secretion of IL-1! and IL-12p70 in BMDC (Peters and Raghavan, 2011). Consistent with 
the hypothesis that MEFs treated with thapsigargin are activating towards APCs 
(Mahadevan et al., 2011; Peters and Raghavan, 2011), we find greater OT-I T cell 
proliferation induced by OVA-expressing thapsigargin-treated MEFs compared to UV 
treatment of MEFs (Figure 3.7C compared to 3.11B, upper panel). Furthermore, 
compared to mice immunized with OVA-expressing UV-treated MEFs, mice immunized 
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with OVA-expressing MEFs treated with 200 nM thapsigargin generally induced higher 
numbers of OT-I T cells in the draining lymph node (Figure 4.1). Enhanced OT-I T cell 
numbers were independent of calreticulin expression in the antigen donor cell. 
Madadevan et al. (2011) argue that pro-inflammatory cytokines produced by M$ in 
response to unknown secreted factors from ER-stressed cells support tumor growth and 
metastasis, as tumor growth and metastasis are supported by an inflammatory 
environment [reviewed in (Grivennikov et al., 2010)]. However, enhanced 
immunogenicity of tumor cells is observed upon treatment of tumor cells with 
thapsigargin and cisplatin compared to cisplatin alone (Tesniere et al., 2010). Hence, 
although thapsigargin may induce ER stress (and thus inflammation), under certain 
contexts the inflammatory consequences of thapsigargin treatment could be exploited to 
induce a more potent anti-tumor immune response.  
It is important to note that the immunostimulatory effect of the conditioned media 
on BMDC in our prior studies was attributed to the release of thapsigargin sequestered in 
the membrane of treated cells into the conditioned media, as direct treatment of BMDC 
with thapsigargin induced secretion of a similar profile of inflammatory cytokines (Peters 
and Raghavan, 2011). Interestingly, immunizing mice with 5 µM thapsigargin treated 
cells inhibited the proliferation of antigen-specific CD8 T cell responses against cell-
associated antigen (Figure 3.8B). The inhibition was to a level similar to that induced by 
LPS treatment of antigen donor cells (Figure 3.13B). The time at which APCs are 
stimulated with adjuvant (before or after encountering antigen donor cells) can drastically 
affect CD8 T cell responses against cell-associated antigen (Bouvier et al., 2011). If an 
APC matures prior to encountering cell-associated antigen, cross-presentation of the cell-
associated antigen will be extremely inefficient. On the other hand, if APC maturation 
occurs after the uptake of cell-associated antigen, cross-presentation of the cell associated 
antigen will be enhanced. In our experiments, it is possible that excess drug released by 
K42 cells treated with 5 µM thapsigargin reached the dLN prior to the antigen donor 
cells, thus promoting a pro-inflammatory response but simultaneously inhibiting cross-
presentation via inhibition of antigen uptake.  
Our data support a model in which cross-presentation of cell-associated is slightly 
enhanced if APCs encounter antigen donor cells and activating signals at the same time. 
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First, 200 nM thapsigargin treatment of cells does not enhance the proliferation of OT-I T 
cells against cell-associated antigen compared to the UV-treatment of cells (Figure 4.3A). 
However, thapsigargin treatment of antigen donor cells did appear to have slightly 
enhanced the percentage of OT-I T cells recovered (Figure 4.3B). If drug was not 
secreted to a level necessary to activate APCs before the arrival of treated MEFs, the 
APC would encounter residual drug or secreted factors that induce activation upon the 
arrival or phagocytosis of the antigen donor cells. Second, thapsigargin treatment of cells 
with either 5 µM or 200 nM thapsigargin greatly enhanced the cross-presentation of cell-
associated antigen in vitro compared to UV treatment of cells (Figure 3.7C compared to 
3.11B, and data not shown). In this assay, BMDCs have instant access to antigen donor 
cells. However, it is possible that BMDCs respond differently than the relevant APC in 
vivo.  
We found that LPS induced inhibition of CD8 T cell responses against cell-
associated antigen, even at low doses (Figure 3.13B). Whereas the thapsigargin treated 
cells were washed multiple times before injection, the LPS was added to the cells directly 
prior to injection. Thus, LPS was free to drain with the PBS to the dLN. It is likely that 
the LPS matured the APC before the arrival of the MEFs. Thus, even low levels of LPS 
were able to inhibit proliferation, as the antigen donor cells did not sequester LPS. These 
findings are extremely relevant for the generation of cell-based vaccines. Adjuvants have 
the ability to enhance CD8 T cell responses against cell-associated antigen, but the timing 
of their delivery and the timing of the arrival of cell-associated antigen into the draining 
lymph node need to be considered. This is especially important since the draining of cells 






Figure 4.3. Compared to UV treatment of MEFs, thapsigargin treatment of MEFs may 
induce greater recovery of OT-I T cells. Recipient mice were injected i.v. with CFSE 
labeled OT-I T cells. Twenty-four hours later, the mice received PBS, 2.5-5x105 THP-
treated or UV-treated K42(WT CRT) and K42(CRT-/-) OVA expressing cells s.c. (A) 
Proliferation was measured 4 days later in the dLN (inguinal). Left panel: The control 
immunization with PBS is depicted in filled grey. Data are representative of 2-3 mice per 
group. Right panel: Quantification of proliferating OT-I T cells. Each point represents the 
average OT-I T cell proliferation from 2-3 mice and is an independent experiment. Three 
independent experiments are represented. (B) The percentage of OT-I T cells as a 
function of all CD8 T cells recovered is depicted. Each point represents the average OT-I 




Roles for calreticulin in inducing immunogenicity of dying cells  
Although surface calreticulin mediates the uptake of thapsigargin treated cells by 
BMDC in vitro (Peters and Raghavan, 2011), we did not observe enhanced activation of 
CD8 T cell responses against OVA-expressing K42(WT CRT) cells compared to 
K42(CRT-/-) cells in vitro or in vivo (Figure 3.7 and 3.8). It possible that calreticulin in 
isolation of other danger signals is not sufficient to impact CD8 T cell proliferation. The 
laboratories of Kroemer and Zitvogel have proposed that HMGB1 and ATP release, and 
induction of surface calreticulin on drug-treated cells are necessary for immunogenicity 
of antigen donor cells [reviewed in (Kepp et al., 2011)]. The idea that all three are 
required for immunogenicity is partially supported by another group. The laboratory of 
Agostinis has recently shown that tumor cells treated with photodynamic therapy, which 
induces reactive oxygen species mediated ER stress, are as immunogenic as mitoxantrone 
treated cells (Garg et al., 2012). Mitoxantrone, an anthralcylin, has been suggested by 
Kroemer’s group to be immunogenic due to its ability to induce surface calreticulin on 
tumor cells and induce the secretion of ATP and HMGB1 (Apetoh et al., 2007; 
Ghiringhelli et al., 2009; Obeid et al., 2007b). Garg et al. (2012) show that photodynamic 
therapy of tumor cells induces ATP secretion and surface calreticulin on tumor cells. 
HMGB1 secretion and the requirement for calreticulin for immunogenicity were not 
assessed in the study. Thus, in Chapter 3, calreticulin mediated phagocytosis may have 
not translated to an enhanced CD8 T cell response, as neither ATP nor HMGB1 are 
secreted from thapsigargin treated cells (Peters and Raghavan, 2011). 
The proposed roles of HMGB1 and ATP in tumor cell immunogenicity are for 
pro-IL-1! synthesis and NLRP3 inflammasone activation to mediate IL-1! secretion, 
respectively [reviewed in (Kepp et al., 2011)]. The proposed role of surface calreticulin is 
to mediate uptake of tumor cells. As calreticulin is upregulated prior to PS in response to 
anthracyclins, it was suggested that calreticulin-mediated uptake of tumor cells may 
induce differential processing of antigen donor cells compared to PS-mediated uptake 
[reviewed in (Kepp et al., 2011)]. It is possible that the high innate stimulating activity of 
thapsigargin-treated cells [(Peters and Raghavan, 2011) and Figure 4.3 may have masked 
potentiating activities of calreticulin. It is possible that with certain drug treatments, 
calreticulin, HMGB1 or ATP are not necessary for immunogenicity, as APC can become 
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directly activated in response to residual drug or via factors secreted from drug treated 
tumor cells under ER stress (Mahadevan et al., 2011; Peters and Raghavan, 2011). As 
thapsigargin may have masked potentiating influences of calreticulin, it is important to 
examine high activity drug treatments or effects of other cell surface calreticulin-inducing 
drug treatments upon T cell activation.  
Calreticulin-mediated uptake may be more crucial for drug treatments that do not 
directly activate APCs or in an immunosuppressive environment typical of tumor cells. 
However, as drug treated cells will eventually upregulate PS, why is calreticulin-
mediated uptake so crucial for immunogenicity? As mentioned above (Kepp et al., 2011), 
it has been suggested that while PS-mediated uptake may induce “silent” removal of the 
apoptotic cells, calreticulin may induce an immunogenic uptake of cells. This hypothesis 
has not yet been proven. Ours is the first study to directly test this concept, but clearly 
more studies are needed in other drug treatment contexts for more a more complete 
understanding of how calreticulin contributes to tumor cell immunogenicity. Assessing 
the trafficking of cells and stability of cell-associated antigen within an APC after PS- or 
calreticulin-mediated uptake is crucial in further understanding why surface calreticulin is 
immunogenic. PS-mediated uptake by APC traffics cell-associated antigen to lysosomes, 
which degrade antigen quickly (Peng and Elkon, 2011). It is possible that calreticulin-
mediated uptake traffics cell-associated antigen to early endosomes, which are conducive 
for cross-presentation (Burgdorf et al., 2007).  
Impacts of trogocytic transfer on CD8 T cell proliferation  
It may be important to note that chemotherapeutic drugs that induce cell surface 
calreticulin on tumor cells may have secondary impacts on MHC class I presentation that 
can affect CD8 T cell activation. Reduced levels of calreticulin in the PLC lead to the 
reduced steady-state levels of tapasin and MHC class I and reduced levels of surface 
MHC class I (Figure 2.3 and 2.7). Accordingly, while thapsigargin treatment induces 
cell-surface calreticulin, cell-surface MHC class I is diminished (Jeffery et al., 2010). 
Hence, the trogocytic transfer of MHC class I molecules from drug-treated cells to APC 
is expected to be reduced as well. Although we did not find a role for trogocytic transfer 
in the proliferation of naïve of CD8 T cells, such transfer may have a much more 
significant role in the proliferation of memory CD8 T cells (Wakim and Bevan, 2011). 
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Studies examining the role of surface calreticulin in the immunogenicity of tumor cells 
focus on a mouse model in which naïve anti-tumor CD8 T cells are generated (Obeid et 
al., 2007b). However, memory CD8+ T cells generated against established tumors are 
likely to exist in human patients with solid tumors. The expansion of anti-tumor memory 
CD8 T cells may be partially dependant on trogocytic transfer of MHC class I molecules 
from drug-treated tumor cells. However, if drug-treated tumor cells express diminished 
levels of cell surface MHC class I, the expansion of memory CD8 T cell may be 
compromised. Examining the ability of drug-treated tumor cells to activate naïve and 
memory CD8 T cells is then of further interest, as relevant modes of antigen transfer may 
differ between the two sets of CD8 T cells.  
 
Modes of antigen transfer relevant to cross-presentation 
 Our data indicate that mannose receptor-mediated uptake is not critical for the 
cross-presentation of soluble OVA, as discussed in Chapter 3. A number of other 
endocytic receptors have also been implicated in the cross-presentation of antigen. LOX-
1, SREC-I, and SR-A have all been suggested to mediate uptake and cross-presentation 
of HSP-associated antigens (Berwin et al., 2004; Berwin et al., 2003; Delneste, 2004). In 
terms of mechanism, the C-type lectin receptor DC-SIGN is shown to traffic antigen to 
early endosomes, which were favorable for cross-presentation (Tacken et al., 2011). 
Notably, receptors that mediate uptake of antigen may become downregulated on 
activated APCs. For example, another C-type lectin receptor, CLEC9A, expressed on 
human DCs mediates uptake and cross-presentation of antigen. However, expression of 
the receptor is reduced after DC maturation induced by TLR ligands (Schreibelt et al., 
2012). As calreticulin is non-essential for the cross-presentation of fused and bead-
associated OVA (Figure 3.4 and 3.5), there is likely a high level of redundancy in the 
receptors that mediate uptake and cross-presentation of soluble or particulate antigen. 
However, APC maturation may induce a loss of receptor redundancy. Upon the down-
regulation or internalization of redundant receptors, receptors that remain on the cell 
surface could become crucial for cross-presentation. 
 Nevertheless, the uptake of antigen may is not the only factor that determines the 
fate of an exogenous antigen. Peptidoglycan (PGN) is a ligand for the nucleotide-binding 
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oligomerization domain-like (Nod-like) receptors. Nod-like receptors are cytosol 
localized innate immune receptors that can induce NF-'b activation. Although DCs 
exposed to LPS and PGN phagocytose antigen donor cells to similar levels, PGN inhibits 
the cross-presentation of cell-associated antigen whereas LPS does not inhibit cross-
presentation (Wagner and Cresswell, 2012). It is worth noting that a conventionally 
derived source of LPS inhibited cross-presentation, whereas cross-presentation was not 
inhibited by highly purified LPS. It is possible that contaminants were present in the LPS 
that we used in our cross-presentation assay, which could have inhibited cross-
presentation in a manner independent of LPS. Nonetheless, a network of signals enables 
an APC to successfully cross-present and prime naïve and memory CD8 T cells. 
Phagocytic/endocytic receptors and innate signaling may drastically change depending on 
the environment and antigen source (soluble vs. cell-associated). Understanding the 
impacts that each have on cross-presentation is crucial if cross-presentation is to be 
harnessed for vaccine design or for the treatment of established tumors.  
 We found trogocytic transfer of antigen to be relevant in vitro but not in vivo for 
inducing the proliferation of naïve CD8 T cells in response to cell-associated antigen 
(Figure 3.11 and 3.12). Trogocytic transfer may be relevant for expanding memory CD8 
T cells, but not naïve CD8 T cells (Wakim and Bevan, 2011). However, we found that 
naïve OT-I T cells were activated primarily by trogocytic transfer of antigen in vitro 
(Figure 3.11). Thus, it is possible that naïve CD8 T cells could be activated via trogocytic 
transfer of antigen onto APCS under certain conditions in vivo. The APCs that 
phagocytose antigen may not have a role in directly activating CD8 T cells. Rather, a 
secondary APC subset could acquire MHC class I-peptide complexes from APCs that 
cross-presented antigen. The secondary APC subset could be the relevant subset that 
primes naïve CD8 T cells (Qu et al., 2009). In this scenario, trogocytic transfer of antigen 
from one APC subset to another mediates activation of CD8 T cells. In our in vivo model, 
it is possible that APCs capable of acquiring MHC class I-peptide complexes were not 
present in the dLN or did not have access to antigen, thus rendering trogocytic transfer 




APCs relevant for cross-presentation 
 As discussed in Chapters 1 and 3, if specific receptor mediated uptake is crucial 
for the cross-presentation of certain antigens, elucidating relevant APC subset in vivo is 
vital. Receptor expression, antigen processing capacity and lymph node localization of 
APCs can drastically affect the ability of an APC to cross-prime CD8 T cells. A number 
of studies have been undertaken to identify relevant cross-presenting APCs in vivo in a 
number of different dLNs (Asano et al., 2011; del Rio et al., 2007; Desch et al., 2011). 
We have not yet investigated which APC subsets are relevant for uptake and presentation 
of pre-apoptotic cell derived antigen following subcutaneous immunizations. Thus, we 
used BMDC for in vitro cross-presentation assays, which limited our ability to accurately 
assess the role of calreticulin in the cross-presentation of antigen in vitro. For in vitro 
assays, it may be more relevant to immunize mice and use dLN to activate CD8 T cells ex 
vivo. dLN from immunized mice can also be re-stimulated in vitro with relevant antigens 
to assess memory responses (Figure 3.8D). Although these alternatives may not allow for 
complete cellular and molecular dissection of antigen presentation events in vitro, they 
may offer more physiologically relevant insights into processes relevant to priming of 
CD8 T cells by cell-associated antigens.  
 
 In summary, the work described in this thesis led to the development of a novel 
model for PLC formation and elucidated novel roles for calreticulin in MHC class 
assembly. This work also contributed to a better understanding of general cellular 
processes including mechanisms of ER retention and the calnexin/calreticulin chaperone 
cycle. We also assessed factors that influence CD8 T cell proliferation, including 
calreticulin, innate signaling, and antigen transfer. Although this work contributes 
towards a better understanding about how calreticulin functions in a cell, more research is 
needed to better understand the immunogenic role of calreticulin.  
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